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INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is a complex cardiac disease with heteroge-
neity in genotype, clinical expression, prognosis and therapeutic modalities.1,2 The 
disease, which is defi ned as a hypertrophied left ventricle in the absence of appar-
ent causes of hypertrophy, is caused by mutations in genes encoding for sarcomeric 
proteins.3 The prevalence of HCM in the general population is 0.2%.4 The clinical 
presentation may vary from non-symptomatic to severely disabled.5 Sudden cardiac 
death is the most devastating complication in the natural history of HCM, often 
occurring in young, previously asymptomatic patients.6 Since the introduction of 
HCM as a clinical entity in 1958,7 extensive research has been performed regarding 
genetics, diagnosis, prognosis and therapy. However, correct diagnosis and optimal 
management of HCM patients may still off er diffi  culties to the physician. For instance, 
only recently it became apparent that even with a normal echocardiogram, patients 
may be carrier of a HCM-causing mutation.8,9 Therefore, optimal management of 
HCM patients requires extensive knowledge of the natural history, the extensive 
genetic variations and the indications for medical and invasive treatment.
PROGNOSIS AND TREATMENT
The fi rst data on the natural history of HCM were initially derived from referral-
based populations, which consisted of young, often seriously disabled patients 
referred for advanced care.10 These patients personify a selected minority and their 
clinical course seems to represent the worst end of the disease spectrum. Annual 
cardiac mortality rates in these populations were as high as 4%-6%.11-14 In contrast, 
recent data suggest that HCM has a fairly benign prognosis.15-19 Yet, the continu-
ous research for new knowledge of risk markers still remains important to identify 
patients at increased risk for (sudden) cardiac death.
Therapeutic strategies in HCM are multifaceted and may vary during the course 
of the disease. The general advise for patients who remain symptomatic, despite 
optimal medical treatment, and demonstrate a left ventricular outfl ow tract (LVOT) 
gradient of ≥ 50 mm Hg, is invasive treatment.20 Currently, the two most frequently 
used invasive therapies are surgical septal myectomy and percutaneous translumi-
nal septal myocardial ablation (PTSMA).
Septal myectomy entails partial resection of the hypertrophied septum of the left 
ventricle to alleviate the LVOT obstruction. Since HOCM patients often demonstrate 
abnormalities of the mitral valve or its subvalvular apparatus, we frequently com-
bine septal myectomy with mitral leafl et extension (MLE).21
12
C
ha
p
te
r 1
PTSMA, introduced as an alternative to surgery, entails the injection of highly con-
centrated ethanol into one or more septal perforator branches of the left descend-
ing coronary artery to produce a localised septal myocardial infarction, resulting 
in remodelling (shrinkage) of the septum, enlargement of the narrowed outfl ow 
tract and reduction of the LVOT gradient. Compared to surgery, the defi nite role of 
PTSMA in HOCM has not been established yet.
PERSPECTIVES OF THE PRESENT THESIS
The aim of the present thesis is to evaluate the natural history in the largest “Dutch” 
community-based cohort of HCM patients and to present the follow-up outcome of 
HOCM patients with drug-refractory symptoms after PTSMA and septal myectomy 
in combination with MLE.
After a mean follow-up of 8 years, we describe the outcome of 225 HCM patients, 
referred to the Thoraxcenter between 1970 and 1999. In this population, we studied 
prognosis as well as risk markers for sudden cardiac death and clinical deteriora-
tion.22 The non-referral base of the study population allowed us to evaluate prog-
nosis and to calculate mortality rates, which are regarded as representative for the 
“average” HCM patient. Furthermore, nine consecutive female patients out of this 
HCM population were followed during pregnancy and delivery.23 From this experi-
ence, we tried to formulate a general advise on the management during and after 
pregnancy.
Septal myectomy in combination with MLE, a modifi ed mitral valve repair tech-
nique originally developed by Carpentier,24 is a surgical technique, developed in 
the Thoraxcenter, to treat symptomatic HOCM patients with an enlarged anterior 
mitral valve leafl et. Previously, we demonstrated the superiority of this combined 
technique as compared to myectomy alone. In the present thesis, we describe the 
long-term follow-up outcome of 29 patients, treated with this combined surgical 
approach. The study emphasizes on the multifactorial origin of the LVOT obstruc-
tion and in particular on the role of the mitral valve in this process. Furthermore, the 
study examined the safety and durability of this modifi ed technique, in particular in 
respect to the mitral valvular function.
We studied the outcome of the largest cohort of HCM patients, who underwent 
PTSMA in the Netherlands. Patients underwent the procedure at the Thoraxcenter 
of the EMC Rotterdam or The Antonius Ziekenhuis Nieuwegein. The purpose of the 
study was to identify predictors of outcome after PTSMA and to compare our results 
to the outcome of other centers. Furthermore, we studied the value of two additional 
techniques, that have been introduced to optimize the PTSMA procedure. The fi rst 
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technique, myocardial contrast echocardiography (MCE), was evaluated on its use 
as a tool to predict the site and size of the septal myocardial infarction. The correla-
tion of MCE-related parameters to the MRI-determined volume and location of the 
septal myocardial infarction distinguished this study from other studies. The second 
technique, intracardiac echocardiography, using the Acunav®-probe, continuously 
provides the operator with high quality images which may be benefi cial to guide 
the PTSMA procedure. We evaluated this technique on operator-dependency and 
on its value as PTSMA-guide.
Currently, only few centers have studied whether PTSMA is equally eff ective as 
septal myectomy in HCM patients.25-27 We describe the 1-year follow-up results of 
43 patients, who underwent PTSMA, and of 29 patients, who underwent surgery.28 
We compared the outcome of the two techniques in respect to hemodynamic and 
clinical outcome to obtain more insight in the advantages and disadvantages of 
each of the two therapies. We evaluated the role of PTSMA in relation to surgery and 
compared our fi ndings to the studies of others.25-27
14
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treatment
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INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is a complex, inherited cardiac disease that 
has been subject of intense investigation since its fi rst description in 1957. Over the 
past 40 years, understanding has evolved regarding the diagnosis, prognosis and 
treatment of HCM. Analyses of HCM populations from non-referral centers have re-
fi ned the insights in the natural history and the occurrence of sudden cardiac death, 
which is the most devastating component of its natural history. Therapeutic strate-
gies are diverse and may vary during the course of the disease. Optimal therapy 
depends on symptoms, hemodynamic fi ndings and the presence of risk factors for 
sudden cardiac death. At present, invasive therapy for patients with obstructive 
HCM and drug-refractory symptoms includes surgery or percutaneous transluminal 
septal myocardial ablation. 
This report summarises the diagnostic criteria, clinical course and therapeutic 
management of HCM. Also, attention is paid to certain issues of special interest in 
this disease.
Diagnosis 
Hypertrophic cardiomyopathy (HCM) is a heterogeneous disease, fi rst described as 
a clinical entity in 1957.1 The diagnosis is based on the echocardiographic existence 
of a hypertrophied, non-dilated left ventricle (LV) in the absence of apparent causes 
for hypertrophy such as aortic valve stenosis and hypertension.2 The disease is 
caused by mutations in genes encoding for the proteins of the cardiac sarcomere.3 
Usually, the left ventricular wall is thickened with a varying degree of hypertrophy, 
ranging from mild (13-15 mm) to massive (>30 mm). 4-6 Adults with increased left 
ventricular thickness secondary to diseases such as amyloidosis, metabolic diseases 
such as glycogen storage disease and Anderson-Fabry disease and syndromes 
such as Friedreich’s ataxia and Noonan’s syndrome are usually excluded from HCM. 
Routine physical examination is often not a reliably tool to suspect nor to establish 
HCM. A typical systolic heart murmur is only in patients with the obstructive type of 
HCM (HOCM). The murmur, which often increases with a Valsalva manoeuvre, origi-
nates from obstruction of blood fl ow in the left ventricular outfl ow tract (LVOT). This 
obstruction is caused by the hypertrophied septum and systolic anterior motion 
of the anterior mitral valve (SAM). The Venturi mechanism, fl ow drag of the leafl ets 
and/or anterior displacement of the papillary muscles, which allows the mitral valve 
to protrude into the outfl ow tract, may cause the latter phenomenon. As a result 
of SAM, a posterior directed mitral regurgitation jet may frequently be visualized 
due to malcoaptation of the anterior and posterior mitral valve leafl ets (fi gure 1A). 
In HOCM, color-fl ow Doppler echocardiography typically demonstrates turbulence 
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Figure 1. Esophageal multiplane echocardiography.
Panel A: Cross sectional view through the LVOT at approximately 160 degrees shows SAM of the anterior mitral valve leafl et (AMVL). Mal-
coaptation of the anterior and posterior mitral leafl ets is clearly seen.
Panel B: With color-fl ow imaging, the mitral regurgitation jet, which is directed towards posterior, is visualized. Also note the turbulent fl ow 
within the LVOT, which is caused by the obstruction.
Abbreviations: Ao = Ascending Aorta. LA = Left Atrium. LV = Left Ventricle. LVOT = Left Ventricular Outfl ow Tract. MR = Mitral Regurgitation jet.
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of blood fl ow in the LVOT and, if present, a posterior directed mitral regurgitation 
jet (fi gure 1B). Doppler echocardiography is used to record the typical “daggered-
shaped” signal (fi gure 2) and to calculate the severity of obstruction using the sim-
plifi ed Bernoulli equation (P = 4v2). LVOT obstruction is observed in approximately 
25% of patients with HCM.7 
The 12-lead electrocardiogram demonstrates abnormalities in 75 to 95% of all pa-
tients, including signs of left atrial enlargement, left ventricular hypertrophy, T-wave 
abnormalities, pathological Q-waves and atrial fi brillation.8,9 Electrocardiography 
remains an important tool of screening at any age, especially since it may be the 
only abnormal fi nding even in the presence of a normal echocardiogram. Originally, 
a normal echocardiogram at adulthood was thought to exclude the diagnosis of 
HCM. Advances in genetic research, however, provided evidence that individuals 
with a disease-causing mutation may develop hypertrophy at any stage in life. For 
instance, late-onset left ventricular hypertrophy (even after middle age) has been 
demonstrated in patients with a myosin-binding protein C (MYBPC) or troponin T 
mutation.10-13 If the specifi c genetic mutation is unknown, fi rst degree family mem-
bers of patients with HCM should therefore undergo routine echocardiographic 
screening every two years at young age and every 5 years after adolescence.14 In in-
dividuals with co-existing hypertension or in highly trained athletes, the diagnosis 
1 m/sec
Figure 2. Continuous wave Doppler, characteristic for the dynamic outfl ow tract obstruction in HOCM patients. Note the late-peaking “dagger-
shaped” appearance of the velocity envelope.
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may be more diffi  cult since these circumstances may contribute to LV hypertrophy. 
However, hypertensive patients without HCM usually have concentric LV hypertro-
phy. In these individuals, the extent of the hypertrophy usually does not exceed 15 
mm and SAM is usually absent.15 In the presence of mild hypertrophy and a positive 
HCM family history, genetic testing might be the only tool to exclude the presence 
of HCM in hypertensive individuals. In trained athletes, left ventricular hypertro-
phy is always mild (≤ 16 mm), left atrial enlargement and diastolic dysfunction are 
absent, at electrocardiography prominent q-waves are absent and regression of 
hypertrophy can be demonstrated on deconditioning.16,17
Prevalence
Epidemiological studies, using echocardiography estimate the prevalence of HCM 
at approximately 1 in 500 persons.18 This number may be an underestimation since 
not all genetically aff ected patients necessarily demonstrate the echocardiographic 
abnormalities. In theory, genetic screening is the best method to estimate the true 
prevalence of HCM in the society. However, it is thought that a large number of 
mutations still await identifi cation and besides that, genetic screening is complex, 
time-consuming and expensive.
Pathology
The distribution of hypertrophy in HCM is heterogeneous, characteristically asym-
metrical and in about one-third of the patients localized in a single segment.2 The 
anterior septum is usually predominantly involved in the hypertrophic process. How-
ever, concentric, apical, and atypical distributions are also present. Right ventricu-
lar hypertrophy can coexist with left ventricular hypertrophy, yet right ventricular 
hypertrophy unaccompanied with hypertrophy of the left ventricle is not observed 
in patients with HCM. Apical hypertrophy is most often seen in the Japanese HCM 
population. This type is often associated with negative T-waves on the electrocar-
diogram and LVOT obstruction is usually absent.19 The main pathological fi ndings 
in patients with HCM are hypertrophy and disorganisation of the myocardial cells 
called “myocyte disarray”, medial hypertrophy of the intramyocardial coronary ar-
teries (small vessel disease) and interstitial fi brosis.20-22 Myocardial disarray has been 
observed in normal hearts and in individuals with congenital heart disease, but in 
these settings the disarray is usually mild. Extensive myocyte disarray, occupying 
substantial portions of the left ventricular wall, is a highly sensitive and specifi c 
marker for the diagnosis of HCM.7
Symmetrical and asymmetrical left ventricular hypertrophy is also seen in several 
metabolic and syndromic diseases, and diseases like amyloidosis and phaeochro-
mocytoma. However, myocyte disarray is absent in these diseases, mutations in 
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the sarcomeric genes are lacking and the clinical course of most of these diseases 
diff ers from the patient with HCM.22 The disorganisation of the cellular architecture 
and myocardial fi brosis in HCM probably serve as arrhythmogenic substrates which 
predispose to electrical instability as noted by the presence of extensive cellular 
disarray in young patients who die suddenly.20 The substrate is likely the source of 
fatal ventricular tachyarrhythmia leading to sudden death in these patients, either 
primarily or in association with triggers as myocardial ischemia, hypotension, supra-
ventricular tachyarrhythmia’s, diastolic dysfunction, LVOT obstruction and physical 
exertion.7
Genetic mutations
HCM is an inheritable disease with an autosomal, dominant pattern.23 The disease is 
caused by mutations in one of ten genes, each encoding for proteins of the cardiac 
sarcomere.24 The most commonly aff ected proteins are ß-myosin heavy chain, car-
diac troponin T and MYBPC.25-27 To a lesser extent, mutations have been described 
in the cardiac troponin I, regulatory and essential myosin light chains, titin, α-tropo-
myosin, α-actin and α -myosin heavy chain.24,28-30 In HCM, most gene abnormalities 
are missense mutations that result in a single amino acid substitution within or 
close to important functional domains.31 For instance, the β-myosin heavy chain 
protein consist of 1936 amino acids and in one of the most reported mutations, the 
β-myosin heavy chain Arg403Gln, the amino acid arginine is replaced by glutamine at 
coding position 403. In the Dutch HCM population, a mutation in the MYBPC gene is 
responsible for at least 45% of patients with HCM and in 60% of them the 2373insG 
mutation is the causal genetic defect.32 Interestingly, the phenotypical expression of 
the disease varies not only between individuals with an identical genetic mutation 
but also exhibits interfamilial phenotypic variation, whereby aff ected individuals 
from the same family display distinct clinical and morphological manifestations.22 
This indicates that the phenotypical expression of the mutation is infl uenced by 
multifactorial causes such as sex, life-style, risk factors and modifi er genes.33-35
Clinical course
The fi rst data concerning the natural history of HCM were derived from hospital-
based populations. However, the cohort of patients in these tertiary centers com-
prised for the most seriously disabled patients referred for advanced care. These 
patients personify a selected minority and their clinical course seems to represent 
the worst end of the disease spectrum. Annual mortality rates in these patients 
were as high as 4% - 6%.36-40 We now know that these fi gures are not representative 
for the “average” patient with HCM and data from non-referral centers suggest a 
more benign prognosis with an annual mortality of less than 1%.41-47 Follow-up of 
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the HCM population in the Thoraxcenter of the Erasmus Medical Center disclosed 
similar mortality rates: cardiac death was 0.8%/year and sudden cardiac death was 
0.6%/year, respectively.48 It is important to realise that the majority of patients with 
HCM may remain a lifetime without symptoms. If the patient has symptoms, typical 
complaints are dyspnoea, exertional angina, palpitations and (pre)syncope.45 Dys-
pnoea, which is the most common complaint, can result from a variety of mecha-
nisms, such as diastolic dysfunction, LVOT obstruction, marked mitral regurgitation 
and severe left ventricular systolic dysfunction in patients with “end stage” disease. 
Exertional chest pain occurs in approximately 25% of patients with HCM, usually in 
the setting of a normal coronary arteriogram. The development of angina may be 
induced by an increase in myocardial oxygen demand or a reduction in myocardial 
blood fl ow and oxygen supply. Factors that increase myocardial oxygen demand are 
myocyte hypertrophy, increased myocardial mass, and LVOT obstruction, whereas 
impaired vasodilator reserve, small vessel disease, and inadequate capillary density 
reduce myocardial blood fl ow. Approximately 20% of patients have complaints of 
(pre)syncope. Syncope is a complex entity since multiple mechanisms may be in-
volved, leading to an inadequate cardiac output or abnormal peripheral vascular re-
fl ex. These mechanisms include supraventricular and ventricular tachyarrhythmia’s, 
conduction abnormalities and atrioventricular nodal block, LVOT obstruction, myo-
cardial ischemia during exertion, diastolic dysfunction and ventricular barorefl ex 
activation with inappropriate vasodilatation.48
Sudden death (SD) is the most tragic event in this disease and it can be the fi rst 
manifestation of HCM in patients who are unaware of their disease or in those who 
are mildly symptomatic.49 The prevention of SD in the individual patient remains 
one of the most challenging goals in the management of HCM. SD can occur at any 
age, at rest but in many cases during vigorous exercise. The patients at higher risk 
for SD comprise approximately 10-20% of the total HCM population. They may be 
identifi ed by the presence of one or more of the following risk factors: 1) survivors 
of sudden cardiac death, 2) spontaneous (non)sustained ventricular tachycardia, 3) 
family history of multiple sudden deaths at young age, 4) (pre)syncope, 5) hypo-
tensive blood-pressure response during exercise or 6) extreme LVH.31,39,50-54 To date, 
there are no convincing data that patients with LVOT obstruction or patients with a 
specifi c causal gene are at particularly high risk for SD.44,55,56
High-risk patients were generally treated with either ß-blockers, verapamil or an-
tiarrhythmic drugs like amiodarone.55,56 However, none of these drugs are proven to 
be eff ective in preventing SD.7 The automatic implantable cardioverter-defi brillator 
(ICD) is the fi rst device to treat potential fatal arrhythmias eff ectively and to alter 
the natural history of the HCM patient.57-60 Recently, the ICD proved to be very ef-
fective in patients who had survived a cardiovascular collaps.57 Primary prevention 
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in high-risk patients may also be eff ective. The American College of Cardiology and 
the European Society of Cardiology stated to implant the ICD in HCM patients who 
survived SD and advised ICD therapy in patients having two or more risk factors, 
other than surviving a cardiac arrest.14
THERAPEUTIC MANAGEMENT
Medical treatment
Therapeutic strategies in HCM patients are multifaceted and may vary during the 
course of the disease. The choice for the optimal therapy depends mainly on the 
presence of symptoms, a LVOT gradient, and the presence of risk factors for SD 
(Table 1). Medical treatment is usually not indicated in the absence of symptoms. 
In patients with dyspnoea, chest pain and/or (pre)syncope, ß-blockers or the cal-
cium antagonist verapamil are the preferable drugs to relieve complaints.61,62 Both 
drugs are negative inotropic and chronotropic and reduce myocardial ischemia 
and angina trough lowering heart rate, left ventricular contractility and myocardial 
wall stress during systole. By decreasing heart rate and reducing ischemia, left ven-
tricular fi lling improves, which may consequently diminish symptoms of dyspnoea 
and (pre)syncope. Moreover, ß-blocking agents may reduce the exercise-generated 
Table 1. Therapeutic strategies for patients with HCM.
Asymptomatic Symptomatic
Non-obstructive ObstructiveFollow-up
Pending risk factors* Medical therapy**
ACE-inhibitor, 
diuretics, digitalis
ICD
Therapy failure
HTX
Septal myectomy
PTSMA
± MLE
Hypertrophic cardiomyopathy
* = Risk factors as described in text.
** = Medical therapy as described in text. HTX = Heart Transplantation. MLE = Mitral
Leafl et Extension. AICD = Automatic Implantable Cardioverter Device.
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increase in obstruction. Verapamil should be administered with caution in patients 
with obstruction since this drug may aggravate the LVOT gradient and increase 
clinical symptoms.63
Disopyramide, an antiarrhythmic drug with negative inotropic properties may 
serve as an alternative in patients with obstruction, who are unresponsive to treat-
ment with ß-blockers or verapamil.64-66 The drug may be combined with low doses of 
a ß-blocker to potentiate its eff ect.67 Unfortunately, disopyramide frequently causes 
intolerable side eff ects in elderly patients because of its vagolytic properties. 
An estimated 5% of the patients progress to a dilated type of cardiomyopathy 
with signs of heart failure. In this group, symptoms are treated with diuretics, digi-
talis, ACE-inhibitors, and ß-blockers. If patients do not respond to medical therapy, 
heart transplantation may be considered.68,69
Invasive therapy
Invasive therapy is indicated in patients with persisting symptoms, despite optimal 
medical treatment and a LVOT gradient of more than 50 mm Hg. 
Surgical therapy
Cleland described the fi rst invasive procedure to treat HOCM patients; further de-
velopments were accomplished by Morrow in the late 1960s.70,71 The Morrow proce-
dure entails partial resection of the hypertrophied septum. Mortality rate was high 
in the fi rst series of patients but the results dramatically improved with growing 
experience of the surgeon and increased understanding of the pathophysiology 
of HOCM.67,72-74 Recent results from experienced centers report mortality rates of 
<2%.75-79 Originally, a rectangular septal through was created, starting directly un-
der the aortic annulus, which is usually the thinnest portion of the septum, and 
ending just below the tip of the mitral leafl ets. This approach could lead to several 
complications, including a ventricular septum defect, conduction disturbances and 
aortic valvular regurgitation.80 Nowadays, a 2-3 mm subaortic muscular ring is pre-
served at operation to prevent these serious complications.
Preferably, resection of the septal bulge is performed to the base of the papillary 
muscles (extended myectomy). In doing so, not only the LVOT is widened but also 
the direction of blood fl ow is changed. Before surgery, the midseptal bulge redi-
rects the fl ow direction so that it comes from a lateral and posterior direction. In this 
way, fl ow gets behind the mitral valve and pushes it to the septum (fl ow drag). After 
extended myectomy, fl ow tracks more anteriorly and medially abolishing SAM and 
obstruction (Figure 3A and B).81,82 
Intraoperative transoesophagial echocardiography is frequently used to judge the 
maximal septal thickness, distance of maximal thickness from the aortic annulus, lo-
Hypertrophic cardiomyopathy in daily practice 27
cation of mitral valve and septal contact, expansion of the septal bulge towards the 
apex, anatomy of the mitral valve and its subvalvular apparatus and to guide surgical 
intervention. Abnormalities of the mitral valve and subvalvular apparatus include 
an increase in length of the anterior mitral valve leafl et, increase in mitral valve area, 
abnormal laxity of the mitral valve, anterior position of the papillary muscles and 
hypertrophy as well as fusion of the papillary muscles.82 These abnormalities may 
lead to residual SAM even after a successful myectomy resulting in inadequate relief 
of obstruction and persistence of mitral regurgitation.83-86 Therefore, some surgeons 
have applied several modifi cations to the (extended) myectomy procedure. First, 
mitral valve replacement has been performed in these patients. Although this ap-
proach has superior hemodynamic results compared to myectomy, the application 
of this technique is limited due to serious complications related to the long-term 
use of anticoagulants in these often young patients.87 Alternative techniques that 
often combine septal myectomy with a mitral valve repair technique, have been 
developed to provide an optimal surgical outcome.88-91 
McIntosh et al. introduced a combined approach of septal myectomy and mitral 
leafl et plication in patients with elongated and enlarged anterior mitral leafl ets.88 
This technique aims at shortening the abnormal anterior mitral valve to counteract 
its property to protrude into the LVOT during systole. First, the region of leafl et-sep-
tal contact, which is characterized by a small fi brotic area, is identifi ed. At this point, 
interrupted sutures are placed perpendicular to the long axis of the leafl et. Leafl et 
tissue is not resected to avoid restriction in leafl et mobility (fi gure 4A).
Swistel et al. described an alternative mitral valve repair technique in combination 
with myectomy and papillary muscle mobilization.92 In contrast to the technique 
Figure 3. Panel A: The streamlines of fl ow circumvent the hypertrophied septum, which bulges into the outfl ow tract. The fl ow may hit the 
anterior mitral leafl et on its posterior surface, dragging it toward the septum. Abnormal mobility of this leafl et is facilitated due to leafl et 
elongation and anterior displacement of the papillary muscles.
Panel B: Once the streamlines of fl ow have been straightened by septal myectomy (dashed area indicated by asterisk), blood fl ow runs directly 
from the apex towards the outfl ow tract. Also, the fl ow hits the leafl et on its anterior surface, pushing the leafl et towards posterior.
Abbreviations: AML = Anterior Mitral Leafl et. AO = Ascending Aorta. IVS = InterVentricular Septum. LA = Left Atrium. LV = Left Ventricle. PML 
= Posterior Mitral Leafl et. PW = LV Posterior Wall.
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described by McIntosh et al., the plication sutures are applied in a medial-lateral 
position, which will not only shorten but also stiff en the anterior mitral valve leafl et 
to prevent its post-operative movement into the LVOT.
Messmer et al. described a technique to correct the hypertrophied papillary mus-
cles by partial resection of the papillary muscles.93 The technique aims to reduce the 
diameter of the papillary muscles and separate them from the myocardial wall and 
from each other (Figure 4B). This allows the papillary muscles to assume a more pos-
terior position in the left ventricle and it permits the mitral valve to assume its more 
normal posterior position, explicitly out of the LVOT. Both mitral plication methods 
have resulted in satisfactory hemodynamic outcome in patients who were at risk of 
residual SAM and LVOT obstruction after septal myectomy alone.
Normally, surgical therapy for HOCM is performed by a transaortic approach. The 
transmitral approach is an alternative approach, especially in patients with an ob-
struction at the mid-ventricular or at papillary muscle level.94 First, the mitral valve 
is visualized through a left atriotomy. The anterior mitral valve leafl et is detached 
from the annulus, leaving both commissures intact. By pushing the leafl et aside, 
the left ventricular cavity is opened and the region of myocardial hypertrophy as 
well as the obstructive lesion (the contact area between septum and mitral leafl et) 
may be more carefully identifi ed. The thickened septum that bulges into the LVOT is 
resected. This method especially allows careful inspection of the portion of the left 
ventricle that reaches towards the apical region and creates both the possibility to 
excise myocardial tissue at this level and to mobilize and resect part of the hyper-
trophied papillary muscles. In the presence of a prominent SAM, the surgeon may 
Figure 4. Panel A: Mitral plication: One (or more) sutures are placed perpendicular to the long-axis of the mitral leafl et, starting at the chordal 
insertion into the leafl et, near the fi brotic contact lesion to prevent residual systolic anterior motion after completed septal myectomy (indicated 
by the asterisk).
Panel B: Papillary mobilisation: Partial resection (indicated by the dashed lines) of the anterior lateral (asterisk) and the posteromedial (double 
asterisk) papillary muscles, which separates them from each other and from the myocardial wall. Mobilisation also allows them to assume a 
more posterior position in the left ventricle. Site of septal myectomy is clearly seen. RV = Right Ventricle. 
Panel C: Mitral leafl et extension: Through an oblique incision in the ascending aorta, the septal hypertrophy and the anterior mitral leafl et are 
visualized. The myectomy trough (indicated by the asterisk) and the inserted patch are clearly seen.
Abbreviations: AO = Ascending Aorta. IVS = InterVentricular Septum. LA = Left Atrium. LCA = Left Coronary Artery. LV = Left Ventricle. PW = 
LV Posterior Wall. RCA = Right Coronary Artery.
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additionally perform a mitral leafl et plication with sutures placed in such a manner 
to approximate the redundant and thickened primary chordae tendinae. The trans-
mitral approach has limited applicability but may be preferred in the paediatric 
group or in patients with a complex type of LV obstruction, due to limitations of the 
transaortic view.
In our institution, a new surgical technique has been developed to treat symp-
tomatic patients with HOCM and an enlarged anterior mitral valve leafl et.95 The 
technique entails septal myectomy in combination with anterior mitral leafl et ex-
tension via a transaortic approach. After myectomy, a gap is created in the anterior 
mitral leafl et trough a longitudinal incision, starting at the subaortic hinge point to-
wards the rough zone. Then, an oval autologous pericardial patch is inserted using 
three running sutures (Figure 4C). The patch creates a horizontal, but not a vertical 
widening of the leafl et. It appears counterintuitive to enlarge a leafl et, which itself is 
already abnormally enlarged (Figure 5). Why then does leafl et extension work? First, 
the pericardial patch is grafted in the center portion of the anterior leafl et, where 
SAM typically reaches a maximum. By extending the patch across the bending point 
of the mitral valve, we hypothesize that we stiff en the central parts of the buckling 
LA
LV
Ao
IVS
PW
LV
LA
Figure 5. Panel A: Post-operative two-dimensional echocardiogram from the apical three chamber long-axis view. The site of the inserted 
pericardial patch is clearly seen (arrow). Residual systolic anterior motion is absent.
Panel B: Two-dimensional echocardiogram from the apical two chamber long-axis view. The echocardiographic still-frame clearly demonstrates 
the pericardial patch, which has been inserted into the anterior mitral valve leafl et (between arrows).
Abbreviations: AO = Ascending Aorta. IVS = InterVentricular Septum. LA = Left Atrium. LV = Left Ventricle. PW = LV Posterior Wall.
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anterior leafl et, preventing abnormal mobility.96-98 Second, stiff ening of the valve 
may counteract Venturi forces. Third, the widening of the leafl et may cause a lateral 
shift of the chordae attaching central portions of the valve, subsequently stretching 
and erecting these chordae thus enhancing leafl et coaptation. Fourth, mitral leaf-
let extension could also add positively to maintenance of valve tethering once the 
streamlines of fl ow are normalized by septal myectomy.81 Recently, we described 
the sustained improvement of this method during long-term follow-up.78
Refi nement and modifi cations of the classical Morrow resection resulted in more 
eff ective surgical methods to treat symptomatic HOCM patients. As previously men-
tioned, complication rates are low and clinical outcome is excellent.77,99
ALTERNATIVE INVASIVE THERAPIES
A subset of patients, who might benefi t from operation, may not be ideal surgi-
cal candidates due to concomitant diseases or advanced age. Others may not have 
access to the few experienced surgical centers. Therefore, two treatment modali-
ties have been proposed as alternatives to surgery. First, dual-chamber pacing was 
considered to be benefi cial in reducing both symptoms and the LVOT gradient.100,101 
Randomized, crossover clinical trials, however, could not confi rm the benefi cial re-
sults of the initial studies: the reduction in LVOT obstruction was unpredictable and 
signifi cantly less when compared to surgical therapy. Besides that, the amelioration 
in functional class was believed to be a placebo eff ect.102,103
Percutaneous transluminal septal myocardial ablation (PTSMA) is another inter-
ventional technique.104 Ethanol is introduced into one or more septal perforator 
branches of the left descending coronary artery (LAD) to produce a localised myo-
cardial infarction, which in turn results in shrinkage of the basal septum, enlarge-
ment of the narrowed LVOT and reduction of the outfl ow gradient and mitral regur-
gitation. The procedure is considered a success if the residual LVOT gradient is <30 
mm Hg or there is at least a 50% reduction in LVOT obstruction immediately after 
the procedure. Due to remodelling of the left ventricle, the LVOT gradient will even 
decrease weeks to months after PTSMA. With regard to clinical outcome, mortality 
(<2%) is comparable to surgical therapy.105-108 Furthermore, non-randomized studies 
show that myectomy and PTSMA are similarly associated with subjective improve-
ment in NYHA functional class.105-107 However, surgery yields a more favourable 
outcome with respect to fewer early complications, greater exercise capacity and 
oxygen consumption and from time to time more complete relief of obstruction.109 
The early complications after PTSMA relate to anterior myocardial infarction due 
to leakage of alcohol in the LAD, dissection of the LAD and myocardial infarction 
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distal to the septal myocardium due to abnormal anatomy of the septal branches. 
The application of myocardial contrast echocardiography (MCE) has diminished 
these complications and adverse results are now reported infrequently.110,111 Yet, 
the risk for permanent pacemaker therapy is up to ten times greater with PTSMA 
as compared to myectomy and the potential risk of life-threatening ventricular 
tachyarrhythmia’s emanating from myocardial necrosis is of particular concern in 
HCM given the unpredictable arrhythmogenic substrate.14,109,112
Until recently, only three studies have compared the results of surgical myectomy 
to PTSMA.105-107 These nonrandomised studies reported that surgical myectomy 
and PTSMA are equally eff ective at reducing LVOT obstruction and lead to similar 
subjective improvements in functional capacity. It is true that the resting LVOT 
gradient is signifi cantly lower in the myectomy group than in the PTSMA group 
after three months,106 but the residual LVOT gradient is comparable one year after 
intervention.105,107 The greatest diff erence comparing the two interventional strate-
gies in these three studies is the incidence of complete heart block necessitating 
permanent pacemaker therapy (2 to 8% after surgery vs. 15 to 24% after PTSMA, 
respectively).105-107 Just recently, Ralph-Edwards et al. reported the results of a non-
randomised study comparing PTSMA versus isolated myectomy.113 There were no 
deaths during post-procedure hospitalization, but during two year follow-up cardi-
ac related death occurred in 6% after PTSMA versus 0% after myectomy underscor-
ing the possibility of late-onset ventricular tachyarrhythmia’s in the presence of a 
healed intramyocardial scar in patients with an already unstable electrophysiologic 
substrate. The patients undergoing PTSMA had signifi cantly higher post-interven-
tional resting LVOT gradients, and the NYHA functional class as well as residual SAM 
were signifi cantly worse. The optimal composite outcome at follow-up, defi ned as 
survival, NYHA functional class I, no post-procedure pacemaker placement, and a 
follow-up resting LVOT gradient of less than 20 mm Hg was noted in 22% of patients 
in the PTSMA group and 73% of patients in the myectomy group.
Recently, we have compared the outcome in HOCM patients with an enlarged an-
terior mitral valve leafl et after PTSMA or surgical intervention in 43 and 29 patients, 
respectively.108 At surgery, myectomy was combined with anterior mitral leafl et ex-
tension, as described before. In our study, the equivalence of PTSMA versus surgery 
was observed with regard to the eff ect on the LVOT obstruction and the improve-
ment in functional class at 1-year follow-up. However, mitral regurgitation and re-
sidual SAM of the mitral valve were less after surgical intervention. Of importance, 
PTSMA was related with more peri-procedural complications and re-interventions 
due to persistence of the LVOT obstruction: death 5% vs. 0%; large anterior myocar-
dial infarction 2% vs. 0%; permanent pacing 9% vs. 0%; re-intervention 9% vs. 3% 
after PTSMA and surgery respectively. 
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At present, septal myectomy remains the gold standard to treat patients with 
HOCM. Structural LVOT anomalies including the mitral apparatus, direct insertion of 
a papillary muscle into the anterior mitral leafl et, fusion of the papillary muscles to 
the ventricular septum, as well as fi brous attachments between the septum and the 
mitral valve may result in persistence of obstruction after PTSMA. During operation, 
the surgeon may widen and reconstruct the LVOT by treating these morphologic 
abnormalities under direct visualisation. PTSMA is a selective alternative to surgery, 
especially in patients without structural anomalies of the mitral valve and subvalvu-
lar apparatus and important comorbidity or at advanced age.114 To defi ne the role of 
PTSMA in the treatment of HOCM, it would be necessary to perform a randomised 
trial in a large population comparing these two treatment modalities.115 However, 
such a study is diffi  cult to achieve due to the heterogeneity of the disease, the lim-
ited number of patients and the many centers required worldwide to obtain suf-
fi cient data in a reasonable time span.115
ISSUES OF SPECIAL INTEREST
Pregnancy
Pregnancy is accompanied by major physiological changes. Cardiac output increas-
es by 30 to 50% due to augmentation in plasma volume, there is a modest increase 
in heart rate and a decrease in peripheral resistance. In addition, cardiac output 
increases by a further 20% during labour due to increased venous return with each 
uterine contraction and sympathetic response to stress and pain.116,117 These physio-
logical demands may be expected to aff ect the course of pregnancy. However, most 
data suggest that pregnancy is generally well tolerated in HCM patients despite the 
often marked hypertrophy, the diastolic dysfunction and the LVOT obstruction in 
the HCM-aff ected heart.14,116-118 In asymptomatic patients, clinical deterioration dur-
ing pregnancy is uncommon.118 Yet, in patients with cardiac complaints before preg-
nancy, progression of symptoms of heart failure may occur in a minority of patients. 
Careful monitoring and collaboration with a dedicated cardiologist may minimize 
complications in patients who have signs of heart failure. Maternal mortality ap-
pears to be confi ned to women with a high-risk clinical profi le.14
Endocarditis
Infective endocarditis is a known, yet uncommon complication of HCM.119 Endo-
carditis in HCM is almost exclusively confi ned to patients with a LVOT obstruction 
under basal conditions and to nonobstructive patients with intrinsic mitral valve 
disease, such as mitral valve prolapse.14,119 In most cases, the site of vegetations is the 
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anterior mitral valve leafl et. However, vegetations can also be present on the aor-
tic valve or the endocardium of the LVOT at the point of mitral-septal contact.120,121 
Patients with the nonobstructive type of HCM, including those with a LVOT obstruc-
tion under provocation, are at negligible risk for endocarditis and consequently do 
not require prophylaxis.119 Antibiotic prophylaxis for endocarditis is only indicated 
in patients with the obstructive type of HCM and in patients with intrinsic mitral 
valve disease.
Participation in sport
Although SD is a long-recognized entity in HCM, the recent deaths of several well-
known athletes have focused new attention on this devastating and often unpre-
dictable complication of HCM. Several studies have found that HCM is the principal 
cause of SD in young athletes under 35 years of age, accounting for approximately 
one third of cardiac arrests in the USA.122-124 SD in HCM is usually the result of an 
interaction between triggers (myocardial ischemia, diastolic dysfunction, LVOT ob-
struction, systemic arterial hypotension and supraventricular tachyarrhythmias) and 
an unstable electrophysiological substrate (myocardial disarray, myocardial fi brosis 
and expansion of the interstitial collagen compartment) which may lead to fatal ven-
tricular tachyarrhythmias.14,56 Physical exertion may also constitute a trigger of SD in 
patients with HCM and there is indirect evidence that identifi cation and disqualifi -
cation of individuals with HCM from competitive sports may prevent SD.7,14,124,125 In 
the 26th Bethesda conference report guidelines are presented for athletic eligibility 
or withdrawal of the athletes from sports. The guidelines state that young athletes 
with HCM are discouraged from participating in competitive sports, with the excep-
tion of low-intensity sports such as walking, golf and bowling.126,127 For older ath-
letes (>35 years), a less restrictive policy is probably a more proper approach. If risk 
factors for SD are absent, modest, nonvigorous physical activities may be permitted. 
There is no evidence that genetically aff ected family members without phenotypi-
cal expression of the disease are at increased risk for SD. Therefore, in the absence of 
a family history of SD and cardiac symptoms, participation in sports activities is not 
discouraged in these individuals.14 The incidence of SD from cardiovascular diseases 
in young athletes is as low as 1 to 2 in 100.000 athletes. This means that extensive 
pre-participation screening is not feasible in this population considering the cost-
benefi t relation and the expected large numbers of false-positive results. In 2004, 
a meeting of the ad-hoc working group on Sudden Cardiovascular Death in sport, 
held under the umbrella of the International Olympic Committee, discussed about 
measures that can help prevent SD. The results were summarized in the “Lausanne 
Recommendations”, which seek to identify athletes at risk of sudden cardiac death 
in order to advise them accordingly. The most important recommendation com-
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prises cardiovascular screening of young competitive athletes before participation, 
including questions concerning the athletes’ personal and family history, a physical 
examination and a 12-lead ECG. The European Society of Cardiology recommends 
similar measures in a consensus document concerning pre-participation screening 
of young competitive athletes for prevention of sudden death122. The recommenda-
tions can detect patients with a cardiovascular disease like HCM and prevent fatal 
events by excluding these individuals from sport participation.123
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ABSTRACT
Objectives. This study evaluates the clinical course and identifi es risk factors for 
sudden cardiac death and clinical deterioration in hypertrophic cardiomyopathy 
(HCM) in a large community-based population. Comparison was made with data 
from 6 tertiary referral and six non-referral institutions.
Background. HCM is a disease with marked heterogeneity in clinical presentation 
and prognosis. Risk factors for sudden cardiac death are not well defi ned in patients 
free of referral bias. 
Methods. Between 1970 and 1999, 225 consecutive patients, mean age (± SD) 41 ± 
16 years, were examined and followed at yearly intervals.
Results. Forty-four deaths were recorded of which 27 cases were cardiovascular. 
Fourteen patients died suddenly, six were successfully resuscitated and seven pa-
tients died of congestive heart failure. The annual mortality, the annual cardiac mor-
tality and annual mortality due to sudden death were 1.3%, 0.8% and 0.6% respec-
tively. At least one New York Heart Association (NYHA) functional class deterioration 
was reported in 33% of the patients with a signifi cant (≥ 50 mm Hg) left ventricular 
outfl ow tract (LVOT) gradient in contrast to 7% without obstruction. The presence 
of syncope was related to sudden cardiac death (p<0.05). Younger age and more 
severe functional limitation discriminates patients from in hospital-based centers 
from the ones in community-based centers. 
Conclusions. HCM is a benign disease in an unselected population with a low inci-
dence of cardiac death. Syncope was associated with a higher incidence of sudden 
cardiac death and patients with a signifi cant LVOT obstruction were more suscep-
tible to clinical deterioration.
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INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is a complex cardiac disease with a hetero-
geneous genetic, morphologic and clinical spectrum.1,2 In recent years, numerous 
mutations in diff erent genes, encoding for proteins of the cardiac sarcomere, have 
been found to be responsible for this disease.3-6 Unfortunately, the same mutation 
will not always result in identical morphological and clinical features.7,8 Environmen-
tal as well as genetic factors may modify the phenotypic expression of the mutated 
gene.3,8,9 
The diverse clinical and genetic characteristics make it diffi  cult to establish gen-
eral guidelines for the treatment of symptoms and to predict which patient is prone 
to sudden death. Most of our knowledge concerning the natural history and risk for 
premature sudden cardiac death (SCD) has been derived from the study of hospi-
tal-based populations.10-18 These studies reported an annual mortality rate of 2 to 
4% in adults and 6% in children. However, the clinical outcome and perception of 
risk factors in HCM is profoundly aff ected by a bias in patient selection.19 Studies 
from non-referral centers suggested a more benign clinical course and fairly favor-
able prognosis with an annual mortality of ≤ 1%.20-26 However, risk factors for SCD 
in patients with HCM have not been extensively studied in these community-based 
populations. The purpose of the present study was to evaluate the clinical course 
and to identify the presence of risk factors for SCD and clinical deterioration in a 
population of relatively unselected patients with HCM.
We compare our results with the results from hospital-based and community-
based populations.
METHODS
Patient selection
Before 1979, only M-mode echo and 2 DE and no Doppler were available in our insti-
tution and the diagnosis of HCM was also made by the presence of typical clinical, 
electrocardiographic and/or angiographic fi ndings. The diagnosis of HCM was later 
on based on the echocardiographic fi nding of a non-dilated hypertrophic left ven-
tricle in the absence of diseases known to cause ventricular hypertrophy1,2 Patients 
who visit our HC clinic are relatively unselected and consist of patients who are: 
1) diagnosed and treated at our centre; 2) referred from the community for estab-
lishment of the diagnosis or advice on management; 3) transferred from outlying 
hospitals for advanced care; 4) self-referred family-members of patients.
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Follow-up
Between 1970 and 1999, 225 consecutive patients were examined initially and fol-
lowed at yearly intervals. The population included 113 patients reported earlier.22 
The other 112 patients consisted of patients who were brought to our attention 
from 1990. At fi rst visit, clinical characteristics including age at diagnosis of HCM, 
family history of HCM or sudden death in a fi rst degree relative at a young age (<40 
years), or both, symptoms, New York Heart Association (NYHA) functional class and 
the drugs prescribed, were recorded. Physical examination and baseline laboratory 
studies were performed including ECG, M-mode and two-dimensional echocar-
diography (as well as Doppler echocardiography after 1985) and in the majority of 
patient’s 24-hour ambulatory Holter monitoring was carried out. Cardiac catheter-
ization was performed only in patients with symptoms refractory to medical therapy 
in whom surgical treatment was considered. Follow-up information was obtained 
within 6 months from August 1999 at the outpatient clinic or, if the patient moved 
out of Rotterdam, from their private cardiologist. No patient was lost to follow-up. 
Cardiac death was defi ned as death caused by congestive heart failure or sudden 
death. All deaths witnessed within one hour of onset of symptoms or in subjects 
known to be normal functioning 24 hours before, were assumed to be SCD. Patients, 
who were successfully reanimated after cardiac arrest during follow-up, were classi-
fi ed as SCD for the purpose of analysis.
Review of the literature on prognosis in patients with HCM
To compare our study fi ndings, we reviewed the literature on prognosis in HCM in 
both hospital-based and community-based institutions. A total of 9 studies from 6 
hospital-based centres and 6 studies from 6 community-based centres were found 
for comparison. 
Statistics
Data are expressed as mean value ± SD. Cumulative survival estimates and 95% 
confi dence intervals (CIs) were calculated according to the Kaplan-Meier method. 
Among patients subgroups the log-rank test was used to evaluate diff erences in 
survival between subgroups. The yearly cumulative mortality rate was calculated on 
the basis of all available follow-up time. To assess risk factors for cardiac death and 
clinical deterioration univariate and multivariate analysis was performed using the 
Cox regression model.
The chi-squared test was used to compare clinical characteristics from referral and 
non-referral centers.
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RESULTS
Baseline characteristics
The clinical characteristics of the 225 patients with HCM are listed in Table 1. The 
majority of the patients were male (n = 130). At fi rst visit, 63 patients (28%) were 
younger than 30 years and 20 (9%) were older than 65 years. The mean age (± SD) at 
diagnosis of HCM was 37 ± 17 years and 41 ± 16 years at presentation to our institu-
tion. A positive family history of HCM was present in 110 patients (49%), of whom 
52 patients (23%) also reported a sudden death in a fi rst degree relative. Reported 
symptoms included angina in 58 patients (26%), dyspnea in 81(36%), syncope in 43 
(19%) and palpitations in 43 patients (19%). At presentation, 100 patients (44%) were 
Table 1. Baseline characteristics of 225 patients with HCM.
Number (%)
Patients 225
Male/Female 130 (58%) / 95 (42%)
Age (y)
 <30
 30-65
 >65
 63 (28%)
142 (63%)
 20 (9%)
mean age (years ± SD)
 at diagnosis
 at initial visit
 37 ± 17
 41 ± 16
Family history
 Positive
 Positive + SD
110 (49%)
 52 (23%)
Symptoms
 Angina pectoris
 Dyspnea
 Syncope
 58 (26%)
 81 (36%)
 43 (19%)
NYHA
 I
 II
 III
 IV
100 (44%)
101 (45%)
 24 (11%)
  0
Therapy
 Beta-blocker
 Ca-antagonist
 Beta-blocker and Ca-antagonist
 Antiarhythmics
 Other
 No medication
 47 (21%)
 72 (32%)
 16 (7%)
 18 (8%)
 11 (5%)
 61 (27%)
Interventricular septal width
 ≥ 25 mm
 < 25 mm
 30 (13%)
195 (87%)
LVOT gradient (mm Hg)
 ≥ 50 mmHg (at rest/provocation)  98 (44%)
48
C
ha
p
te
r 3
asymptomatic or had trivial symptoms (NYHA functional class I), 101 patients (45%) 
had mild symptoms of exertional angina and/or dyspnea (class II) and 24 patients 
(11%) were moderately symptomatic (class III). Initially, patients were treated with 
beta-blocking agents, calcium antagonists, a combination of beta-blocking agents 
and calcium antagonists, antiarrhytmics or other cardiac therapy in 47 (21%), 72 
(32%), 16 (7%), 18 (8%) and 11 patients (5%) respectively. Sixty-one patients (27%) 
did not take medication. 
At echocardiography, mean interventricular septum width was 21 ± 4 mm (range 
16 - 40 mm), thirty patients (13%) had marked left ventricular hypertrophy (inter-
ventricular septal width ≥ 25 mm). Left ventricular outfl ow tract (LVOT) gradient, at 
rest or provocation was ≥ 50 mmHg in 98 patients (44%), as determined by Dop-
pler echocardiography or cardiac catheterization. At the initial visit, 7 patients (3%) 
presented with persistent atrial fi brillation (AF). Episodes of ventricular tachycardia 
(VT) on 24-hour ambulatory Holter monitoring were registered in 73 of the 149 pa-
tients, in whom recordings were available. At presentation, two patients had been 
treated by septal myectomy for LVOT obstruction.
Clinical outcome
During follow-up 44 deaths were reported. Twenty-seven deaths (mean age 49 ± 
17 years) could be attributed to cardiovascular causes: 20 (mean age 44 ± 15 years) 
of these died suddenly, of whom 6 were successfully resuscitated from a witnessed 
cardiac arrest and 7 patients (mean age 64 ± 10 years) died of congestive heart 
failure (3 patients underwent orthotopic heart transplantation which is considered 
a heart failure death). Seventeen patients (mean age 63 ± 16 years) died of non-car-
diac causes: four patients died from cerebrovascular accidents and thirteen deaths 
0 5 10 15 20
years
0
20
40
60
80%
100
225 129 69 41 18 
Patients with 
HCM
General
population
Probability of cardiac survival % 
Figure 1. Kaplan-Meier survival curve of 225 patients with hypertrophic cardiomyopathy (HCM) and aged-matched controls. Numbers above 
horizontal axis refer to number of patients at each follow-up period.
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were associated with chronic obstructive lung disease (3 patients) or malignant 
diseases (10 patients). The annual mortality, the annual cardiac mortality and the 
annual mortality for sudden death was 1.3%, 0.8% and 0.6% respectively. The 5, 10 
and 15 years cumulative cardiac survival in our population was 96%, 91% and 78% 
respectively (Figure 1).
During follow-up, 57 patients underwent septal myectomy, either alone (29 pa-
tients) or in combination with anterior mitral leafl et extension (22 patients)27, mitral 
valve replacement (3 patients) or coronary artery bypass grafting (3 patients). There 
was 1 perioperative death. After surgical intervention, fourty-seven patients (82%) 
had improvement of symptoms and 36 patients (63%) were symptom-free. A total 
of 10 patients had implantation of a permanent pacemaker, three because of post-
operative AV-block, three for sick sinus syndrome, three for treatment of the LVOT 
obstruction and one patient received an implantable cardioverter-defi brillator after 
successfully treated ventricular fi brillation.
Magnitude of left ventricular hypertrophy
Thirty patients had marked left ventricular hypertrophy at presentation. SCD was 
demonstrated in 5 of these patients (17%) compared to sudden death of 15 (13%) 
in 195 patients without marked hypertrophy. There was no signifi cant diff erence in 
survival for patients with or without marked left ventricular hypertrophy (p = 0.10 
and p = 0.13 respectively). 
Presence of LVOT obstruction
At the initial evaluation, 98 patients had a LVOT obstruction. SCD was established 
in 10 (10%) of 98 patients with obstruction and in 10 (8%) of 127 patients without 
obstruction respectively. No diff erences in cardiac death and SCD were found for 
this variable. During follow-up (mean 7.5 ± 7 years) deterioration in at least one 
functional NYHA class was experienced by 33 patients (33%) with a LVOT gradient 
and in the 57 patients who underwent septal myectomy functional deterioration 
was present in 24 cases (42%) (fi gure 2). In contrast, only 9 patients (7%) had func-
tional deterioration in the non-obstructive group of 127 patients (mean follow-up 
8.4 ± 6.7 years) (fi gure 3). In the patients who had surgery, the LVOT gradient did not 
change over time. However, “end stage” disease with deteriorated systolic function 
was established in 4 of the 41 not-operated patients with a LVOT obstruction. 
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NYHA  I
NYHA II
NYHA III
NYHA IV
27 (10) 19 36
52 (33)
Initial
visit
Latest visit or
before surgery
40 (26)
19 (14) 37 (31)
2
19
1
1 died
perioperative
After
surgery
14
9(6)
4(4)
5
28(19)
18 (14)
1
3(1)
15(13)
1
17
8
1
19 11
1
Figure 2. Chart showing New York Heart Association (NYHA) classifi cation in patients with a left ventricular outfl ow tract gradient of ≥ 50 
mm Hg at rest or provocation. The total number of patients with obstructive hypertrophic cardiomyopathy is expressed in bold (n = 98). The 
patients treated by surgical therapy are expressed in italics (n = 57). The fi rst column represents the NYHA class of the patients at presentation 
to our institution. The second column represents the NYHA class of nonoperated patients at their latest visit or the NYHA class of patients treated 
by surgery just before operation. The third column represents the NYHA class of patients treated by surgery at their latest visit.
75
47
5 4
39
84NYHA I
NYHA II
NYHA III
Initial visit Latest visit
68
7
15
30
2
1
2
2
Figure 3. Chart showing New York Heart Association (NYHA) functional classifi cation in 127 patients without a left ventricular outfl ow tract 
gradient. The fi rst column represents the NYHA class of the patients at presentation to our institution. The second column represents the NYHA 
class of the patients at their latest visit.
Presence of AF
At the latest visit, 24 patients (mean age 57 ± 11 years) had persistent AF. Persistent 
AF was present at initial evaluation in 7 patients. Cardiac death and SCD was noted 
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in 4 (16%) and 2 (8%) patients with persistent AF compared to 23 (11%) and 18 (9%) 
patients in sinus rhythm, p = 0.49 and p = 0.89 respectively. The presence of AF 
had no infl uence on functional deterioration as assessed by the NYHA classifi cation; 
p = 0.10. One patient with persistent AF died from an ischemic cerebrovascular ac-
cident. 
Presence of VT
Episodes of non-sustained and/or sustained VT on 24-hour Holter monitoring were 
present in 73 of 149 patients in whom one or more recordings were available. SCD 
was established in 8 (11%) patients with VT and 6 (8%) patients without VT on 24-
hour Holter monitoring respectively. There was no signifi cant diff erence in cardiac 
death and SCD in patients with VT on 24-hour Holter monitoring, p = 0.76 and p = 
0.78 respectively. Sustained VT was demonstrated in only 7 patients of whom one 
patient died suddenly. 
Multivariate statistical analysis
For the purpose of analysis, patients were divided according to known or suspected 
risk factors for SCD including age, family history of HCM and/or sudden death, his-
tory of syncope, NYHA classifi cation, presence of AF, presence of VT on 24-hour 
ambulatory monitoring, severe left ventricular hypertrophy (≥ 25 mm) and LVOT 
obstruction (≥ 50 mm Hg). By multivariate analysis, only syncope was an indepen-
dent predictor for SCD: RR 4.3 (95% confi dence interval 1.8-5.9). Furthermore, only a 
LVOT obstruction was an independent predictor for functional deterioration during 
the follow-up period: RR 1.16 (95% CI 1.08 – 1.25) for every increase of 10 mm Hg.
Review of the literature on prognosis in HCM
Nine reports originated from 6 referral centers and as a consequence the population 
in these studies consisted of highly selected patients (Table 2).13-21 In the other six 
reports patients came from 6 nonreferral centers and in these studies the popula-
tion was considered non-selected (Table 3).22-27
From the available data it can be appreciated that both annual mortality and an-
nual cardiac mortality is distinctly higher in referral centers compared with non-
referral centers, 2.4% to 5.9% versus 0.0% to 2.0% and 1.5% to 3.5% versus 0.0% 
to 1.3% respectively. In general, the most striking diff erences comparing baseline 
characteristics in hospital-based and community-based populations were the 
younger age and the more severe functional impairment of patients in referral cen-
ters (p<0.001 and p<0.001 respectively). This might well produce the discrepancy in 
clinical outcome in selected patients. 
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DISCUSSION
The natural history of HCM has been the subject of much debate among research-
ers. Observational studies from tertiary referral centres have estimated the annual 
cardiac death to be 2-4% in adults10-17 and as high as 6% in children.13,28 These stud-
ies from major referral institutions have been infl uenced by selection biases.19 In 
community-based studies, patients with HCM have a more favourable prognosis 
with an annual mortality of approximately 1 percent.20-26 
Patient-selection biases might lead to misleading conclusions about the signifi -
cance of risk factors for sudden death. The present study investigates the role of risk 
factors for sudden death in a community-based population of patients with HCM.
Clinical characteristics in selected and unselected patients
At the time of the initial visit, mean age was 41 years and almost 90% of the patients 
had no or mild cardiac symptoms. These fi ndings are comparable with two other 
large unselected community-based trials from Cecchi et al.24 and Kyriadikis et al.25 
and in contrast with the fi ndings in tertiary referral centres. This dissimilarity in clini-
cal characteristics has undoubtedly infl uenced clinical outcome. However, we can 
only speculate how younger age and more severe functional limitation adversely 
infl uence prognosis in hospital-based patients with HCM. A malignant family his-
tory with sudden death at young age or surviving cardiac arrest and presence and 
symptoms of HCM in the very young have been related with adverse outcome and 
this might persuade the general cardiologist to refer these patients to institutions 
known to have special interest in HCM.1 Second, the management of patients with 
HCM is diffi  cult once symptoms appear. Myocardial ischemia, abnormal diastolic 
function and LVOT obstruction may all result in symptoms of angina, dyspnea and 
syncope.1 The contribution of each of these mechanisms to the clinical picture dif-
fers from patient to patient. The general cardiologist may choose to refer the patient 
if his client becomes severely symptomatic.1 
Clinical outcome and risk factors for sudden death
The annual cardiac mortality in our study was 0.8%. Cardiac death is caused by heart 
failure or occurs sudden and unexpected. Many HCM patients who die suddenly are 
adolescent persons or young adults and have previously been symptom-free.29 The 
stratifi cation of risk of sudden death remains unsettled. There seems to be agreement 
among investigators that there is a small subgroup of patients who are particularly 
at high risk for sudden death. Especially, patients who have survived cardiac arrest, 
young patients with a family history of multiple sudden cardiac deaths and those 
with a malignant gene mutation are at substantial risk for premature death. Young 
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age11,13,15, syncope13,30, family history of HCM and SCD13,30, functional cardiovascular 
status13, presence of VT17, positive exercise test15,31, presence of a LVOT gradient18, 
marked left ventricular hypertrophy32 and an abnormal blood pressure response 
during exercise33 are also reported as risk factors of SCD. These data are derived 
from hospital-based populations and are therefore infl uenced by referral bias. The 
latter phenomenon plays a less important role in community-based populations 
with HCM.
However, none of the community-based institutions have examined the role of 
risk factors for sudden death. In the studies by Cecchi et al. and Kyriakis et al. risk 
factors for combined sudden and heart failure-related HCM death were reported. 
Nevertheless, it is obvious that the process leading to death in patients with in-
tractable congestive heart failure diff ers from the mechanism causing sudden 
unexpected death in patients with HCM. Heart failure results from systolic and/or 
diastolic dysfunction and SCD results from ventricular tachycardia or fi brillation, 
either as a primary event or as a secondary phenomenon triggered by myocardial 
ischemia, diastolic dysfunction, LVOT obstruction, hypotension or supraventricular 
tachycardia.1,34 In our study, risk factors for cardiac death due to congestive heart 
failure could not be detected. However, syncope was associated with SCD at multi-
variate analysis.
Syncope is a complex entity since several mechanisms may be responsible for this 
symptom including supraventricular and ventricular tachyarrhythmias, bradyar-
rhythmias, heart block, diastolic dysfunction, myocardial ischemia, autonomic dys-
function and LVOT obstruction. Since the contribution of each of these mechanisms 
diff ers from patient to patient the treatment of syncope must be individualized. 
At multivariate analysis, only a signifi cant LVOT gradient was related to deteriora-
tion in functional state.
Study limitations
HCM can be caused by a mutation in one of the genes that encode proteins of the 
cardiac sarcomere. At present, there are obstacles to the translation of HCM genetic 
research into practical clinical applications and routine clinical strategy. Exercise-
induced hypotension is common in young patients with HCM and this fi nding has 
been associated with an increased risk of sudden death. However, until 1999 we did 
not routinely perform exercise-tests in patients with HCM.
Conclusions
The results in our study show that prognosis of HCM in a community-based popula-
tion is benign and confi rm the current opinion on the natural history in HCM. The 
most striking fi nding was a substantial diff erence in the clinical stability of patients 
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with and without LVOT obstruction. In non-obstructive patients, a prolonged stable 
clinical course is noticed. In obstructive patients, we found a progressive decline in 
functional status during follow-up. Furthermore, syncope was the only risk factor 
associated with sudden death.
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INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is a heterogeneous disease in respect to 
genetics, morphology and clinical appearance. In 1957, Brock fi rst described the 
disease as a clinical entity, which is characterized by a non-dilated, hypertrophied 
left ventricle (LV) in the absence of underlying pathology, such as hypertension or 
aortic valve stenosis.1,2 
Within the past years, HCM has been object of extensive research. The insights in 
prevalence and natural history of this disease have been enlarged. In this report, we 
give an overview of the various facets with special attention to prevalence, clinical 
presentation, prognosis and treatment modalities. First, we describe the anatomy 
and genetic changes that characterize this cardiac disease.
Anatomy
HCM is usually diagnosed using two-dimensional echocardiography, which will 
demonstrate the characteristic features of asymmetrical, myocardial hypertrophy. 
The hypertrophy usually becomes apparent before adolescence but a normal echo-
cardiogram at adultery does not exclude the development of hypertrophy at a later 
period in life, since development of HCM at an advanced age has been described.3,4
In the Western world, 90% of the patients demonstrate hypertrophy either in 
the septum and/or the lateral border of the LV.5,6 Normally, the thickness of the left 
ventricular wall is less than 11 millimetres whereas in HCM patients, it may exceed 
15 millimetres. In approximately 5% of Western patients, hypertrophy is solely re-
stricted to the LV apex. Apical HCM, however, is found in almost three-quarters of 
the Asian HCM patients.7
The site of hypertrophy is also of prognostic signifi cance: apical HCM is associ-
ated with a benign prognosis.8 Besides myocardial hypertrophy, HCM expresses 
several other distinctive features such as a chaotic structure of the myocardial fi bres 
(myocardial disarray)9, small vessel disease with thickening of the media wall10 and 
myocardial fi brosis presumably due to micro-infarctions.11 The mitral valvular appa-
ratus frequently demonstrates abnormalities, including enlargement and abnormal 
mobility of the anterior mitral valve leafl et (AMVL).12
HCM can be divided into two types: an obstructive and a non-obstructive from. 
Approximately, 25% of the patients demonstrate the obstructive form. The fl ow 
obstruction, which begins at the level of the left ventricular outfl ow tract (LVOT), 
is caused by the hypertrophied septum that bulges into the LVOT and an abnormal 
mobility of the AMVL, which is dragged into the LVOT. The echocardiographic still-
frame (Figure 1) demonstrates the bending of the AMVL towards the septum during 
systole. This phenomenon is called systolic anterior motion.
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The LVOT gradient is dynamic, i.e. it can fl uctuate over time. The severity of the 
obstruction is dependent on several factors, i.e. activation of the sympathetic ner-
vus system, physical activity of the patient or blood pressure. Physical exercise for 
instance increases both pulse rate and myocardial contractility, which will result in 
an increase of the LVOT gradient.
The gradient can be measured non-invasively, using transthoracic echocardiog-
raphy, at the level of the LVOT and it is expressed as a velocity value (in meters 
per second). At the catheterization laboratory, the gradient is determined using an 
invasive method. After positioning a catheter in the cavity of the LV, the ventricular 
pressure is measured. Then, the catheter is pulled back into the LVOT and the aorta 
ascendens, respectively. This allows determination of the diff erence in pressure be-
tween the LV and the LVOT, which is representative for the LVOT gradient. The pull 
back of the catheter into the aorta ascendens allows separate determination of a 
pressure gradient over the aortic valve.
Non-obstructive HCM may be divided according to the left ventricular systolic 
function, which can either be normal or reduced. The reduced systolic LV function 
LV
IVS
Ao
LA
Figure 1. Transthoracic echocardiographic still-frame. Apical 3-chamber view. The arrow indicates the site of systolic anterior motion of the 
anterior mitral valve leafl et. Outfl ow tract obstruction is created in the presence of septal hypertrophy and systolic anterior motion.
Ao = Aorta Ascendens. IVS = InterVentricular Septum. LA = Left Atrium. LV = Left Ventricle.
Hypertrophic cardiomyopathy: a fascinating disease with a benign prognosis 63
in this HCM form may be caused by myocardial ischemia or infarctions. HCM may 
eventually progress to a dilated cardiomyopathy.13 
Genetics
Familiar HCM is characterized by gene mutations encoding for cardiac sarcomeric 
proteins of the contractile apparatus.14 The disease is characterized by a dominant, 
autosomal inheritance pattern.
Momentarily, more than 100 diff erent mutations located on 8 diff erent genes 
have been identifi ed. Several authors have investigated the correlation between 
genotype and phenotypical expression. In other words, the authors investigated 
whether a specifi c mutation in HCM individuals or family members leads to a spe-
cifi c disease expression and/or prognosis.15,16 The outcome of these investigations, 
however, demonstrated again the heterogeneity of HCM. Although certain genetic 
mutations seem to negatively infl uence prognosis of certain families, no linear cor-
relation has been found between unrelated patients, who had identical genetic mu-
tations. Apparently, lifestyle, risk-factors and (environmental) modifi er-genes may 
infl uence the prognosis of the patient.
Prevalence
In several echocardiographic surveys, the prevalence of HCM in the Western world 
has been estimated at 1 in 500 persons.17,18 Theoretically, determination of gene mu-
tations would be a more precise method to estimate the prevalence of HCM since 
certain individuals are carrier of a genetic mutation without expressing the disease. 
In practice, however, genetic screening is expensive and labour intensive. Besides, 
this method would only be eff ective if all HCM mutations were known.
CLINICAL PRESENTATION
The majority of HCM patients are asymptomatic. Referral to the HCM outpatient 
clinic is often initiated after the incidental detection of a cardiac murmur or as a 
screening routine after the diagnosis of HCM has been established in a family mem-
ber. Physical examination usually does not reveal the diagnosis although a typical 
cardiac murmur may be present during systole, which may be aggravated with the 
Valsalva manoeuvre. A mitral regurgitation murmur may be noted, often in patients 
who also demonstrate a systolic anterior motion on 2-D echocardiography. The 12-
lead electrocardiogram is abnormal in approximately 75% of the HCM patients. It 
usually indicates the presence of left ventricular hypertrophy but signs of patho-
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logical Q-waves or left atrial enlarged may also be present. The electrocardiogram of 
patients with apical HCM typically demonstrates “giant negative T-waves”.
The most striking complication of HCM is sudden cardiac death (SCD), which can 
occur in any HCM patient, independent of the presence of complaints or the type 
of hypertrophy.
Symptoms include angina pectoris, dyspnoea, and palpitations or (near-) syncope 
and may be aggravated by several mechanisms including:
1) Abnormal diastolic function. During diastole, blood enters the LV cavity. In the 
presence of diastolic dysfunction, blood entrance into the LV is impaired. The left 
ventricular pressures in these patients are usually raised and the amount of blood 
that enters the ventricle during diastole is reduced. During exercise, pulse rate in-
creases and the diastolic fi lling period (i.e. the time interval during which blood en-
ters the LV) is shortened. This results in a reduction of stroke volume. Also, diastolic 
dysfunction may result in raised pulmonary pressure, which consequently leads to 
symptoms of dyspnoea.
2) Left ventricular outfl ow tract obstruction. LVOT obstruction develops during ven-
tricular contraction (systole). Contractile forces are increased in the presence of a 
gradient and raise the left ventricular oxygen demand. This may cause a disruption 
of the balance between oxygen delivery and consumption, which results in symp-
toms of angina pectoris. If the gradient is extremely high, the ejection fraction may 
be substantially impaired causing hypotension and syncope.
Hypertrophic cardiomyopathy
LVOTG Diast. dysfunctionĹLV mass
Myocardial ischemia
Small VD
Figure 2.  Simplifi ed scheme of factors, which might induce or promote myocardial ischemia in HCM.
↑ LV = increased Left Ventricular mass due to hypertrophy. VD = Vessel Disease. LVOTG = Left Ventricular Outfl ow Tract Gradient. Diast = 
Diastolic.
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3) Myocardial ischemia without coronary artery disease. HCM patients often demon-
strate small vessel disease. The luminal diameter of the intramural coronary vessels 
is often reduced due to thickening of the media. This as well as other factors (fi gure 
2) may cause reduced oxygen delivery to the myocardium resulting in complaints 
of severe angina pectoris.
Each of the above mentioned factors might contribute to the patients’ symptoms. 
The infl uence as well as the contribution of each of these factors needs to be as-
sessed in the individual patient to optimize medical or invasive therapy.
PROGNOSIS
The natural history of HCM has been object of extensive research. Until recently, 
annual cardiac mortality was estimated at 2 to 6% for adults and at 4 to 6% for chil-
dren.19 These data, however, appeared to be derived from hospital-based popula-
tions including severely symptomatic patients who were referred to tertiary centers 
for advanced care. These patients are not comparable to the “average” HCM patient. 
Recent analysis from non-referral centers demonstrated that the natural history of 
HCM follows a more benign course. Annual cardiac mortality is now estimated at 
0.6 to 1%. The risk of SCD is dramatically lower as previously estimated. Analysis 
of 225 patients, followed at our HCM outpatient clinic, demonstrated an annual 
cardiac mortality of 0.8% (Table 1). Patients in this group are relatively unselected 
and consist of patients who are: 1) diagnosed and treated at our center; 2) referred 
from the com munity for establishment of the diagnosis or advice on management; 
Table 1. Cumulative survival diagram of 225 unselected HCM patients followed at our HCM outpatient clinic. Figures above the horizontal axis 
indicate the patients “at risk”. The annual cardiac mortality is 0.8%. Survival rates after 5, 10, 15 years are 96%, 90% and 78%, respectively.
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3) transferred from outlying hospitals for advanced care; 4) self-referred family-
members of patients.
Risk stratifi cation for sudden cardiac death
The most striking complication in HCM patients is SCD. Although only a minority 
of the HCM population is at high risk for SCD, each individual patient should be 
carefully screened for risk factors. Patients at increased risk for SCD are: 1) survivors 
of “out-of-hospital” cardiac arrest,20,21 2) those with a positive family history of SCD22 
or 3) those with malignant genetic mutations23. The infl uence of the third factor is 
still subject of debate. Other proposed factors to increase the risk for SCD include 
the presence of: 1) symptoms at a young age,24 2) syncopal attacks,25 3) (non-)sus-
tained ventricular tachycardia at 24-hours ambulatory ECG monitoring,26 4) atrial 
fi brillation,27 5) a signifi cant LVOT gradient28 or 6) exercise-induced hypotension.29 
The contribution of each factor, however, is currently unknown. 
An automatic implantable cardioverter defi brillator (ICD) is the only device which 
has proven to alter the natural history of HCM. Candidates for ICD implantation are 
patients who were successfully resuscitated from “out-of-hospital” cardiac arrest, 
who experienced syncope due to ventricular arrhythmias or had a recording of 
sustained ventricular tachycardia (lasting more than 30 seconds) during 24-hours 
ambulatory ECG monitoring.
TREATMENT STRATEGIES
Table 2 demonstrates a therapeutic fl owchart for HCM patients. The choice of treat-
ment mainly depends on the severity of symptoms and/or the presence of a signifi -
cant LVOT obstruction (≥ 50 mm Hg).
Non-obstructive hypertrophic cardiomyopathy
Merely three-quarters of HCM patients do not demonstrate a LVOT gradient. These 
patients are initially screened for risk factors and followed at the outpatient. In the 
presence of complaints, i.e. angina or dyspnoea, patients are treated with either 
beta-blockers or calcium antagonists. Both drugs reduce cardiac oxygen consump-
tion by lowering the pulse rate and cardiac contractility. Besides, blood fl ow into 
the LV during diastole will improve. Thus, symptoms of dyspnea or dizziness may be 
reduced.30-32 In patients who remain symptomatic, beta-blockers may be combined 
with calcium antagonists. Of notice, medical therapy has not proven to be of posi-
tive infl uence on the prognosis of HCM.
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Treatment of patients with HCM and a reduced LV systolic function is similar to 
patients with heart failure, including ACE-inhibitors, diuretics or possibly digitalis.33
Obstructive hypertrophic cardiomyopathy
Symptomatic patients with HOCM are initially treated with beta-blockers, calcium 
antagonists or a combination of these drugs. Calcium antagonists, however, must 
be prescribed with caution since the drug may aggravate the LVOT gradient due to 
arterial vasodilatation.34 Patients, who remain symptomatic despite optimal medical 
treatment in the presence of a LVOT gradient of at least 50 mm Hg, are candidates for 
invasive treatment. At present, several invasive procedures have been proposed. 
1) Surgical treatment (septal myectomy). Cleland described the fi rst invasive proce-
dure to treat HOCM patients, further developments were accomplished by Morrow in 
the late 60’s.35,36 The technique entails partial removal of the hypertrophied septum 
to enlarge the LVOT outfl ow tract. In the vast majority of patients, septal myectomy 
results in reduction of the LVOT gradient and leads to a dramatic improvement of 
symptoms.37,38 The increase in surgical experience has lowered operative mortality 
from 8% to less than 2%. Furthermore, refi nement of the surgical technique has de-
creased the operative complication rate. Surgery, however, may be encountered by 
several complications, including 1) conduction disturbances necessitating the im-
Table 2. Therapeutic fl ow chart as used in our HCM outpatient clinic. 
DDD-pacing = Dual chamber pacing. HTX = Heart Transplantation. ICD = automatic Internal Cardioverter Defi brillator. NYHA = New York Heart 
Association. PTSMA = Percutaneous Transluminal Septal Myocardial Ablation. SD = Sudden Death. VT = Ventricular Tachycardia.
Obstructive Non-obstructive
Asymptomatic No therapy
Mild symptoms
(NYHA class II)
β-blocker or
verapamil
Severe symptoms
(NYHA class III or IV)
Treatment failure
Combination of
β-blocker and
verapamil
Normal systolic
function
Impaired systolic
function
Ace-inhibitor
Diuretics, Digitalis
Treatment
failure
HTX
Asymptomatic No therapy
Mild symptoms
(NYHA class II)
β-blocker or
verapamil
Severe symptons
(NYHA class III or IV)
Combination
of β-blocker
and verapamil
Treatment failure
Surgical
myectomy
PTSMA
DDD-pacing Survivors SD
Sustained VT
Amiodarone
ICD
Diltiazem
+/- β-blocker
Nifedipine
+/- β-blocker
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plantation of a permanent pacemaker (0-15%), 2) ventricular septal defects, caused 
by too extensive resection of septal myocardium or 3) damaging of the papillary 
muscles or chordae, attached to the mitral leafl ets, resulting in mitral regurgitation. 
Surgical myectomy is performed in a few selected centers by experienced surgeons 
in the fi eld. Under these conditions, mortality and morbidity rates are very low.
2) Permanent pacemaker implantation. Dual-chamber pacemaker implantation 
has been introduced as an alternative to surgery. Initially, it appeared an eff ective 
therapy to reduce the LVOT obstruction and to ameliorate clinical symptoms. The 
hypothesized working mechanism is complicated. Pacing alters the depolarization 
as well as the contraction pattern of the ventricles. Usually, the basal septum is the 
fi rst myocardial segment that contracts during systole and that consequently bulg-
es into the LVOT. Consequently, the LVOT diameter reduces just before the LV ejects 
most of the blood through the LVOT into the aorta. Therefore, it would be benefi cial 
to start the depolarization and contraction pattern at the apical region. This could 
be achieved by placing a ventricular pacemaker lead in the right ventricle. During 
ventricular pacing, the contraction of the LV starts at the apex and moves towards 
the basal septum. Under these conditions, most blood has been ejected into the 
aorta and the consequences of LVOT narrowing due to septal contraction during 
the late systolic phase, are minimized. The preliminary results achieved by pacing 
were promising, demonstrating reduction of the LVOT gradient and improvement 
of the clinical condition. The results of a randomized double-blinded trial, compar-
ing several periods of alternating pacing in the same patients, were discouraging.39 
The results of this study indicated that clinical improvement was at least partly 
based on a “placebo-eff ect” and reduction of the LVOT gradient was signifi cantly 
less as compared to surgical myectomy. In our clinic, pacemaker implantation to 
treat HOCM is only considered if the surgical risk is deemed to high due to the pres-
ence of co-morbidity and/or an advanced age. 
3) Percutaneous transluminal septal myocardial ablation. Recently, Dr. Sigwart 
introduced percutaneous transluminal septal myocardial ablation (PTSMA), a new 
modality to treat patients with HOCM and drug-refractory symptoms.40 The tech-
nique entails the injection of ethanol into one or more septal arteries arising from 
the left anterior descending artery. The ethanol induces a myocardial infarction 
within the myocardial area provided by this septal artery. As a result, septal hyper-
trophy diminishes, the LVOT widens due to remodeling and consequently, the LVOT 
gradient reduces. Since the introduction of PTSMA, more than 300 patients have 
been treated by this technique. The short-term results are promising, morbidity rate 
is low and gradient reduction is signifi cant.41 The fi rst PTSMA procedure in the Neth-
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erlands was performed at the Dykzigt Hospital in 1999. The advantage of PTSMA, 
performed at the catheterization laboratory, is its less invasive character as com-
pared to surgery. In addition, the duration of in-hospital stay is reduced. Whether 
the eff ects of PTSMA will lead to sustained improvement during long-term follow-
up and whether the procedure is capable of competing with surgical myectomy 
cannot be exactly determined at present. An important question that remains to be 
answered is whether the induction of a septal myocardial infarction by injection of 
ethanol may induce ventricular arrhythmias during long-term follow-up.
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SUMMARY
Hypertrophic cardiomyopathy is a heterogeneous disease with a wide spectrum 
of clinical and hemodynamic manifestations. Pregnancy is generally considered a 
safe undertaking in patients with hypertrophic cardiomyopathy; nevertheless car-
diac symptoms can develop or deteriorate during pregnancy. Between 1988 and 
1998, the authors followed 9 consecutive patients during pregnancy and delivery. 
A general advise on the management during and after pregnancy as well as recom-
mendations for delivery are described.
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INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is a heterogeneous disease characterized by 
a diversity in anatomical, hemodynamic and clinical presentation.1-4 The clinical 
picture may diff er from patient to patient: although the majority is asymptomatic, 
some patients have symptoms of angina, heart failure or syncope.5,6 Pregnancy and 
delivery is usually well tolerated in patients with HCM.7,8 However, the combination 
of physiological changes and altered hemodynamic state in pregnancy and delivery 
may worsen symptoms and induce venous pulmonary congestion.7,9 Therefore, ad-
vise concerning pregnancy and delivery should be individualized in these patients. 
We report the outcome of nine pregnant women with HCM and present general 
advice for management of pregnancy and delivery.
METHODS
Between 1988 and 1998, nine consecutive patients with HCM out of the Thoraxcenter 
cardiomyopathy clinic were followed during pregnancy and delivery. The diagnosis 
of HCM was based on the echocardiographic fi nding of a nondilatated hypertro-
phied left ventricle in the absence of known causes of left ventricular hypertrophy.10 
At the time of the initial visit, clinical characteristics including age at diagnosis, fam-
ily history of HCM or presence of sudden cardiac death in a fi rst degree relative, or 
both, history of syncope or sudden death, symptoms, New York Heart Association 
functional class and pharmacological therapy were recorded. Physical examination 
and baseline laboratory studies were performed, including twelve-lead electrocar-
diography and echocardiography. Furthermore, clinical characteristics, physical and 
echocardiographic examination were reevaluated before pregnancy, at midgesta-
tion and within 3 months after delivery by one cardiologist (FTC). Cardiac follow-up 
was intensifi ed if the gynecologist, who followed the patient during pregnancy in 
the outpatient clinic, suspected a deterioration of the cardiac condition. All patients 
had undergone 24-hour Holter monitoring before pregnancy. Information on deliv-
ery was obtained from the patients’ gynecologist.
RESULTS
Baseline characteristics
The clinical characteristics of 9 study patients are listed in Table 1. One patient (pa-
tient no. 2) already had delivered to 2 children before the diagnosis of HCM was 
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made. Since we included only patients who could be followed during pregnancy 
and labour, we eliminated these pregnancies from our study. Nine patients were 
included with 20 pregnancies. The mean age at fi rst presentation to our institu-
tion was 22 ± 6 years. Seven patients reported a family history of HCM, of whom 6 
patients also reported sudden death in a fi rst-degree relative at a young age (<40 
years). Four women had experienced one or more syncopal attacks before preg-
nancy. Five women were asymptomatic before pregnancy, the symptoms recorded 
in the remaining patients included dyspnea in 4 patients and exertional angina in 3 
patients. All symptomatic patients were in functional class II according to the New 
York Heart Association. Five women had undergone septal myectomy because of 
the presence of a left ventricular outfl ow tract (LVOT) obstruction ≥ 50 mm Hg at 
rest and complaints of angina or dyspnea despite therapy with betablockers and/or 
verapamil. In 4 patients this procedure took place before the fi rst pregnancy. The 
LVOT gradients, as presented in Table 1, were evaluated one to six months before 
the fi rst pregnancy in 6 patients, before the third pregnancy in patient no. 2 and 
before the fourth pregnancy in patient no. 5, respectively. All patients were in sinus 
rythm during the study. On 24-hour Holter monitoring, fi ve patients had one or 
more episodes of nonsustained ventricular tachycardia and in one patient (no. 4), 
an episode of sustained ventricular tachycardia was recorded without symptoms.
Follow-up during pregnancy
During pregnancy, four patients were treated with drugs, of whom 2 patients used 
verapamil (Table 1). Patient no. 3 discontinued verapamil at the fi rst trimester of 
both pregnancies and restarted the drug after delivery. Patient no. 8 continued 
Table 1. Clinical characteristics of pregnant patients with hypertrophic cardiomyopathy
Pt. 
number
Year of 
birth
Family 
history 
SD
Syncope NYHA 
class
Medication LVOTG
(mmHg)
VT on 
Holter
Year of 
operation
Pregnancies
Pre During
1 1962 + + I – – 15 + 1984 1988, 1990
2 1966 0 0 II – – 25 0 1986*, 1987*, 1991
3 1967 0 0 I V V  5 + 1994, 1995
4 1958 + + II – –  4 + 1985 1994
5 1967 + + I – D 10 + 1991 1988(A), 1989, 
1989(A) 1993, 1995
6 1957 + 0 I – –  5 + 1992(A), 1993, 1995
7 1966 + + II Dis Dis 50 + 1986 1988(A), 1991, 1994
8 1964 – 0 II V V, B 36 0 1997
9 1962 + 0 I – – 12 0 1995 1996(A), 1998
A = spontaneous abortion, B = beta-blocker, D = diuretic, Dis = disopyramide, LVOTG = left ventricular outfl ow tract gradient, NYHA = New 
York Heart Association, pre = medical therapy before pregnancy, SD = sudden death, V = Verapamil, VT = Ventricular Tachycardia, + = present, 
0 = absent, (–) = no therapy, * = not included in the study.
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verapamil throughout pregnancy. At midterm evaluation, the LVOT gradient had 
increased from 36 mm Hg before pregnancy to 90 mm Hg. Verapamil was discontin-
ued at 21 weeks because of the increase in the LVOT obstruction and was replaced 
by metoprolol. On echocardiographic examination, four weeks later, the LVOT gra-
dient had decreased to 30 mm Hg. Pregnancy and delivery were uncomplicated 
afterwards. In patient no. 7 disopyramide was stopped during the fi rst trimester of 
both pregnancies and restarted after delivery. Two patients (no. 2 and no. 5) had 
worsening of symptoms during pregnancy. Patient no. 2 was seen in our outpatient 
clinic at 38 weeks of her third pregnancy for progression of angina and dyspnea on 
exertion. At physical examination, there were no overt signs of heart failure and 
she fulfi lled her term without pharmacological therapy. Symptoms disappeared 
after delivery. Diuretic therapy was indicated in one patient (no. 5) at the end of the 
fourth pregnancy for relief of symptoms of heart failure. Doppler echocardiography 
revealed that the LVOT gradient did not change signifi cantly during pregnancy in 8 
of 9 patients.
Delivery
Nine women had 20 pregnancies, fi ve of whom ended in spontaneous abortion. The 
fi rst pregnancy of patient no. 5 ended in the delivery of a stillborn child at 27 weeks. 
This patient was hospitalized because of excessive vaginal bleeding due to abruptio 
placentae. After delivery, the patients’ recovery was uncomplicated. Autopsy of the 
female fetus of 640 grams did not reveal any cardiac abnormality. The remaining 
four spontaneous abortions took place in the fi rst trimester of pregnancy; autopsy 
was not performed in these cases. No child nor mother died in the perinatal period. 
Thirteen children were born by vaginal delivery, two intrauterine growth retarted 
children were born by cesarean section at 39 weeks because of fetal distress. The 
birthweight averaged 2868 ± 716 gram (range 1280 – 4160 gram) and the ranges 
of the Apgar score were 6 to 10 and 7 to 10 after 5 and 10 minutes respectively. 
Endocarditis prophylaxis because of distinct anterior motion of the mitral valve and 
concomitant mitral valve regurgitation was administered in 9 of 16 deliveries.
Follow-up after delivery
Uptill now, cardiac abnormalities are not found on echocardiographic examination 
in the 15 live-born children after a mean follow-up of 5 ± 3 years (range 0.5 - 10 
years). Two women (no. 4 and 7) had cardiac events during follow-up. Both patients 
were transmitted to local hospitals after resuscitation because of ventricular fi bril-
lation, 5 and 8 months respectively after the latest pregnancy. Patient no. 7 stayed 
comatose. Patient no. 4 recovered without neurological injury, she was treated by 
implantation of a cardioverter defi brillator because of periods of sustained ventricu-
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lar tachycardia despite antiarrhythmic drug therapy. In the other 7 patients, clinical 
status was not diff erent as compared to the period before pregnancy.
DISCUSSION
In this paper, we report the outcome of 20 pregnancies in 9 patients with HCM. Our 
cohort represents the heterogeneity in clinical presentation of this disease: while 
5 patients were asymptomatic, 4 patients had complaints of angina or dyspnoe, 6 
patients had ventricular tachycardia on 24-hour Holter monitoring and septal my-
ectomy because of LVOT obstruction had been performed in fi ve patients. From 20 
pregnancies, 15 children were born alive, 13 by vaginal delivery and two by cesar-
ean section. The results of our study show that pregnancy is generally well tolerated 
in patients with HCM.
Five pregnancies ended in spontaneous abortion. The number of abortions in our 
cohort is higher than expected (normally 10% of pregnancies end in a spontaneous 
abortion in the fi rst trimester). It is not known whether HCM in the fetus caused the 
abortion since autopsy was not routinely performed. 
Hemodynamic changes during pregnancy and its infl uence on hypertrophic 
cardiomyopathy
During pregnancy, important changes in the hemodynamic state take place. There 
is a reduction in the peripheral resistance beginning from the 12th week of ges-
tation,11 nevertheless blood pressure is unchanged in most patients since cardiac 
output is increased by 30-50%.12 In the last trimester, compression of the inferior 
caval vein by the expanding uterus can result in a decrease of venous return.13,14 
During delivery, pain and stress causes sympathetic stimulation which leads to an 
increase in heartrate and contractility and furthermore the Valsalva manoeuvre may 
reduce venous return.13,14 
The increase in contractility and decrease in pre- and afterload can augment the 
obstruction in patients with obstructive HCM, which in turn may lead to deteriora-
tion of the clinical condition.9,13,14 In patients with HCM and diastolic dysfunction, 
the increase in intravascular volume and rise in heartrate is detrimental and may 
cause worsening of symptoms and pulmonary venous congestion.15
Drug therapy during pregnancy in hypertrophic cardiomyopathy 
If the patient is asymptomatic, therapy with drugs should be avoided. In symp-
tomatic patients, beta-adrenergic blocking agents are prescribed traditionally. 
Beta-blockers reduce myocardial oxygen demand and relief symptoms of angina 
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and dyspnea through lowering heart rate, reducing left ventricular contractility 
and reducing the exercise generated increase in obstruction.3,16,17 The use of these 
drugs in pregnancy is relatively safe. There are no reports indicating that therapy 
with beta-blockers results in fetal malformation.18 Intra-uterine growth retardation, 
neonatal bradycardia and neonatal hypoglycaemia are reported in a small number 
of patients.7,8,19,20 Verapamil is also widely used in the management of patients with 
HCM. Like beta-adrenergic blocking drugs, verapamil reduces myocardial oxygen 
consumption by its negative inotropic and chronotropic eff ect. Moreover, the drug 
may have a benifi cial eff ect on diastolic function.21,22 In patients with obstructive 
HCM, verapamil may increase the LVOT gradient through the vasodilatating proper-
ties of the drug.23 No teratogenic eff ects have been described in patients treated 
with verapamil for acute management of maternal supraventricular arrhythmias.24 
The eff ects of chronic administration of verapamil on the course of pregnancy is still 
unclear.
Recommendations during labour and delivery in hypertrophic cardiomyopathy
The use of betamimetic drugs for tocolysis is contraindicated in patients with ob-
structive HCM, because the LVOT gradient increases and symptoms may worsen.8 
Analgesia during labour is useful to diminish sympathetic stimulation.13,14 Epidural 
analgesia is not contraindicated, however adequate volume-expansion and care-
ful blood pressure monitoring is necessary, to avoid hypotension especially in 
patients with obstructive HCM.25,26 Hemodynamic monitoring by pulmonary artery 
catheterization should be considered in patients who are severely symptomatic or 
have signs of heart failure to guide drug therapy.9 According to the statement of the 
American Heart Association patients with HCM are at moderate risk for acquiring 
endocarditis.27 In our institution, antibiotic prophylaxis is recommended in patients 
with distinct systolic anterior motion of the mitral valve and LVOT obstruction, and 
in patients with moderate to severe mitral regurgitation. In general, vaginal delivery 
is considered safe and cesarean section is reserved for obstetric indications.
General recommendations
The risk of inheritance in familial HCM is 50%. However, it is important to note that 
patients with identical gene mutations display variable clinical manifestations or 
even fail to express the disease.28-30 In HCM patients with a child’s wish it is impor-
tant to explain the risk of inheritance and the risk of worsening of symptoms during 
pregnancy. Cardiac follow-up during pregnancy is necessary for the surveillance of 
the patients’ clinical condition, to start or change therapy if symptoms worsen or 
to hospitalize the patient if there are overt signs of heart failure. Postpartum blood 
loss should be replaced by intravenous fl uids, especially in patients with obstructive 
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HCM, because of the potential aggravation of the pressure gradient across the LVOT. 
After birth, echocardiographic evaluation should be performed every 2 to 5 years 
in children (or sooner when cardiac symptoms develop) lasting until adulthood to 
recognize signs of HCM.
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ABSTRACT
Background: Mitral leafl et extension (MLE) combined with septal myectomy is a 
new surgical approach to treat hypertrophic obstructive cardiomyopathy (HOCM) 
and an enlarged mitral leafl et area. The study presents the long-term clinical results 
and outcome of this technique.
Methods and Results: MLE entails grafting a glutaraldehyde-preserved autologous 
pericardial patch onto the center portion of the anterior mitral valve leafl et. Twenty-
nine patients with HOCM were studied. Mean follow-up (± SD) was 3.4 ± 2.1 years 
(range 3 months to 7.7 years). The preoperative calculated mitral leafl et area was 
16.7 ± 3.4 cm2. New York Heart Association functional class improved signifi cantly 
from 2.8 ± 0.4 to 1.3 ± 0.4 (P<0.05), width of the interventricular septum decreased 
from 23 ± 4 to 17 ± 2 mm (P<0.05), left ventricular outfl ow tract gradient decreased 
from 100 ± 20 to 17 ± 14 mm Hg (P<0.01), severity of mitral regurgitation graded 
on a scale from 0 to 4+ decreased from 2.5 ± 0.9 to 0.5 ± 0.6 (P<0.01), and severity 
of the systolic anterior motion of the mitral valve graded on a scale from 0 to 3+ 
decreased from 2.9 ± 0.3 to 0.5 ± 0.7 (P<0.01) postoperatively. There were no deaths 
associated with surgery.
Conclusions: Long-term follow-up shows sustained improvement in functional sta-
tus, reduction of outfl ow tract obstruction, and attenuation of mitral regurgitation 
and systolic anterior motion of the mitral valve. In this respect, the new technique 
widens the surgical applications in HOCM.
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INTRODUCTION
Hypertrophic obstructive cardiomyopathy (HOCM) is a heterogeneous disease 
characterized by asymmetrically distributed left ventricular hypertrophy and left 
ventricular outfl ow tract (LVOT) obstruction.1 Dynamic LVOT obstruction is induced 
by thickening of the interventricular septum and systolic anterior motion (SAM) 
of the mitral valve. Several invasive therapeutic modalities have been developed 
to diminish outfl ow tract obstruction by reduction of the interventricular septum 
width. The most commonly performed intervention is surgical myectomy accord-
ing to the technique developed by Morrow et al.2 Hypertrophic cardiomyopathy, 
however, frequently presents with several anatomic alterations of the mitral valve 
apparatus, including increased mitral leafl et area (MLA), length, and laxity, as well 
as anterior displacement of the papillary muscles.3-12 These structural abnormalities, 
which are not corrected after a successful myectomy, may predispose to residual 
SAM and result in a suboptimal outcome with persistence of outfl ow obstruction 
and mitral regurgitation (MR).13-15 We therefore performed anterior mitral leafl et 
extension (MLE), one of several repair techniques originally developed by Carpen-
tier16, in combination with myectomy in patients with HOCM and an enlargement of 
the anterior mitral leafl et. We have shown that the combined technique resulted in 
good short-term functional and hemodynamic outcome compared with myectomy 
alone in these patients.17 In this report, we present the long-term follow-up results 
of this combined surgical approach.
METHODS
Patient selection
Patients are selected for surgery at our hypertrophic cardiomyopathy clinic on the 
basis of the following indications: (1) a signifi cant LVOT gradient ≥ 50 mm Hg at rest 
or on provocation and (2) New York Heart Association (NYHA) functional class II to 
IV despite optimal medical treatment consisting of beta-blocking agents, calcium 
channel blockers, or both. Cardiac catheterizations for invasive hemodynamic mea-
surements and visualization of the coronary anatomy and transthoracic echocar-
diography were performed routinely before surgery. The echocardiographic images 
were collected by a single echocardiographer and stored on videotape for off -line 
analysis.
The mitral valve leafl et area was used as a selection criterion to perform MLE in 
conjunction with myectomy. First, the mitral valve opening area was measured 
offl  ine from transthoracic echocardiographic images in the parasternal short-axis 
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view by tracing the innermost margins of the mitral valve at the point of maximal 
opening. The demarcated area was calculated with a dedicated software program.18 
Next, the leafl et area was calculated with the formula previously validated by Klues 
et al: mitral valve leafl et area = 4.64 + 2.17 × mitral valve opening area.19
Between 1991 and 1999, 32 patients were accepted for surgical correction, and 
29 patients met the selection criteria for MLE. The fi nal decision to perform MLE 
was made perioperatively by the surgeon after visual inspection and epicardial 
echocardiographic observation of papillary muscle length and mitral valve laxity, 
as well as leafl et area. If, in the surgeon’s view, these morphometric abnormalities 
made myectomy alone unlikely to yield optimal results, the leafl et-extending patch 
was additionally grafted. The surgical procedures, which were approved by the local 
institutional review committee, were performed by one surgeon (LAvH). All subjects 
gave oral informed consent.
Surgical technique
Cardiac surgery was performed by standard techniques of cardiopulmonary bypass 
with moderate hypothermia and crystalloid cardioplegic arrest (St Thomas’s solu-
tion). An autologous pericardial patch was harvested, trimmed of fat and extrane-
ous tissue, immersed for 10 minutes in 0.62% glutaraldehyde, and then placed in 
a normal saline bath. The patch was treated with glutaraldehyde for ease of ma-
nipulation and collagen cross-linking. After the ascending aorta was opened by an 
oblique incision, myectomy was performed to the left of an imaginary line through 
the nadir of the right coronary cusp with a locally designed electrocautery device, 
described in detail elsewhere.20 The entire surgical procedure was monitored with 
epicardial echocardiography by the surgeon.
When, in the surgeon’s opinion, adequate septal myectomy had been achieved, 
anterior MLE was performed. The procedure has been explained previously.21 In 
brief, a gap was created in the anterior mitral leafl et through a longitudinal incision, 
starting at the subaortic hinge point to the rough zone. Then, an oval autologous 
pericardial patch, 2.5 cm wide and 3 cm long, was grafted onto the center portion of 
the anterior mitral leafl et with 2 running polypropylene sutures. The surgical results 
were assessed with transesophageal and epicardial echocardiography immediately 
after the patient was weaned from bypass and at a systolic blood pressure of ≥ 
100 mm Hg, with special attention to the width of the interventricular septum, the 
residual LVOT gradient, MR, and SAM. None of the patients had an indication for 
reinstitution of cardiopulmonary bypass because of a suboptimal surgical result.
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Follow-up
The clinical characteristics collected before the intervention included assessment 
of symptoms, NYHA functional class, and drugs prescribed. Physical examination 
and baseline laboratory studies were performed, including electrocardiography, 
transthoracic echocardiography, and cardiac catheterization.
The echocardiographic data were reviewed by 2 physicians who were unaware 
of the patient’s medical history. Echocardiography was performed 1 week before 
surgery and was subsequently repeated 1 week, 3 months, and at yearly intervals 
after surgery.
At the site of myectomy, the mean interventricular septal thickness was calculated 
from the septal width in diastole from both the parasternal short-axis and long-axis 
views. The severity of the MR was graded (on a scale from 0 to 4+) by color fl ow 
Doppler echocardiography. The severity of the SAM of the anterior mitral valve was 
determined from the 2D images and was graded on a scale from 0 to 3+ depending 
on the mitral-septal distance (grade 0 indicates no SAM and grade 3+ indicates brief 
or prolonged contact between mitral valve and septum). Peak LVOT gradient was 
estimated with Doppler echocardiography by the modifi ed Bernoulli equation (P = 
4V2), where P is the pressure gradient and V is Doppler-determined blood velocity. 
MLA was calculated as described above from the preoperative echocardiograms.
Follow-up information was obtained at the hypertrophic cardiomyopathy clinic 
by 1 cardiologist (FJtC). Because echocardiography has become a non-invasive and 
standard routine to assess postoperative results, repeated catheterization was not 
performed in this group.
Statistical Analysis
Data are expressed as mean ± SD values. The paired Student’s t test was determined 
to compare continuous variables. Preoperative and postoperative patient charac-
teristics compared were NYHA functional class, number of drugs prescribed, width 
of the interventricular septum, LVOT gradient, severity of MR, and grade of the SAM 
of the anterior mitral valve leafl et.
RESULTS
Baseline clinical characteristics
The baseline characteristics of the 29 patients are listed in Table 1. Fifteen patients 
were male. Mean age was 44 ± 13 years (range 21 to 64 years). The majority of pa-
tients (76%) had class III symptoms according to NYHA classifi cation, and 24% of pa-
tients had class II symptoms. Two patients had been resuscitated successfully from 
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an out-of-hospital cardiac arrest. All patients were treated with drugs. Beta-blocking 
agents, calcium antagonists or the combination of these drugs were prescribed in 
41%, 38%, and 21% of patients, respectively. Interventricular septal thickness av-
eraged 23 ± 4 mm (range 17 to 35 mm), and mean left ventricular posterior wall 
thickness was 13 ± 3 mm (range 9 to 19 mm). The mean LVOT gradient was 100 ± 
20 mm Hg. Most patients had moderate to severe MR (mean grade 2.5 ± 0.9). All 
patients had typical marked SAM of the anterior mitral valve leafl et (mean grade 2.9 
± 0.3). The calculated MLA was 16.7 ± 3.4 cm2 (normal<12 cm2). Signifi cant coronary 
artery disease was demonstrated in a single patient in whom bypass grafting was 
performed simultaneously during the MLE and myectomy procedure.
Clinical Outcome
Preoperative and postoperative data at 3 months and at the latest follow-up are 
presented in Table 2. The mean follow-up was 3.4 ± 2.1 years (range 3 months to 
7.7. years). None of the patients died during surgery or during short-term follow-up. 
One surgical complication occurred at 3 months’ follow-up and involved a patient 
with rapid-onset dyspnea. Echocardiography revealed a severe MR jet at the side 
of the inserted patch. At acute surgical intervention, the patch appeared dehiscent 
because of a loosened suture. After correction, the patient’s clinical course was un-
complicated. During the follow-up period, patients were either asymptomatic or 
had mild symptoms (70% of them were in NYHA functional class I, and 30% were 
in class II). The number of cardiac drugs prescribed decreased signifi cantly; before 
Table 1. Baseline characteristics of the 29 patients with hypertrophic obstructive cardiomyopathy treated with myectomy and mitral leafl et 
extension.
N(%)
Sex (M/F) 15(52%)/14(48%)
Mean age (years ± SD) 44 ± 13
Follow-up (years ± SD) 3.4 ± 2.1
Symptoms
 dyspnea
 angina
 (pre) syncope
 out of hospital resuscitation
19 (66%)
14 (48%)
7 (24%)
2 (7%)
NYHA class
 II
 III
7 (24%)
22 (76%)
Medical therapy
 Betablocker (b)
 Calciumantagonist (c)
 Combination (b) and (c)
12 (41%)
11 (38%)
6 (21%)
Abbreviations: NYHA = New York Heart Association, SD = sudden death; M = male, F = female, N = number.
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intervention, the number of cardiac drugs used was 1.5 ± 0.7, whereas after surgery, 
the number of drugs decreased to 0.5 ± 0.7. In 1 of the 2 patients with atrial fi brilla-
tion before surgery, sinus rhythm was restored and was maintained under medical 
treatment postoperatively. No patient needed permanent cardiac pacing. In relation 
to the preoperative data, we found a mean reduction in septal thickness of 5.9 ± 
2.3 mm after the surgical procedure. Moreover, short-term follow-up demonstrated 
that the LVOT gradient, MR, and SAM of the mitral valve were signifi cantly reduced. 
At the latest patient visit, the benefi cial results were maintained compared with the 
data at 3 months’ follow-up.
Preoperative and postoperative echocardiograms from the same patient after 
MLE and myectomy are shown in fi gure 1.
Figure 1. Preoperative (PRE) and postoperative (POST) 2D echocardiograms in parasternal long-axis view in a patient treated by combined 
approach. Arrows in the postoperative image indicate respectively site of myectomy and patch in anterior mitral leafl et. LV indicates left 
ventricle; MV, mitral valve; and LA, left atrium.
Table 2. Pre- and postoperative characteristics at three months and at the latest visit in 29 patients with hypertrophic obstructive 
cardiomyopathy treated with myectomy and mitral leafl et extension.
Pre Post* Post**
Clinics
 NYHA Class  2.7 ± 0.5 1.4 ± 0.5 1.3 ± 0.4
 Number of drugs  1.5 ± 0.7 0.6 ± 0.8 0.5 ± 0.7
Echocardiography
 IVS (mm)  23 ± 4.0 18 ± 2.5 17 ± 2.3
 LVOTG (mm Hg) 100 ± 21 19 ± 15 17 ± 14
 MR (grade)  2.6 ± 0.7 0.5 ± 0.7 0.5 ± 0.6
 SAM (grade)  2.9 ± 0.3 0.6 ± 0.6 0.5 ± 0.7
 LA (mm) 47 ± 8 45 ± 10 45 ± 9
 MLA (cm2) 16.7 ± 3.4
*post-operative follow-up at three months. ** post-operative follow-up at latest visit.
Abbreviations: IVS = Interventricular Septal Width. LA = Left Atrium. LVOTG = Left Ventricular Outfl ow Tract Gradient. MR = Mitral 
Regurgitation. NYHA = New York Heart Association functional class. SAM = Systolic Anterior Motion. MLA = Mitral Leafl et Area.
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DISCUSSION
An obstructive outfl ow tract gradient is present in 20% to 25% of HOCM patients1 
and results primarily from septal hypertrophy. Besides the myocardium, the anato-
my of the mitral valve apparatus also frequently appears anomalous and may add 
to the obstruction component. Normally, the mitral valve leafl ets coapt below the 
outfl ow tract as they are pulled posteriorly by the papillary muscles, where they do 
not impede the outward-directed blood fl ow. Well-recognized elements that may 
disrupt this coaptation mechanism are valve elongation and anterior displacement 
of the papillary muscles, which predispose to SAM.4-12,19,22,23 Consequently, outfl ow 
tract obstruction and MR may persist after successful surgical myectomy. Therefore, 
mitral valve replacement has been alternatively performed to counteract residual 
SAM in patients regarded as less-suitable candidates for septal myectomy.4,14,24-26 
The thromboembolic complications due to long-term use of anticoagulants restrict 
the benefi cial use of an artifi cial valve prosthesis.27 Mitral leafl et plication has been 
introduced as a successful alternative to mitral valve replacement.4 
At our institute, we developed an alternative surgical procedure after septal my-
ectomy that aims to reduce the risk of a residual outfl ow obstruction due to SAM of 
the mitral valve. The technique entails septal myectomy in combination with a patch 
of autologous pericardium inserted into the anterior mitral valve leafl et. Initially, pa-
tients treated with the combination of myectomy and MLE were selected primarily 
on the basis of the echocardiographic fi ndings of an elongated MLA. After a short-
term follow-up period, we concluded that application of the combined technique 
resulted in superior hemodynamic results compared with myectomy alone. In the 
present study, we report the long-term follow-up results of this alternative approach 
in a larger patient population. Within the next period, 29 of 32 patients selected for 
surgical myectomy demonstrated an enlarged mitral valve leafl et area (16.7 ± 3.4 
cm2), which was signifi cantly above values of a control group of patients (<12 cm2). 
Clinical and hemodynamic parameters including functional class, reduction of the 
LVOT gradient, and attenuation of MR and SAM showed sustained improvement 
during this period. In 90% of the patients treated with the combined technique, 
SAM was reduced to grade 0 (absent) or grade I (mild). It is important to realize that 
the severity of MR is related to the presence of SAM.28 Indeed, mitral valve incompe-
tence was absent or trivial in 97% of patients in the present study.
We regard MLE as a safe addition to myectomy because there was no mortality in 
the present study. In addition, no ventricular septal defects or complete AV block 
was seen. One patient needed reoperation because of a dehiscent pericardial patch. 
Mitral valve function was maintained without echocardiographic observation of a 
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restricted mitral valve opening. In this respect, the combined technique might serve 
as a good alternative to septal myectomy alone in selected patients.
MLE: Why Does It Work? 
In most patients with hypertrophic cardiomyopathy, the abnormal motion of the 
mitral valve in systole plays a key role in creating the outfl ow tract obstruction.6,7 
Several factors may be responsible for this phenomenon. The Venturi mechanism 
and fl ow drag of the leafl ets due to increased mitral leafl et length, laxity, and ante-
rior displacement of the papillary muscles allow the valve to protrude in the outfl ow 
tract.4 Also, inward displacement of the papillary muscles toward each other results 
in chordal slack in the central leafl et portion and consequently SAM in the central 
portion of the valve.5 To counteract these forces, the pericardial patch is grafted 
in the center portion of the anterior leafl et, where SAM typically reaches a maxi-
mum.5,8,11,23 By extending the patch across the bending point of the mitral valve, we 
hypothesize that we stiff en the central parts of the buckling anterior leafl et, pre-
venting abnormal mobility. In addition, the patch increases the width of the leafl et, 
which results in a horizontal extension. The widening of the leafl et may cause a lat-
eral shift of the chordae attaching central portions of the valve. This displacement 
stretches the chordae, erects them, and enhances leafl et coaptation.28 
Enlargement of the leafl et area could also add positively to maintenance of valve 
tethering once the streamlines of fl ow are normalized by septal myectomy.28 During 
systole, the blood fl ow in the septal hypertrophied heart is forced to go around 
the septum and fl ows partially toward the posterior part of the anterior leafl et. The 
force of this streamline of fl ow pushes the valve into the LVOT. After septal myec-
tomy, the fl ow stream straightens, hitting the mitral valve onto the anterior surface 
and pressing the leafl ets toward the left atrium. The force that directs the enlarged 
valve posteriorly is linear to the leafl et area exposed to that fl ow. In fact, the patch 
appears tightened in systole, the anterior leafl et is directed toward the left atrium, 
and SAM and MR are abolished (Figure 1).
Septal myectomy is the most widely used surgical therapy in drug-refractory hy-
pertrophic cardiomyopathy, with benefi cial results in reducing outfl ow obstruction 
and MR. Because the outfl ow tract obstruction is multifactorial in origin, several 
diff erent methods besides the classic myectomy have been developed to treat this 
heterogeneous disease. The present study cohort consisted of selected patients 
who demonstrated enlarged MLAs and typical SAM, as previously described by 
Klues et al19. This subset of patients with obstructive cardiomyopathy is particularly 
predisposed to residual SAM after a successful myectomy and would therefore ben-
efi t from the MLE procedure.
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Mitral valve plication is another approach to avoid residual obstruction in selected 
patients.3 It was designed to avoid mitral valve repair with a prosthesis, and hemo-
dynamic results were encouraging, as in the present study. The selection criteria for 
plication included not only a relatively thin ventricular septum or an abnormal mi-
tral valve apparatus but also a persistent obstruction after myectomy. In the present 
study, we did not treat previously operated patients. Also, we could not compare 
MLE to the results with valve prosthesis because this has not been a routine proce-
dure at our institute.
Recently, percutaneous transluminal septal myocardial ablation (PTSMA) has been 
introduced as a new, nonsurgical approach to reduce septal width.29 The procedure 
leads to localized thinning and contractile dysfunction of the septum, expansion of 
the LVOT, and thus reduction of the LVOT gradient. The anatomy of the mitral valve 
apparatus, however, remains unaltered, and at this moment, it is unknown whether 
comparable results can be obtained in this patient group with PTSMA. The present 
technique appears especially useful for patients with failed PTSMA and persisting 
MR.
CONCLUSIONS
MLE in combination with myectomy is an eff ective and safe treatment for patients 
with HOCM. Long-term follow-up demonstrates sustained improvement in func-
tional class, reduction of obstruction, and reduction in the severity of SAM and MR. 
Because the present technique off ers a broadening of the surgical possibilities, we 
believe that MLE could become the preferred choice in persistent LVOT and SAM 
after PTSMA. The technique appears to be especially eff ective in patients with an 
enlarged anterior MLA. Future randomized studies will need to examine the sta-
tus of the diff erent techniques in patients with hypertrophic cardiomyopathy 
and obstruction.
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ABSTRACT
Background: Percutaneous transluminal septal myocardial ablation (PTSMA) is a 
new interventional technique to treat patients with hypertrophic obstructive car-
diomyopathy.
Methods: Small doses of ethanol 96% were injected into a targeted septal artery 
causing a chemical myocardial infarction. Three patients were evaluated, including 
a follow-up of three months.
Results: There were no complications during the procedure. Left ventricular out-
fl ow tract gradients reduced from 120 ± 40 mm Hg to 25 ± 5 mm Hg. At follow-up, 
all three patients showed improvement in validity.
Conclusion: The method requires an echocardiographic contrast determination of 
the myocardium at risk for ethanol treatment, in addition to hemodynamic moni-
toring.
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INTRODUCTION
Hypertrophic obstructive cardiomyopathy (HOCM) is defi ned as a primary, mostly 
familiar and genetically determined myocardial hypertrophy. In about 30% of cases, 
the disease presents with a dynamic obstruction of the left (and occasionally of the 
right) outfl ow tract.1,2
Therapy in severely symptomatic patients aims at reducing the extent of the left 
ventricular outfl ow tract (LVOT) obstruction, either medically using negative ino-
tropic drugs or surgically by myo-myectomy.2 Recently, DDD pacing has also been 
proposed as an alternative therapeutic option.
In 1994, Sigwart injected a small amount of absolute ethanol into the fi rst septal 
branch of the left anterior descending coronary artery of a patient with HOCM.3 The 
objective of this approach was to induce a small, localized myocardial infarction in 
the septal myocardium overlying the LVOT, in eff ect producing a chemical myo-my-
ectomy without the need for open heart surgery.3,4 Since then several studies have 
appeared describing the long-term eff ects in large groups with HOCM patients. 
The method, which is called percutaneous transluminal septal myocardial ablation 
(PTSMA), not only decreases the LVOT gradient, but also improves exercise capac-
ity. The purpose of this report is to describe the fi rst experience with PTSMA in the 
Netherlands.
Description of the method and the role of myocardial contrast echocardiogra-
phy for targeted delivery of ethanol into the septal artery branch of choice are de-
scribed.
PATIENTS AND METHODS
Between October 1999, when PTSMA for HOCM was initiated in our institution 
(with the help of Professor U. Sigwart from the Royal Brompton Hospital, London, 
UK) and December 1999, three patients were treated. Inclusion criteria for PTSMA 
were moderate or severe symptoms (NYHA functional class II or III) despite optimal 
medical treatment and a pressure gradient across the LVOT (both measured using 
transthoracic cardiac echo Doppler and invasively during cardiac catheterization) 
of ≥ 50 mm Hg at rest. Detailed clinical data are shown in Table 1, and the study 
protocol is presented in Table 2.
The 2D echo Doppler examination was performed using the guidelines of the 
American Society of Echocardiography. LVOT gradients were assessed using con-
tinuous wave Doppler at rest and after the Valsalva manoeuvre. Mitral regurgitation 
and systolic anterior motion (SAM) of the mitral valve were graded on a 0-3 scale, 
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Table 1. Clinical characteristics of the three study patients. 
Patient NYHA IVS LVOTG MR SAM LA LV ED/ES
Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post
1 3 2 20 18 64 30 2+ 1+ 3 2 50 50 40/19 40/19
2 3 1 18 16 150 16 2+ 1+ 2 1 40 40 42/25 42/25
3 3 1 19 17 150 30 3+ 1+ 3 1 39 40 31/18 31/18
Clinical and echocardiographic characteristics of the three PTSMA-treated patients. Data are presented before and three months after the 
procedure. Abbreviations: NYHA = New York Heart Association functional class. IVS = Interventricular septum (mm). LVOTG = Left ventricular 
outfl ow tract gradient (mm Hg). MR = Mitral regurgitation (grade). SAM = Systolic anterior motion (grade). LA = Left atrium (mm). LV ED/ES = 
Left ventricular end-diastolic and end-systolic dimensions (mm). For further explanation see text.
Table 2. Study protocol
Before During 3 months follow-up
Clinical examination X X X
ECG X X X
2D-echo/Doppler X X X
CAG X
Haemodynamics X X
Exercise test X X
PostPre
BA
Figure 1.  Left ventricular outfl ow tract gradient. The LV-pressure curve in relation to the aortic pressure curve before (panel A) and after (panel 
B) the procedure is depicted. There is a signifi cant reduction of the LVOT-pressure gradient after the procedure.
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where 0 = absent and 3 = severe with complete septal mitral apposition. Symp-
tom-limited bicycle exercise test in the upright position was performed using 20W 
protocol (increased by 20W every minute) under continuous monitoring of heart 
rate and blood pressure.
Intervention
The patients underwent PTSMA as described by Sigwart.3 The right and the left 
femoral arteries were cannulated using a standard Judkins technique.
Professor Sigwart performed the fi rst investigation in our department. A 6F pace-
maker lead was placed in the right ventricle, an 6F pigtail catheter was positioned 
into the left ventricle and a 7F Judkins guiding catheter in the ascending aorta. 
The LVOT gradient was measured at rest, during the Valsalva manoeuvre and after 
a ventricular extra systole. Continuous monitoring of the LVOT pressure gradient 
was performed during the whole procedure (fi gure 1). After an i.v. standard bolus 
of 10,000 U heparin, the ostium of the left coronary artery was intubated and the 
large fi rst septal branch identifi ed on the coronary arteriogram. This was followed 
by insertion of a 0.014 inch guide wire into this septal branch and then a 2.0 x 10 
mm balloon was placed in the proximal part of the target artery (fi gure 2).
When a satisfactory balloon position was achieved, the guide wire was pulled back 
and 1 ml of echo contrast agent (Sonovue, Altana Pharma, Bracco, Italy) was injected 
through the balloon catheter shaft during simultaneous registration of transthoracic 
2D echo (fi gure 3A). This makes it possible to determine the part of the myocardium 
supplied by the targeted septal artery and also to visualize any leakage of contrast, 
which appears in the left ventricular cavity. If this was the case, the balloon was re-
positioned and the procedure repeated. If no leakage occurred and the myocardial 
Pre
Pre Post
Figure 2. Coronary arteriography before and after PTSMA. Observe that the septal branch disappeared after the procedure.
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was slowly injected through the balloon catheter shaft. If necessary the procedure 
was repeated until a maximum of 6 ml ethanol was given. Five minutes after ethanol 
injection the balloon was defl ated and coronary arteriography repeated. The LVOT 
gradients were continuously determined again. If the results were not satisfactory 
the whole procedure, including contrast echo injection, was repeated. Not only the 
LVOT gradients, but also the presence of mitral regurgitation as assessed from 2D 
echo Doppler were taken into account during the procedure.
RESULTS
Acute results
In these three patients one septal branch per patient was occluded by injection 
of 4-6 ml 96% ethanol. There were no complications during the PTSMA procedure. 
Continuous recording of the LVOT gradient revealed a reduction of the gradient 
from 120 ± 40 mm Hg to 25 ± 5 mm Hg. During the procedure, AV conduction was 
prolonged and in two patients complete 3rd degree AV block occurred. However, at 
the end of the procedure only one patient needed temporary pacing. No patient 
had AV block up to 48 hours after the procedure. Maximal CK levels were 2100 IU, 
2100 IU and 2500 IU, respectively. 
B
Figure 3. Panel A. Two-dimensional echocardiogram during PTSMA. 1.5 ml Sonovue® is injected into the targeted septal branch under 
continuous monitoring of 2D echo. The targeted myocardium is shown as an opacifi cation of echo contrast in the myocardium. For further 
explanation, see text.
Panel B. Two-dimensional echocardiogram after PTSMA. Observe the myocardial thinning and the site of infarction after PTSMA. This has 
probably caused remodeling of the left ventricle. Also, systolic anterior motion is absent. 
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In one patient 2nd degree AV block occurred after 48 hours, which resumed after 
another 24 hours of monitoring. Two patients were sent home on day 3; one patient, 
who had 2nd degree AV block, was sent home on day 5.
Follow-up at three months
All patients were seen in the outpatients’ clinic between six weeks and two months 
by the principal investigator (Dr. ten Cate). All three showed an improvement in va-
lidity from NYHA class III to II and I (one and two patients, respectively). All patients 
showed an improvement in exercise time from seven to ten minutes
DISCUSSION
Our preliminary results in these three patients confi rm studies of others describ-
ing larger patient groups and longer follow-up.3-7 In this respect, although rather 
preliminary, these results are in agreement with the results obtained by surgical 
myectomy and valvuloplasty.
PTSMA requires no thoracotomy and, if necessary, the procedure can be repeated 
on another occasion, if the gradient is not abolished satisfactory. This makes it a 
highly attractive therapeutic procedure.
As with any new procedure, safety precautions are of outmost importance. Since 
leakage of ethanol into the left anterior descending or larger branches can cause 
signifi cant myocardial infarction, we would advise the use of contrast echo to de-
termine the myocardium at risk and to see online whether leakage might occur into 
the LV cavity during the whole procedure.7
We consider it very important to keep the indications for PTSMA similar to those 
for surgery, namely inadequate medical treatment together with an LVOT gradient 
of ≥ 50 mm Hg at rest. 
The long-term eff ects of the present therapeutic procedure are favorable.4-6 How-
ever, HOCM is a heterogeneous disease with a heterogeneous clinical presentation 
and outcome. This means that experience with this technique should be restricted 
to cardio-thoracic centers experienced to treat patients with HOCM. Ideally, PTSMA 
should be compared to surgical therapy in a randomized, prospective trial to de-
termine its signifi cance in the treatment of this fascinating disease. Therefore, we 
agree with a recent Editorial by the group of Spencer who pleaded for a registry of 
patients with PTSMA to be able to determine undesired side eff ects.8
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ABSTRACT
Background: Transthoracic myocardial contrast echocardiography to guide percu-
taneous transluminal septal myocardial ablation (PTSMA) is an important additional 
technique to optimize hemodynamic outcome and to minimize adverse eff ects dur-
ing and after the procedure. The use of intracardiac echocardiography has not been 
previously investigated.
Methods: Intracardiac echocardiography was performed in 18 consecutive patients 
with hypertrophic obstructive cardiomyopathy. The target septal branch was cho-
sen, based on the septal risk-area (SRA) visualized by intracardiac echocardiography 
after injection of an ultrasound contrast agent into the septal artery. In 12 patients, 
myocardial infarct size was evaluated by magnetic resonance imaging (MRI), 4 days 
after PTSMA.
Results: The mean interventricular septal width at intracardiac echocardiography 
was 21 ± 4 mm. During ethanol administration, a backscatter signal enhancement 
of the SRA was detected, allowing precise determination of its surface area. Using 
planimetry, the mean surface area of SRA after ethanol injection measured 1.8 ± 0.8 
cm2. This area correlated well with the volume of the myocardial infarction on MRI 
(22 ± 7 cc, r = 0.80). The invasive left ventricular outfl ow tract (LVOT) gradient was re-
duced from 74 ± 35 mmHg to 8 ± 16 mmHg (p<0.0001) at the end of the procedure. 
In one patient, a venous dissection occurred during introduction of the intracardiac 
echocardiography catheter, which did not allow its further use.
Conclusions: Intracardiac echocardiography is an accurate technique to monitor 
ethanol administration during PTSMA. The method is useful to predict the extent of 
the planned myocardial infarction.
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INTRODUCTION
The presence of a left ventricular outfl ow tract (LVOT) obstruction is strongly re-
lated to symptoms in patients with hypertrophic obstructive cardiomyopathy.1-3 
Percutaneous transluminal septal myocardial ablation (PTSMA) has emerged as an 
eff ective treatment modality for these patients, resulting in clinical and hemody-
namic improvement comparable to surgery.4-8 Transthoracic myocardial contrast 
echocardiography (MCE) has been shown to be of benefi t for target vessel selection 
to guide PTSMA.9 Furthermore, prevention of retrograde spill of ethanol into the 
left anterior descending coronary artery as well as misplacement of the myocardial 
infarction as source of potentially fatal complications were observed with this ap-
proach.10 Intracardiac echocardiography is an invasive tool, recently introduced in 
our clinical setting, which might have the ability to provide a precise visualization 
of cardiac and valvular anatomy to guide interventional procedures.11-13 The aim of 
the current study was to evaluate the role of intracardiac echocardiography during 
PTSMA in predicting the extent of the myocardial infarction.
MATERIAL AND METHODS
Patient Population
Between September 2003 and February 2005, 19 consecutive patients with hyper-
trophic obstructive cardiomyopathy underwent PTSMA at the Thoraxcenter. In one 
patient, the use of intracardiac echocardiography was abolished due to a venous 
dissection during introduction of the echo-catheter. Patient selection was based 
on the presence of a LVOT gradient ≥ 50 mm Hg, as documented by transthoracic 
echocardiography, and persisting symptoms, despite optimal medical treatment. 
Twelve patients underwent magnetic resonance imaging (MRI), 4 days after the 
procedure. Our institutional review committee approved the study and all patients 
gave informed consent.
Intracardiac Echocardiography Procedure
The AcunavTM –intracardiac probe is a 10F catheter equipped with a linear phased 
array bifrequency (6-7 MHz) transducer. The catheter has a quadric-directional steer-
able tip, with a proximal control unit for tip defl ection. The insertable length of the 
catheter is 90 centimetres. Regular two-dimensional echocardiography along with 
colour Doppler, pulsed and continuous wave Doppler allows comprehensive anatom-
ical and physiological assessment. The probe was interfaced with Sequoia or Cypress 
platform (Siemens Acuson, Mountainview, California), and the images were digitally 
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recorded. Bilateral femoral arterial and venous accesses were obtained by a modifi ed 
Seldinger technique. A 11F venous sheath was placed on the left side to introduce the 
intracardiac echocardiography probe. A temporary pacemaker lead was positioned 
in the right ventricle (Bipolar Electrode Catheter, 5F, Arrow, Germany). The tip of the 
intracardiac echocardiography probe was advanced into the right atrium with the 
piezo-electric crystal facing the free wall of the right atrium. Next, the probe was 
gradually defl ected towards the atrial septum and advanced into the right ventricle 
to obtain a long axis of the left ventricle (LV). LVOT and mitral valve were evaluated in 
echocardiographic secta scan, by Doppler mode. The M-mode of the mitral valve in 
this plane confi rmed the systolic anterior motion and thickness of the interventricular 
septum (IVS). The probe was locked in this position to view the entire proximal and 
midseptum for further imaging during myocardial contrast injection and ablation. 
Coronary angiography was performed in multiple projections to delineate the septal 
perforator branches. The supposed target vessel artery was identifi ed and cannulated 
with a 0.014 inch guide wire. A 2.5 x 9 mm over the wire balloon was advanced into 
the vessel and infl ated at 5-6 atmospheres to prevent retrograde fl ow into the left 
anterior descending coronary artery. After injection of 1 ml ultrasound contrast agent 
(Sonovue, Bracco, Milan, Italy) through the balloon catheter shaft, the myocardial 
area supplied by the vessel (septal risk area, SRA) could be visualized and any leakage 
form the septal branch or an anomalous distribution could be excluded. PTSMA was 
performed according to standard protocol 14. The images obtained during infusion 
of ethanol revealed the progressive appearance of a sharply demarcated area with 
increased echo density in the septum within the SRA producing a marked shadowing 
eff ect (Figure 1). Measuring the invasive residual LVOT completed the procedure. 
Figure 1. Image of the SRA (with ethanol) visualized by intracardiac echocardiography. Note the marked shadowing eff ect. 
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Measurements
The left ventricular outfl ow tract (LVOT) gradient was continuously monitored with 
simultaneous pressure recordings in the LV (6F pigtail catheter) and in the ascend-
ing aorta (7F Judkins guiding catheter).
Echocardiographic measurements included maximal septal thickness, septal 
thickness at the site of treatment, mitral regurgitation (MR) grade, severity of sys-
tolic anterior motion (SAM) of the anterior mitral leafl et and LVOT gradient. Septal 
thickness was measured by intracardiac echocardiography in a long-axis, end-dia-
stolic still-frame of the LV. MR grade was assessed by color-fl ow Doppler intracar-
diac echocardiography and graded on a scale from 0 (no regurgitation) to 4 (severe 
regurgitation). SAM of the anterior mitral leafl et was graded as 0 (absent), 1+ (mild; 
minimal mitral-septal distance >10 mm during systole), 2+ (moderate; minimal mi-
tral-septal distance ≤10 mm during systole) or 3 (marked; brief or prolonged contact 
between the anterior mitral leafl et and septum) 15. The myocardial hyperechoic area 
developed during alcohol injection (ablated area) was off -line planimetrized.
MRI protocol
A clinical 1.5-Tesla MRI scanner with a dedicated cardiac four element phased-array 
receiver coil was used for imaging (Signa CV/i, GE Medical systems, Milwaukee, Wis-
consin). Repeated breath-holds and gating to the electrocardiogram were applied 
to minimize the infl uence of cardiac and respiratory motion on data collection. The 
ce-MRI protocol consisted of cine-MRI and DE-imaging. 
Left ventricular volumes and wall dimensions were assessed with cine-MRI using a 
steady-state free-precession technique (FIESTA) with the following imaging param-
eters: 6-10 seconds per breath-hold per slice (depending on heart rate), 24 phases 
per slice location, Field of View: 36 x 36 cm; TR 3.4; TE 1.4; fl ip angle 45 degrees; 
matrix 160 x 128, bandwidth 83 kHz, 0.75 NEX.) To cover the entire LV, 9 to 12 con-
secutive slices of 8 mm were planned in short axis view (gap of 2 mm) perpendicular 
to the horizontal long axis (4-chamber view) of the LV. 
Myocardial distribution of DE was studied 10-20 minutes following intravenous 
administration of Gadolinium-DTPA (0.1 mmol/kg, Magnevist®, Schering). A 2-D 
T1-weighted inversion recovery gradient-echo sequence with the following imag-
ing parameters was used; FOV: 40 x 32 cm, slice thickness 8 mm gap 2 mm, TR 7.3, 
TE 1.6, fl ip angle 20 degrees, TI 180 - 275 ms, matrix 256 x192, 1 NEX, bandwidth 
17.9 kHz. The inversion time was adjusted per patient to null the signal of remote 
myocardium. Slice locations of the DE-images were copied from the cine images. A 
myocardial segment was judged as non-assessable if the region of DE could not be 
diff erentiated clearly from the healthy myocardium (breathing artefacts, erroneous 
ECG triggering).
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Analysis of MRI
The maximum width of the IVS was measured on cine-images in the LVOT-plane 
by a physician, who was blinded for the intracardiac echocardiography images. 
DE-myocardium was clearly diff erentiated from remote myocardium (nulled signal) 
with the use of an inversion recovery pulse sequence. Data from one patient had to 
be excluded since image quality was impaired. The volume of DE was quantifi ed by 
manually selecting the enhanced regions from the consecutive 2D slices encom-
passing the LV with dedicated software (Cine, GE, 3.4.0, USA). 
Figure 2. Correlation between the surface area (cm2) of the SRA (with ethanol) measured by intracardiac echocardiography and the myocardial 
infarct size (cc) measured by delay-enhancement MRI.
Figure 3. SRA (with ethanol) visualized by intracardiac echocardiography and the corresponding infarcted area visualized by MRI (panel B) after 
ethanol injection in two diff erent septal branches.
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RESULTS
Eighteen patients (mean age 62 ± 13 years; 12 (67%) men) completed the procedure 
under intracardiac echocardiography guidance. The mean baseline NYHA functional 
class was 2.5 ± 0.5. All patients were in sinus rhythm.
The maximum width of the IVS measured by intracardiac echocardiography ranged 
from 15 to 30 mm (mean 21 ± 4 mm), which correlated with the MRI measurements 
(22 ± 4 mm, r = 0.70). Mean IVS thickness on intracardiac echocardiography at the 
level of ethanol injection was 20 ± 4 mm. The mean grade of SAM was 2.2 ± 0.9 and 
a moderate MR was present in 3 patients (17%). 
Ethanol dose injected during the procedure was on average 2.1 ± 0.7 ml. Rest-
ing LVOT gradient was reduced from 74 ± 35 mmHg to 8 ± 16 mmHg (p<0.0001) 
and, after extra systolic beats, reduced from 130 ± 49 mmHg to 34 ± 33 mmHg 
(p<0.0001). In 1 patient, another, more proximally located septal branch was intu-
bated, since occlusion of the fi st selected branch resulted in a moderate proximal 
localization of the ablated area and with a small reduction in LVOT gradient (20 
Figure 4. Triangular shaped ablated area visualized by intracardiac echocardiography during PTSMA (panel A) and corresponding infarct area 
visualized by MRI long axis (panel B).
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mmHg). The procedure was successful and the immediate reduction of LVOT gradi-
ent was higher (50 mmHg). Peak CK-MB and Troponin T was 161 ± 58 IU/L and 2.5 ± 
1.1 UI/L, respectively. 
The mean ablated area (with ethanol) on planimetry was 1.8 ± 0.8 cm2, which 
correlated with the MRI-determined infarcted volume (22 ± 7 cc, r = 0.80) (Figure 2, 
see also fi gure 3, 4, 5). In 1 patient, introduction of the intracardiac echocardiogra-
phy catheter induced a venous dissection. The PTSMA procedure in this patient was 
performed only with transthoracic echocardiography. 
DISCUSSION
The present study demonstrates that intracardiac echocardiography is a accurate 
imaging technique, which can be used to guide ethanol administration during 
PTSMA, particularly in the selection of the appropriate septal branch. Also, the 
surface area of the contrast-enhanced SRA after ethanol injection, as visualized by 
Figure 5. Ablated area visualized by intracardiac echocardiography and corresponding infarct area visualized by MRI long axis (panel B) in a 
patient who underwent PTSMA of two septal branches.
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intracardiac echocardiography, correlated well with the infarcted size measured by 
delay-enhancement MRI, 4 days after the intervention. 
MCE using transthoracic echocardiography is useful in guiding and monitoring 
the PTSMA procedure, with a cumulative impact on the interventional strategy 
reported in about 15-20%. Moreover, it can be helpful in defi ning the end of the 
procedure. An appropriate impregnation of the target region has been reported 
to represent a possible marker to interrupt the procedure, independently of the 
hemodynamic result since the remodelling process that lately occurs, plays a role 
in the reduction of the obstruction.16 During the current procedures, intracardiac 
echocardiography has been used as a complementary tool to transthoracic MCE. 
The technique, however, may be managed in a completely autonomous fashion 
by the interventional team, without the need of constant presence of a standard 
ultrasound device and an experienced operator during the procedure. The echocar-
diographic images with intracardiac echocardiography are more easily obtained as 
compared to transthoracic echocardiography and provide a clear defi nition of the 
cardiac structures with a higher image resolution as compared to the transthoracic 
approach. Furthermore, continuous imaging can be provided during the entire pro-
cedure. As compared to transthoracic echocardiography, intracardiac echocardiog-
raphy can overcome major limitations, including anatomic acoustic barriers (ribs 
and lungs), obesity, thoracic wall deformity and pulmonary conditions, especially 
since the patients are examined in a supine position during PTSMA.
CONCLUSIONS
Intracardiac echocardiography can be used to monitor ethanol administration dur-
ing PTSMA in hypertrophic obstructive cardiomyopathy patients. The surface area 
of the echo-enhanced SRA after ethanol injection correlates well to the volume of 
the myocardial infarction, measured by delay-enhancement MRI. Furthermore, it 
provides high-quality, continuous imaging of the myocardial segments and valvular 
structures involved during the PTSMA procedure.
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ABSTRACT 
Objectives: The study was designed to evaluate the value of myocardial contrast 
echocardiography (MCE) during percutaneous transluminal septal myocardial abla-
tion (PTSMA) in predicting the site and size of ethanol-induced septal myocardial 
infarction (SMI) as determined by magnetic resonance imaging (MRI).
Background: PTSMA entails the induction of a localized SMI with the intention 
to reduce left ventricular outfl ow tract obstruction in symptomatic patients with 
hypertrophic obstructive cardiomyopathy (HOCM). Both site and size of SMI are im-
portant to optimize hemodynamic results and to maximally preserve left ventricular 
function after PTSMA. MCE has been introduced as a tool to accurately predict site 
and size of SMI before defi nite ethanol injection.
Methods and Results: Seventeen consecutive HOCM patients underwent Sono-
Vue® MCE-guided PTSMA and MRI after one month. All patients had SonoVue® 
opacifi cation of the mid anteroseptal and posteroseptal segments. At follow-up, 
91% of these segments showed SMI at MRI. SonoVue® opacifi cation was present in 
41% of the basal anteroseptal and posteroseptal segments. Negative and positive 
predictive values of SonoVue® opacifi cation for basal SMI at MRI were 10% and 
86%, respectively. Despite an excellent correlation between total septal surface 
area at echocardiography and total septal volume at MRI (R = 0.79, P<0.001), there 
was a poor correlation between the SonoVue® opacifi ed septal surface and MRI 
determined fi nal SMI volume (R = 0.09, P = NS). Injected ethanol volume correlated 
signifi cantly with post-PTSMA peak CK-MB fraction (R = 0.73, P<0.001).
Conclusions: MCE has an excellent positive predictive value for the desired mid-
septal site of ethanol-induced SMI. However, SMI frequently extend into more basal 
septal parts and the correlation between the SonoVue® opacifi ed area and SMI size 
at follow-up is poor. SMI size depends primarily on injected ethanol volume. 
Myocardial contrast echocardiography guiding PTSMA 115
INTRODUCTION
Percutaneous transluminal septal myocardial ablation (PTSMA) is a catheter-guided 
procedure to treat patients with hypertrophic obstructive cardiomyopathy (HOCM) 
and drug refractory symptoms. The procedure entails the induction of a localized 
septal myocardial infarction (SMI) by infusion of highly concentrated ethanol into 
one or more septal arteries.1 In the initial series, a relatively high complication rate 
was noted, particularly advanced atrio-ventricular heart block.2-4 Other, less com-
mon, complications included extensive myocardial infarction due to retrograde spill 
of ethanol in the left anterior descending coronary artery or connections from the 
septal system to right ventricular branches.5,6 
Myocardial contrast echocardiography (MCE) may be useful in predicting the site 
and size of the ethanol-induced SMI.7,8 Correct prediction of SMI site is important 
because maximal left ventricular outfl ow tract (LVOT) gradient and systolic anterior 
motion (SAM) reduction can only be reached when the intervention includes the 
area of mitral-septal contact.6,9 Correct prediction of SMI size is important because 
this area should be as minimal as possible to maximally preserve left ventricular (LV) 
function and to reduce post-PTSMA atrio-ventricular conduction disturbances and 
need for permanent pacemaker implantation.10,11 In the present study, we will focus 
on the ability of MCE to predict site and size of ethanol-induced SMI, assessed by 
markers for myocardial necrosis, magnetic resonance imaging (MRI) and transtho-
racic echocardiography (TTE).
METHODS
Patient selection
The study population comprised 17 consecutive HOCM patients with drug-refrac-
tory symptoms, who were referred for PTSMA. All subjects demonstrated a dynamic 
LVOT gradient of ≥ 50 mmHg at rest or on provocation. The hospital’s ethical commit-
tee approved all PTSMA procedures with informed consent given by the patient.
PTSMA procedure
Before PTSMA, all patients underwent diagnostic coronary angiography to exclude 
signifi cant coronary artery disease. PTSMA was performed as previously described.5 
Briefl y, a temporary pacemaker lead was positioned in the right ventricle and hemo-
dynamic assessments, including a LVOT gradient, were performed. During the pro-
cedure, MCE was used to identify the septal region provided by the selected septal 
branch. If the relation of this region to the site of mitral-septal contact was judged 
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satisfactorily, an angioplasty balloon (1.5-2.5 x 10 mm) was infl ated in this branch. 
Then 0.5 ml concentrated ethanol was injected through the balloon catheter shaft 
in 30 seconds. If the LVOT gradient remained >30 mm Hg, the procedure was re-
peated in the same or another septal branch, otherwise the balloon was defl ated 
and coronary angiography was repeated in order to confi rm discontinuation of the 
septal branch. The pacemaker lead was left in situ for at least 48 hours after the 
procedure and the patient was transferred to the clinical department for telemetric 
observation.
Echocardiographic analysis
Before PTSMA and at 6-months follow-up, TTE was performed to evaluate septal 
thickness at the site of treatment, LVOT gradient, grade of mitral regurgitation and 
SAM. Septal thickness was measured in the parasternal long-axis view in an end-
diastolic still-frame (defi ned as the last frame before closing of the mitral valve). 
Peak LVOT gradient was calculated from the colour-guided continuous-wave Dop-
pler velocity using the modifi ed Bernoulli equation. Mitral regurgitation severity 
was assessed by colour fl ow Doppler echocardiography and graded on a scale from 
0 (no regurgitation) to 4 (severe regurgitation). SAM of the anterior mitral valve leaf-
let was graded as 0 (absent), 1 (mild; minimal mitral-septal distance >10 mm during 
systole), 2 (moderate; minimal mitral-septal distance ≤10 mm during systole) or 3 
(marked; brief or prolonged contact between the anterior mitral valve leafl et and 
septum).
MCE study
Imaging was performed using a Sonos 5500 system (Philips, Best, The Netherlands) 
with the S3 transducer. For contrast imaging transmitted frequency was 1.6 MHz 
and received frequency 3.2 MHz with a mechanical index of 1.6. As a contrast agent, 
SonoVue® (Bracco, Milan, Italy) was used, a blood pool ultrasound contrast agent 
based on microbubbles stabilised by a phospholipids shell and fi lled with sulphur 
hexafl uoride gas with a mean size of 2.5μm.12 SonoVue®was administered intra-
coronary as a slow bolus of 1,0 ml. All images were digitally stored and analysed 
off -line by two observers, blinded to the patients’ clinical status. The LV was divided 
into 16 segments according to the American Society of Echocardiography with the 
anterior and posterior septum divided into basal, mid and distal segments.13 The 
segments were scored positive or negative for SonoVue® opacifi cation. From the 
apical 4-chamber view, the end-diastolic horizontal cross-sectional total and Sono-
Vue® opacifi ed septal surface area was planimetered.
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Cardiac Magnetic Resonance Imaging
Cardiac MRI was performed at baseline and 1-month after PTSMA with a 1.5 Tesla 
clinical scanner (Sonata, Siemens) and a four-element phased-array body radiofre-
quency receiver coil. All images were acquired with ECG gating and during repeated 
breath-holds of 10 to 15 seconds, depending on heart rate. Cine images were ac-
quired using a segmented steady-state-free precision sequence in three long-axis 
views and in multiple short-axis views every 10 mm, covering the entire LV from 
base to apex. At 1-month follow-up, contrast-enhanced MRI was also performed. 
Contrast-enhanced (CE) images were acquired 15 to 20 minutes after intravenous 
administration of 0.2 mmol/kg gadolinium-DTPA in the same views as in the cine MRI 
with a 2D, segmented, inversion-recovery, prepared gradient-echo sequence.14-16
Analysis of CE and cine images
Contrast-to-noise ratio of the hyperenhanced area versus a remote nonenhanced 
myocardial area was measured on the short-axis slice demonstrating the largest 
area of hyperenhancement. Contrast-to-noise ratio was calculated using regions of 
interest and defi ned as: (SI
hyperenhanced
 − SI
remote
)/noise, where SI is signal intensity, and 
noise is expressed as the SI standard deviation in a background region of interest. 
Infarct size after PTSMA was measured by manual tracing of the hyperenhanced ar-
eas, which were defi ned as the areas within the septal myocardium with pixel SI val-
ues >4 SD of remote, nonenhanced myocardium. Central dark zones within the area 
of hyperenhancement were included. The center of the infarct area was defi ned as 
the center of the hyperenhanced area on the short-axis image with the largest area 
of hyperenhancement. The interventricular septum was defi ned as the myocardium 
between the anterior and posterior junctions of the right ventricle to the LV. Septal 
myocardial mass was quantifi ed with the MASS software package (MEDIS).
Statistical analysis
Continuous variables were presented as mean ± standard deviation values and were 
compared using Student’s unpaired t-test. Linear regression analysis was used to 
analyze the relationship between the various echocardiographic, MRI-determined 
and PTSMA-related parameters. The Mann-Whitney U test was used to evaluate the 
correlation between diff erent infarction locations and myocardial infarction size 
and the volume of ethanol administered. All statistical signifi cance was set at a P 
value ≤ 0.05.
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RESULTS 
Baseline and follow-up echocardiographic and clinical data
As seen in Table 1, mean septal thickness, LVOT gradient, mitral regurgitation and 
SAM grade all signifi cantly decreased. Mean NYHA functional class improved from 
2.2 ± 0.4 to 1.4 ± 0.6 (P<0.001). Mean injected ethanol volume was 3.8 ± 1.1 ml, 
and mean post-PTSMA peak CK-MB fraction was 273 ± 77 IU/L. As seen in Figure 
1, injected ethanol volume correlated signifi cantly with post-PTSMA peak CK-MB 
fraction (R = 0.73, P<0.001).
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Figure 1. Correlation between peak CK-MB fraction and injected ethanol volume.
Table 1. Baseline clinical and echocardiographic characteristics of the 17 study patients.
Baseline Follow-up P-Value
Male gender 13 (76%)
Age, years 44 ± 13
NYHA, class 2.2 ± 0.4 1.4 ± 0.6 <0.001
IVS, mm 21 ± 3 14 ± 3 <0.001
LVOTG, mmHg 95 ± 29 22 ± 27 <0.001
MR, grade 1.4 ± 0.6 0.8 ± 0.8 0.04
SAM, grade 2.6 ± 0.6 1.5 ± 1.1 0.001
Abbreviations: NYHA = New York Heart Association. IVS = Interventricular Septum. LVOTG = Left Ventricular Outfl ow Tract Gradient. 
MR = Mitral Regurgitation. SAM = Systolic Anterior Motion.
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Prediction of infarct site with MCE
In Figure 2, the relation between SonoVue® opacifi ed septal segments and SMI site, 
as determined by TTE and MRI at follow-up, is shown. All patients had SonoVue® 
opacifi cation of the mid anteroseptal and posteroseptal segments. At follow-up, 
85% of these segments showed SMI at TTE and 91% showed SMI at MRI. SonoVue® 
opacifi cation was present in 41% of the basal anteroseptal and posteroseptal seg-
ments. Negative and positive predictive values of SonoVue® opacifi cation for basal 
septal SMI at TTE were 65% and 43%, respectively. For MRI these values were 10% 
and 86%, respectively. There were no diff erences between prediction of SMI for 
basal anteroseptal and posteroseptal opacifi ed segments.
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Figure 2. Relation between positive or negative echo contrast opacifi ed septal segments (depicted in columns) and the presence or absence of 
septal myocardial infarction at transthoracic echocardiography (TTE, upper two lanes) and magnetic resonance imaging (MRI, lower two lanes), 
at follow-up. Abbreviations: AS = Antero-Septal segment. PS = Postero-Septal segment.
Prediction of infarct size with MCE
Mean horizontal septal cross-sectional surface area at TTE was 15.5 ± 3.8 cm2 (range 
11.0 to 23.0 cm2). Mean septal volume at MRI was 84.8 ± 22.1 cm3 (range 40.6 to 127.9 
cm3). As seen in Figure 3, total septal surface area at TTE correlated signifi cantly with 
total septal volume at MRI (R = 0.79, P<0.001). Mean SonoVue® opacifi ed septal 
surface area was 5.7 ± 2.1 cm2 (range 2.6 to 9.3 cm2) and involved 37.6 ± 15.2% of 
the total septal surface area. Mean septal volume, as determined by the pre- and 
post-interventional MRI images, decreased by 11.7 ± 4.8% and mean SMI volume 
(expressed as percentage of total pre-PTSMA septal volume) was 30.2 ± 11.8%. Total 
myocardial volume (summation of lost and necrotic muscle volume) decreased by 
41.9 ± 14.3%. As seen in Figure 4, SMI volume at MRI correlated signifi cantly to peak 
CK-MB fraction (R = 0.60, P = 0.017). Non-signifi cant correlations were seen between 
SonoVue® opacifi ed septal surface area and injected ethanol volume (R = -0.42), 
peak CK-MB fraction (R = -0.32), and (MRI determined) SMI volume (R = 0.09). As 
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seen in Figure 5, SMI volume at MRI was only related to SonoVue® opacifi ed septal 
surface area when this area was corrected for injected ethanol volume (R = 0.56, 
P = 0.02).
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Figure 3. Correlation between pre-PTSMA horizontal septal cross-sectional surface area at transthoracic echocardiography (TTE) and septal 
volume at magnetic resonance imaging (MRI)
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Figure 4. Correlation between peak CK-MB fraction and infarction volume at magnetic resonance imaging (MRI).
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DISCUSSION
PTSMA is an eff ective therapy to treat patients with symptomatic HOCM. The proce-
dure mimics surgical septal myectomy to relieve the LVOT gradient in that a septal 
trough is created after induction of a localized SMI.3,17 However, due to the anatomic 
variations of the septal perforator coronary arteries, it is diffi  cult to predict the site 
and size of the ethanol-induced SMI.6,9,18 Correct prediction of SMI site is important 
because maximal LVOT gradient and SAM reduction can only be reached if the inter-
vention includes the area of mitral-septal contact.9,19-21 Correct prediction of SMI size 
is important because SMI size should be as small as possible to maximally preserve 
LV function and to minimize atrio-ventricular conduction abnormalities.22,23 
Probatory balloon occlusion of the target septal artery has been propagated as a 
tool to predict the hemodynamic eff ect of permanent septal occlusion after ethanol 
injection.2,24 With this technique, only the acute reduction in LVOT gradient, mainly 
due to a lesser peak acceleration rate of blood fl ow proximal to the obstruction, can 
be assessed.25 Furthermore, spontaneous variability of the LVOT gradient as well as 
the infl uence of various peri-procedural interventions (i.e. use of analgesic agents 
or need for blood volume correction) on the severity of the LVOT gradient may be 
underestimated.
Our study is the fi rst that correlates the site and size of the echo contrast-enhanced 
target septal area to defi nite SMI site and size, as evidenced by MRI.
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Figure 5. Correlation between infarction volume at magnetic resonance imaging (MRI) and SonoVue® opacifi ed septal surface area corrected 
for injected ethanol volume.
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Role of MCE in predicting infarction site
MCE-guided PTSMA was introduced to identify the location of the target sep-
tal area in order to predict the site of ethanol-induced SMI. Several authors have 
demonstrated that, in order to obtain the most eff ective LVOT gradient reduction, 
the opacifi ed septal area should entail the area located proximal and distal from 
the septal-mitral contact site.4,6,26 Additionally, MCE has a major role in ruling out 
involvement of segments distant from the septal target area.6 In our study, the 
positive predictive value of MCE for the site of ethanol-induced SMI was excellent. 
However, SMI extended frequently into more basal septal parts. Importantly, the 
target mid-septal areas were virtually always involved in the infarction area. This is 
an important fi nding because the site of SMI seems of greater importance than its 
defi nitive size26,27 Only three SonoVue® opacifi ed mid septal segments (one antero-
septal and two postero-septal) did not show SMI with MRI at 1-month follow-up. 
Two of the 17 patients (12%) had late PTSMA failure (defi ned as a necessity for re-in-
tervention due to absence of clinical improvement or recurrence of symptoms and 
a signifi cant LVOT gradient). Only in one of these patients, the mid postero-septal 
segment did not show SMI at MRI.
Role of MCE in predicting infarction size
The area of SonoVue® opacifi cation did not correlate to SMI size at follow-up MRI. 
Methodological problems as the cause for this result seem unlikely since an excel-
lent correlation existed between baseline total echocardiographic septal surface 
area and MRI septal volume. In addition to this, there was a good correlation be-
tween SMI volume at MRI and peak CK-MB fraction. Several factors may account for 
the poor correlation between the area of SonoVue® opacifi cation and SMI size at 
follow-up. First, extension of SMI into more basal parts of the septum was poorly 
predicted by MCE. In fact, in most patients SMI extended into more basal parts of 
the septum. Second, the target area is a three-dimensional structure whereas the 
SonoVue® opacifi ed area is a cross-section with only two dimensions. Three-dimen-
sional assessment of SonoVue® opacifi ed volume may provide better predictive 
results. Finally, and probably most importantly, the SonoVue® opacifi ed area was 
inversely related to injected ethanol volume. After the starting bolus of ethanol, ad-
ditional ethanol was injected depending on the LVOT gradient reduction achieved 
with the previous ethanol dose. In agreement with others, we have described that 
ethanol volume is a major determinant of SMI size, whether measured with post-
PTSMA peak CK-MB fractions or SMI volume at MRI.4,27,28 Larger ethanol volumes will, 
until a certain maximum, obviously result in greater SMI volumes. When the Sono-
Vue® opacifi ed area was corrected for ethanol volume (the smallest SMI is expected 
in small SonoVue® opacifi ed areas with small ethanol volumes whereas the largest 
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SMI is expected in larger SonoVue® opacifi ed areas with large ethanol volumes) a 
reasonable correlation with fi nal SMI size was found.
IMPLICATIONS AND CONCLUSIONS
MCE has an excellent positive predictive value for the desired mid-septal site of 
ethanol-induced SMI. However, SMI frequently extend into more basal septal parts 
and the correlation between the SonoVue® opacifi ed area and SMI size at follow-up 
is poor. SMI size depends primarily on injected ethanol volume.
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ABSTRACT
Objectives: To predict outcome after percutaneous transluminal septal myocar-
dial ablation (PTSMA) in patients with hypertrophic obstructive cardiomyopathy 
(HOCM). 
Background: In symptomatic HOCM patients, PTSMA results in hemodynamic 
and clinical improvement comparable to surgical myectomy. However, the risk for 
procedure-related complications and need for re-intervention seems higher with 
PTSMA.
Methods: In 131 consecutive HOCM patients (mean age 56 ± 16 years), treated 
with PTSMA, in-hospital and follow-up complications as well as late PTSMA failure 
(defi ned as unsatisfactory clinical outcome and a signifi cant residual outfl ow tract 
gradient, necessitating re-intervention) were noted. Baseline hemodynamic, clini-
cal, electrocardiographic and echocardiographic variables were examined as deter-
minants for outcome. Also, the eff ect of ethanol volume and the role of a learning 
curve were investigated. 
Results: PTSMA was successful in 90% of patients. Cardiac events, which were re-
corded in-hospital or during follow-up, respectively, were noted in 20 patients and 
included; cardiac death (3 and 1%,resp.), acute myocardial infarction due to ethanol 
leakage (1 and 0%, resp.), coronary dissection (2 and 0%, resp.), non-fatal cardiac 
tamponade (1 and 0%, resp.) and permanent pacemaker (5 and 0%, resp.) or ICD (4 
and 1%, resp.) implantation. Late PTSMA failure was noticed in 12 patients (10%). All 
baseline characteristics were comparable between successful and failed patients. 
Ethanol volume was related to peak CK values (P<0.0001) but not to late PTSMA 
failure or greater need for pacemaker implantation. Late PTSMA failure occurred 
more frequently in PTSMA procedures performed in the early, less experienced time 
period (P<0.0001).
Conclusions: This study confi rms that PTSMA is eff ective to treat HOCM patients 
at the cost of a relatively high complication rate. Late PTSMA failure could not be 
predicted by baseline characteristics but could partially be explained by a learning 
curve eff ect. This implies that PTSMA procedures should be restricted to experi-
enced centres.
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INTRODUCTION
Hypertrophic obstructive cardiomyopathy (HOCM) is an inheritable disease charac-
terised by asymmetrical septal hypertrophy.1. Approximately one-quarter of these 
patients present with a signifi cant left ventricular outfl ow tract (LVOT) gradient, 
which is usually correlated with the degree of complaints.2 Until recently, septal my-
ectomy was regarded as the gold standard therapy for HOCM patients that remained 
symptomatic despite optimal medical treatment. During this surgical procedure, a 
trough within the hypertrophied septum is created by removal of myocardium,3 
which immediately leads to relieve of the LVOT gradient.4
Percutaneous transluminal septal myocardial ablation (PTSMA), introduced in 
1995, mimics surgical myectomy in that it reduces the LVOT gradient by remodelling 
the outfl ow tract.5 During the procedure, a localized septal myocardial infarction is 
induced by injection of ethanol into one or more septal branches, which supply 
that part of the hypertrophied septum believed to produce LVOT obstruction. This 
results in immediate LVOT gradient reduction due to contractile septal dysfunction 
followed by gradual diminution of the obstruction later in time, due to septal thin-
ning and further LVOT widening.6-8 Ethanol should be injected in the myocardial 
area that is located at or near the point of contact between septum and the anterior 
mitral valve leafl et.9,10 The amount of injected ethanol seems related to the fi nal in-
farct size, as refl ected by the rise in creatinine kinase (CK).11-13 However, the eff ect of 
the injected ethanol amount on PTSMA-related complications, as well as on clinical 
and echocardiographic outcome diff ers between various studies.12,14,15 
In the present study, we describe the results of PTSMA, performed at two experi-
enced Dutch centres. We noted the incidence of in-hospital and follow-up events as 
well as long-term PTSMA failure and compared baseline clinical, echocardiographic 
and PTSMA characteristics between patients with successful and failed PTSMA.
METHODS
Patient selection
The study population comprised 131 consecutive patients with HOCM who under-
went PTSMA between 1999 and 2004 at the Thoraxcenter Rotterdam or the Sint 
Antonius Hospital Nieuwegein. Inclusion criteria in both centers were identical and 
included persistent symptoms despite optimal medical treatment and a dynamic 
LVOT gradient ≥ 50 mmHg at rest or on provocation. All patients gave informed 
consent.
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Echocardiography analysis
Transthoracic echocardiography was performed to evaluate the site of hypertro-
phy, mitral valve anatomy and LVOT gradient. Septal thickness was measured in 
the parasternal long-axis view in an end-diastolic still-frame. Peak LVOT gradient 
was calculated from the color-guided continuous-wave Doppler velocity using 
the modifi ed Bernoulli equation. Mitral regurgitation (MR) grade was assessed by 
colour fl ow Doppler echocardiography and graded on a scale from 0 (no regurgi-
tation) to 4 (severe regurgitation). Systolic anterior motion (SAM) of the anterior 
mitral leafl et was graded as 0 (absent), 1+ (mild; minimal mitral-septal distance >10 
mm during systole), 2+ (moderate; minimal mitral-septal distance ≤ 10 mm during 
systole) or 3 (severe; brief or prolonged contact between the anterior mitral leafl et 
and septum).16 Left atrial and ventricular dimensions were measured using standard 
M-mode echocardiography from the parasternal long-axis view.
Percutaneous transluminal septal myocardial ablation
Before the procedure, all patients underwent diagnostic coronary angiography to 
exclude signifi cant coronary artery disease. PTSMA was performed with assistance 
of myocardial contrast echocardiography to identify the septal region provided by 
the selected septal branch.17 Imaging was performed using the Sonos 5500 (Philips, 
Best, The Netherlands) with an S3 transducer. For contrast imaging, transmitted 
frequency was 1.6 MHz and received frequency 3.2 MHz. Mechanical index was 1.6 
and frequency 25 Hz. One milliliter of a contrast agent (SonoVue™, Altana Pharma, 
Bracco, Italy) was administered intracoronary as a slow bolus to identify the septal 
myocardial region supplied by this selected septal branch. If the relation of this 
region to the site of mitral-septal contact was judged satisfactorily, a balloon was 
infl ated in this branch. Then, 0.5 to 1.0 ml concentrated ethanol was slowly injected 
through the balloon catheter shaft in 30 seconds. If the LVOT gradient remained >30 
mm Hg, the procedure was repeated after fi ve minutes in the same septal or another 
septal branch, otherwise the balloon was defl ated, and coronary angiography was 
repeated in order to confi rm discontinuation of the septal branch.
Follow-up
Follow-up data were collected at the outpatient clinic at the latest visit or before a 
re-intervention by the same cardiologist in each centre (FTC and JTB, respectively) 
and included mortality, pacing or defi brillating device implantation, New York Heart 
association (NYHA) class, and the earlier described echocardiographic characteris-
tics. Failed outcome after PTSMA was defi ned as necessity for re-intervention due 
to absence of clinical improvement or recurrence of symptoms and a signifi cant 
LVOT gradient. To analyze clinical and echocardiographic outcome according to the 
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injected amount of ethanol, patients were separated in three groups with a low 
(≤ 2 ml), intermediate (>2 to ≤ 4 ml) or high (>4 ml) amount of injected ethanol, 
respectively. To analyze the infl uence of a learning curve in relation to the PTSMA 
procedure, patients were separated into three groups, according to the experience 
with PTSMA.
Statistical analysis
Continuous variables were presented as mean ± standard deviation. The clinical, he-
modynamic and echocardiographic results of the three ethanol dose groups were 
analysed using the repeated measures of analysis of variance (ANOVA) method 
using the Bonferroni correction. This method was also applied to analyze the infl u-
ence of a learning curve in relation to the PTSMA procedure. Signifi cance was set at 
P<0.05. 
RESULTS 
Baseline characteristics
Baseline clinical, echocardiographic and PTSMA characteristics of the 131 patients 
are presented in Table 1 (fi rst column). Mean age of the patients was 56 ± 16 years, 
mean septal thickness was 19 ± 4 mm and mean LVOT gradient was 83 ± 36 mm Hg. 
Mean volume of injected ethanol was 2.9 ± 1.3 ml. Mean peak creatinine kinase (CK) 
was 1,404 ± 685 U/L and mean peak CK-MB fraction was 200 ± 156 U/L.
In-hospital events
Four patients died in relation to the PTSMA procedure. One patient died in the cath-
eterization laboratory due to refractory ventricular fi brillation after induction of 
the septal infarction. Three patients died at the fi rst day after the procedure due to 
unexplained cardiac tamponade (n = 1), cardiac tamponade caused by a pacemaker 
lead perforation (n = 1) and progressive heart failure (n = 1). One patient underwent 
successful pericardial drainage for cardiac tamponade that occurred after removal 
of the pacemaker lead. In one patient a large anterior myocardial infarction was 
induced due to spill of ethanol in the left anterior descending coronary artery. In 
two patients, dissection of the left anterior descending coronary artery required 
implantation of a drug-eluting stent. Six patients required permanent pacemaker 
implantation for persistent advanced atrioventricular block. In 4 patients a cardiac 
defi brillator was implanted because of ventricular fi brillation (n = 1) and ventricular 
tachycardia (n = 3) late after PTSMA.
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Follow-up events
During a mean follow-up of 17 ± 13 months three additional patients suff ered a car-
diac event (excluding re-interventions which are described later). In one patient a 
cardiac defi brillator was implanted 30 months post-PTSMA because of syncope with 
recorded ventricular tachycardia. Two patients died during follow-up. One patient 
with known poor pulmonary status died 12 months after PTSMA due to pulmonary 
failure. A second patient died suddenly 27 months after PTSMA. Total cardiac events 
are displayed in Table 2.
Electrocardiographic, echocardiographic and clinical characteristics at 
follow-up
As seen in Table 3, 126 patients with available baseline and follow-up data were an-
alysed. In this group, hemodynamic parameters (LVOT gradient, MR and SAM grade) 
and clinical NYHA class all improved signifi cantly (all P<0.001). The 5 patients with 
peri-procedural death or an anterior infarction were excluded from analysis. Base-
line clinical and echocardiographic characteristics in this group were not diff erent 
Table 1. Baseline Clinical, Echocardiographic and PTSMA Characteristics.
All Patients
with PTSMA
(n = 131) *
Successful
PTSMA
(n = 114)
Failed
PTSMA
(n = 12)
Clinical data
 Age at therapy, years 56 ± 16 55 ± 16 61 ± 14
 Male gender 69 (53%) 57 (50%) 6 (50%)
 NYHA class 2.7 ± 0.7 2.6 ± 0.6 2.7 ± 0.7
Echocardiographic data
 Septal thickness, mm 19 ± 4 19 ± 4 19 ± 3
 LVOT gradient, mm Hg 83 ± 36 82 ± 37 93 ± 29
 MR, grade 1.5 ± 0.9 1.4 ± 0.9 1.9 ± 1.0
 SAM, grade 2.4 ± 0.9 2.4 ± 0.9 2.6 ± 0.7
 LVOT, mm 15 ± 4 15 ± 4 15 ± 3
 Left atrium, mm 49 ± 7 49 ± 7 49 ± 6
 LV-EDD, mm 42 ± 6 42 ± 7 43 ± 5
 LV-ESD, mm 24 ± 5 24 ± 5 23 ± 4
PTSMA data
 Septal arteries, n 1.3 ± 0.5 1.3 ± 0.5 1.2 ± 0.4
 Ethanol volume, ml 2.9 ± 1.3 2.9 ± 1.3 2.7 ± 1.3
 Peak CK, IU/L 1,404 ± 685 1,427 ± 707 1,212 ± 476
 Peak CK-MB, IU/L 200 ± 156 198 ± 159 198 ± 93
* = including 4 patients with peri-procedural death and 1 patient with peri-procedural large anterior myocardial infarction who were excluded 
from further analysis. LV-EDD = Left Ventricular End-Diastolic Diameter. LV-ESD = Left Ventricular End-Systolic Diameter. LVOT = Left Ventricular 
Outfl ow Tract. MR = Mitral Regurgitation. NYHA = New York Heart Association functional class. PTSMA = Percutaneous Transluminal Septal 
Myocardial Ablation. SAM = Systolic Anterior Motion.
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from the analysable 126 patients. In these 126 patients, PTSMA was successful in 
114 patients (90%) and failed in 12 patients (10%). Seven of these 12 patients under-
went re-PTSMA after a mean follow-up of 12 months and three patients underwent 
surgical myectomy after a mean follow-up of 14 months. Two patients refrained 
from further invasive intervention. Mean baseline clinical, echocardiographic and 
PTSMA characteristics (Table 1) and the presence of PTSMA-induced right bundle 
Table 2. Total Cardiac Events in 131 HOCM Patients Undergoing PTSMA.
In-hospital
Events
Follow-up
Events
Total
Events
Cardiac death  4 (3%)  1 (1%)  5 (4%)
Acute myocardial infarction  1 (1%)  0 (0%)  1 (1%)
Coronary dissection  2 (2%)  0 (0%)  2 (2%)
Non-fatal cardiac tamponade  1 (1%)  0 (0%)  1 (1%)
Pacemaker implantation  6 (5%)  0 (0%)  6 (5%)
Defi brillator implantation  4 (3%)  1 (1%)  5 (4%)
Re-intervention* - 10 (8%) 10 (8%)
Total events 18 (14%) 12 (9%) 30 (23%)
* = Seven patients underwent re-PTSMA and three patients underwent surgical myectomy.
Table 3. Clinical, Electrocardiographic and Echocardiographic Characteristics at Latest Follow-up. 
All Patients
with PTSMA
(n = 126) *
Successful
PTSMA
(n = 114)
Failed
PTSMA
(n = 12)
Clinical data
 Follow up, months 17 ± 13 14 ± 12 13 ± 11 
 Age at therapy, years 56 ± 16 55 ± 16 61 ± 14
 Male gender 69 (53%) 57 (50%) 6 (50%)
 NYHA class 1.3 ± 0.6 1.2 ± 0.4 2.3 ± 0.9 ‡
Electrocardiographic data
 Right BBB (%) 57 (51%) 51 (52%) 6 (50%)
Echocardiographic data
 Septal thickness, mm 14 ± 4 14 ± 4 16 ± 4 
 LVOT gradient, mm Hg 23 ± 24 18 ± 16  66 ± 36 ‡
 MR, grade 0.6 ± 0.7 0.5 ± 0.6  1.6 ± 1.1 †
 SAM, grade 0.8 ± 1.0 0.7 ± 0.9  1.8 ± 1.1 †
 LVOT, mm 18 ± 5 18 ± 4 16 ± 3 ‡
 Left atrium, mm 47 ± 7 47 ± 7 48 ± 7 
 LV-EDD, mm 44 ± 7 44 ± 7 43 ± 8 
 LV-ESD, mm 27 ± 9 28 ± 9 22 ± 5 ‡
* = excluding the four patients with peri-procedural death and 1 patient with peri-procedural large anterior myocardial infarction. † = P<0.01. 
‡ = P<0.001. Abbreviations see Table 1. BBB = Bundle Branch Block. 
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branch block (Table 3) did not diff er signifi cantly between patients with success-
ful and failed PTSMA. Only age and MR grade at baseline tended to be higher in 
failed patients (both parameters non-signifi cant). Characteristics after failed PTSMA 
included a signifi cantly higher mean LVOT gradient, SAM and MR grade, and NYHA 
class (Table 3).
Echocardiographic, PTSMA and clinical characteristics in relation to ethanol 
volume
In Table 4, pre- and post PTSMA echocardiographic and clinical characteristics for 
patients receiving a low, intermediate or high volume of ethanol are presented. In 
118 of the 126 analysable patients (94%) ethanol volumes were available. In 57 pa-
tients (48%) a low ethanol volume (1.8 ± 0.3 ml), in 47 patients (40%) an intermedi-
ate ethanol volume (3.2 ± 0.5 ml) and in 14 patients (12%) a high ethanol volume 
(5.5 ± 1.0 ml) was used. Larger volumes of ethanol were used in more hypertrophied 
septa (P<0.005) and resulted in greater CK and CK-MB peak values (P<0.0001). The 
decrease in septal thickness was, however, independently of used ethanol volume. 
There was no signifi cant relation between ethanol volume and baseline LVOT gradi-
ent, LVOT gradient reduction or clinical NYHA class at follow-up.
Table 4. Procedural, Echocardiographic and Clinical Characteristics in Relation to Injected Ethanol Volume.
Ethanol Volume
<2ml
(n = 57)
Ethanol Volume
2 to 4 ml
(n = 47)
Ethanol Volume
>4 ml
(n = 14)
Ethanol volume, ml 1.8 ± 0.3 3.2 ± 0.5 5.5 ± 1.0‡
Atrioventricular block 3 2 1
Peak CK, U/L 1,065 ± 422 1,572 ± 685 2,154 ± 883‡
Peak CK-MB, U/L 158 ± 161 187 ± 98 363 ± 196‡
Septal thickness, mm
 baseline
 follow-up
 delta 
18 ± 4
14 ± 3
4 ± 4
20 ± 4
15 ± 5
5 ± 5
22 ± 4†
17 ± 3*
5 ± 4
LVOT gradient, mm Hg
 baseline
 follow-up
 delta
76 ± 35
23 ± 25
53 ± 35
84 ± 38
22 ± 22
62 ± 38
97 ± 29
23 ± 25
74 ± 38
NYHA class
 baseline
 follow-up
 delta
2.7 ± 0.6
1.3 ± 0.6
1.4 ± 0.82*
2.6 ± 0.6
1.2 ± 0.6
1.4 ± 0.7
2.3 ± 0.5
1.4 ± 0.5
0.9 ± 0.7*
Abbreviations as in Table 1. * = P<0.05. † = P<0.005. ‡ = P<0.0001
Infl uence of a PTSMA learning curve
As seen in Table 5, the patients were divided in three groups according to the expe-
rience with PTSMA. Ethanol volume, in-hospital complications (cardiac death, acute 
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myocardial infarction, coronary dissection or non-fatal cardiac tamponade) and the 
need for pacemaker implantation were comparable over time. However, late PTSMA 
failure occurred more often in patients who underwent a PTSMA procedure in the 
early, less experienced time period (P<0.0001). 
DISCUSSION
Invasive therapy for HOCM patients with drug-refractory symptoms aims at acute 
improvement of hemodynamics and sustained clinical improvement during long-
term follow-up. Since 1959, an important number of patients have been treated 
with surgical myectomy.18 Due to its invasive character as well as the complication 
rate, mainly reported in the earlier series,7,13,19 a continuous search for less invasive 
therapies with comparable benefi cial eff ects has been undertaken. Atrioventricular 
sequential pacing was the fi rst non-surgical interventional therapy that claimed a 
high clinical success rate.20 However, results of randomized trials in which the pacing 
mode was alternately turned on and off  were disappointing and its general use in 
HOCM patients was discouraged.21,22 PTSMA was introduced in 1995 as a novel tech-
nique that could mimic septal myectomy.5 Induction of a local myocardial infarction 
in the hypertrophied septum at the site of septal-mitral contact results in relieve of 
the LVOT gradient, reduction in MR and improvement of clinical symptoms.6,14,23,24 
The enthusiasm for PTSMA is refl ected by the huge number of so far performed 
procedures, which probably outnumbers the total number of surgical myectomies 
performed within the past 45 years.25 PTSMA has, however, a relatively high com-
plication rate and re-interventions are sometimes necessary.14 Therefore, optimal 
selection of HOCM patients who really may benefi t from PTSMA is important.
Table 5. In-Hospital Complications, Pacemaker Necessity and Late PTSMA Failure According to Experience.
Early
Experience
(n = 43)
Intermediate
Experience
(n = 43)
Late
Experience
(n = 45)
Ethanol volume, ml 2.7 ± 1.2 3.3 ± 1.3 2.5 ± 0.9
In-hospital complications* 2 (5%) 3 (7%) 3 (7%)
Pacemaker implantation 3 (7%) 2 (5%) 1 (2%)
Late PTSMA failure  9 (21%) 1 (2%) 2 (4%)†
Total events 14 (33%) 6 (14%)  6 (13%)
* = Cardiac death, acute myocardial infarction, coronary dissection or non-fatal cardiac tamponade. † = P<0.0001
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Occurrence of cardiac events
As summarized in Table 2, the need for permanent pacemaker implantation is 
the most frequent in-hospital complication after PTSMA, despite careful contrast 
identifi cation of the target septal branch. However, in accordance to a prior pub-
lication from our group26, our more conservative pacemaker implantation strategy 
resulted in a signifi cantly lower event rate than that reported in the TASH registry.23 
As described before17, PTSMA also has fatal and other complications, such as spill 
of ethanol into the left anterior descending coronary artery, coronary dissection or 
non-fatal cardiac tamponade. Total in-hospital event rate was 14%. Long-term (17 
± 13 months) follow-up was, apart from the later described late re-interventions, 
quite benign with only one late death.
Baseline characteristics as predictors of long-term PTSMA outcome
The vast majority of the 131 studied patients experienced improvement in hemo-
dynamic (reduction in LVOT gradient, MR and SAM grade) and clinical (NYHA class) 
parameters after PTSMA. Hemodynamic and clinical failure of PTSMA during a fol-
low-up of 17 ± 13 months was noticed in 10% of the patients. In other publications, 
PTSMA failure was seen in 6 to 29% of all patients.23,27,28 Unfortunately, none of the 
studied baseline echocardiographic, clinical and PTSMA related characteristics were 
useful in determining long-term PTSMA success rate. In a study by Chang et al.,27 
LVOT gradient reduction immediately after PTSMA in the catheterization laboratory 
and peak CK were independent predictors of successful outcome. These investiga-
tors could, however, also not identify independent predictors from the baseline 
clinical or echocardiographic characteristics to select patients that benefi t most 
from PTSMA. In our study peak CK did not predict successful outcome.
The role of ethanol volume
In our study, the mean volume of injected ethanol was relatively large (2.9 ± 1.3 
ml) as compared to other studies.14,29 Contrary to our expectations, ethanol volume 
did not change over time. In 1999, a maximal ethanol volume of 4 ml was recom-
mended.7 At present volumes of 1-2 ml or even less are suggested.30 Veselka et al. 
reported that clinical and echocardiographic results at 6-months follow-up were 
comparable for injection of 1 to 2 ml and more than 2.0 ml ethanol.12 At present, it 
is still debatable what ethanol volume is preferable. To obtain more insight in the 
eff ect of injected ethanol volume we divided our patients in three groups according 
to this volume. Surprisingly, less ethanol volume in our study did not aff ect the oc-
currence of advanced atrioventricular block, nor was it associated with late PTSMA 
failure. In the TASH registry,23 mean injected ethanol volume was comparable to our 
study. The authors reported occurrence of atrioventricular conduction block, neces-
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sitating permanent pacing, in 9.6%. In our study, only 5% of the patients needed 
permanent pacing for advanced atrioventricular conduction block. Ethanol volume 
has been related to infarct size,13 which was confi rmed in our study. Interestingly, 
the release of peak CK or CK-MB in relation to the amount of ethanol diff ers signifi -
cantly between published studies. In our study CK release was 1,404 IU/L per 2.9 ml 
ethanol, others reported 1,128 IU/L per 1.8 ml and 1,411 IU/L per 2.4 ml,14,15 whereas 
in the TASH registry CK-releases of 483 IU/L per 2.8 ml ethanol were reported.
The role of a learning curve
It is well known that clinical experience infl uences the results of a procedure. As 
seen from results of percutaneous coronary interventions,31,32 a high-volume load for 
operators and institutions is associated with better procedural outcome. The impor-
tance of a learning curve for PTSMA is confi rmed in our study since a high incidence 
of late PTSMA failure was noted in the fi rst group of patients, whereas this number 
signifi cantly reduced with growing experience. At a volume of approximately 20 
treated patients per center per year, late PTSMA failure is currently 4%, which is not 
diff erent from that in other experienced centers.23,27 Surprisingly, we did not notice a 
relation between PTSMA experience and need for pacemaker implantation. 
CONCLUSIONS AND CLINICAL IMPLICATIONS 
The present study confi rms that PTSMA is an eff ective method to treat patients with 
drug-refractory, symptomatic HOCM at the cost of a relatively high complication 
rate. During follow-up late hemodynamic and clinical failure of PTSMA was noticed 
in 10% of the patients. PTSMA failure could not be predicted by baseline clinical, 
electrocardiographic, echocardiographic or PTSMA related characteristics but may 
partially be explained by a learning curve eff ect. This implies that PTSMA procedures 
should be restricted to a limited number of experienced centres.
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ABSTRACT
Background: To compare percutaneous transluminal septal myocardial ablation 
(PTSMA) versus septal myectomy combined with mitral leafl et extension (MLE) in 
symptomatic hypertrophic obstructive cardiomyopathy (HOCM) patients with an 
enlarged anterior mitral valve leafl et (AMVL). Both PTSMA and myectomy reduce 
septal thickness and left ventricular outfl ow tract (LVOT) gradient. However, an un-
corrected enlarged AMVL may predispose to residual systolic anterior motion (SAM) 
after successful standard myectomy or PTSMA. Myectomy with MLE previously 
demonstrated superior hemodynamic results compared to standard myectomy but 
its relative value to PTSMA is unknown.
Methods and Results: Twenty-nine patients (44 ± 12 years) underwent myectomy 
with MLE and 43 (52 ± 17 years) PTSMA. Mitral leafl et area was similar in both groups 
(16.7 ± 3.4 vs. 15.9 ± 2.7 cm2, respectively). After PTSMA two patients died, four 
needed a re-intervention and four a permanent pacemaker for complete heart 
block. After surgery only one patient needed a re-intervention. At one-year follow-
up, LVOT gradients did not diff er between surgical and PTSMA patients (17 ± 14 
vs. 23 ± 19 mm Hg, respectively). Pre-interventional mitral regurgitation grade was 
more severe in the surgical group but with myectomy MLE the residual grade was 
similar as compared to PTSMA. Mean SAM grade decreased signifi cantly more after 
surgery (2.9 ± 0.3 to 0.5 ± 0.7 vs. 2.8 ± 0.5 to 1.3 ± 0.9 grade, P<0.05).
Conclusions. PTSMA in these selected HOCM patients had more peri-procedural 
complications and necessity for re-interventions. Hemodynamic results (SAM grade 
and reduction in mitral regurgitation) were better in surgical patients.
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INTRODUCTION
Hypertrophic obstructive cardiomyopathy (HOCM) is characterised by asymmetrical 
septal hypertrophy 1 that causes a left ventricular outfl ow tract (LVOT) gradient. The 
severity of the LVOT gradient is usually correlated with the degree of complaints.2 
In patients who remain symptomatic despite optimal medical treatment, several 
invasive therapeutical modalities have been introduced. Septal myectomy, a sur-
gical technique developed by Morrow3, is regarded as the standard approach to 
reduce septal thickness and LVOT gradient. This technique proved to be safe with 
excellent hemodynamic results.4-7 Percutaneous transluminal septal myocardial 
ablation (PTSMA) is a non-surgical technique to reduce septal thickness.8 During 
this procedure, ethanol is injected into one or more septal branches of the left an-
terior descending coronary artery (LAD) resulting in a local myocardial infarction 
with contractile septal dysfunction followed by septal thinning, LVOT widening and 
eventual LVOT gradient reduction.9-11
The mitral valve apparatus frequently demonstrates anomalies in HOCM, for in-
stance increased mitral leafl et area, length and laxity as well as anterior displace-
ment of the papillary muscles.12-15 All these abnormalities may predispose to residual 
SAM after successful myectomy. To avoid persistence of LVOT gradient as well as 
mitral regurgitation (MR), we developed mitral leafl et extension (MLE) in addition 
to myectomy.16 Previously, we reported benefi cial eff ects of this novel technique 
compared to standard myectomy.16 Currently, it is not known whether PTSMA is 
equally eff ective in these selected patients. In this report, we present hemodynamic 
and clinical 1-year outcome in HOCM patients with an enlarged anterior mitral valve 
leafl et (AMVL) who underwent PTSMA or myectomy in combination with MLE.
METHODS
Patient selection
The study population comprised 72 patients with symptomatic HOCM despite op-
timal medical treatment. All subjects demonstrated a dynamic LVOT gradient of at 
least 50 mmHg at rest or on provocation and a mitral leafl et area >12 cm2. Between 
1986 and 1999, 29 patients underwent surgical septal myectomy in combination 
with MLE. After august 1999, 43 consecutive patients underwent PTSMA. Our in-
stitutional review committee approved the study and all patients gave informed 
consent.
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Echocardiographic analysis
Transthoracic echocardiography was routinely performed to evaluate the site of hy-
pertrophy, mitral valve anatomy and LVOT gradient. Mitral valve opening area was 
measured in the parasternal short-axis view by tracing the innermost margins of the 
mitral valve at the point of maximal opening. Mitral leafl et area was calculated with 
a previously validated formula (4.64 + 2.17 x mitral valve opening area).17 Follow-up 
measurements included septal thickness at the site of treatment, LVOT gradient, MR 
grade, severity of SAM and left atrial and ventricular dimensions. Septal thickness 
was measured in the parasternal long-axis view in an end-diastolic still-frame. Peak 
LVOT gradient was calculated from the color-guided continuous-wave Doppler ve-
locity using the modifi ed Bernoulli equation. MR severity was assessed by color fl ow 
Doppler echocardiography and graded on a scale from 0 (no regurgitation) to 4 
(severe regurgitation). SAM of the AMVL was graded as 0 (absent), 1+ (mild; minimal 
mitral-septal distance >10 mm during systole), 2+ (moderate; minimal mitral-septal 
distance ≤ 10 mm during systole) or 3 (marked; brief or prolonged contact between 
the AMVL and septum).18 Dimensions of the left atrium and left ventricle (LV) were 
Figure 1. Schematic long-axis cross-sectional view of the left 
ventricle.35 
The patch extension of the anterior mitral leafl et is indicated by 
the asterisk. The surgeons’ view (point A) is orientated towards 
the hypertrophied septum and the anterior mitral leafl et. The two 
sectional planes (3A and 3B) indicate the echocardiographic cross-
sections of the still-frames, which are shown in fi gure 3 (panel A and 
B, respectively). The double asterisk indicates the site of the septal 
myectomy.
Ao = Ascending Aorta. LA = Left Atrium.
Figure 2. The surgeons’ view. 
The surgeon looks through an oblique incision in the ascending aorta 
on the hypertrophied septum and the anterior mitral leafl et. The 
pericardial patch, inserted in the anterior mitral leafl et is clearly seen. 
The asterisk indicates the myectomy trough. The ostia of both the left 
(LCA) and right (RCA) coronary arteries are indicated for orientation 
purposes.
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measured using standard M-mode echocardiography from the parasternal long-
axis view. In the apical 2 and 4 chamber views, the end-systolic and end-diastolic 
still-frames were manually traced to assess the left ventricular ejection fractions.19
Surgical myectomy in combination with MLE
Cardiac surgery was performed using standard techniques of cardiopulmonary 
bypass with moderate hypothermia and myocardial preservation. After aortotomy, 
the septum was partially resected to the left of an imaginary line through the nadir 
of the right coronary cusp using a locally designed modifi ed electrocutting tech-
nique. If myectomy had been completed, the surgeon performed MLE (Figure 1).16 
An autologous pericardial patch is placed across the bending point of the mitral 
valve where SAM is maximal to stiff en the buckling AMVL (Figure 2). The patch ex-
tends the width but not the length of the AMVL, which shifts the centrally attached 
chordae laterally. As a result, the chordae are stretched and erected which will en-
hance leafl et coaptation. Finally, because force produced by blood fl ow against the 
leafl et is proportional to its area, the increased leafl et will be pressed posterior with 
a decrease in SAM and MR. Postoperative results were assessed by transesophageal 
and epicardial echocardiography immediately after weaning from bypass (Figure 3). 
There were no suboptimal results that required reinstitution of bypass.
PTSMA
The right and left femoral arteries were cannulated using standard techniques. A 
temporary pacemaker lead (Temporary Pacing Electrode Catheter, 5F, Bard, USA 
which was later replaced by a Bipolar Electrode Catheter, 5F, Arrow, Germany) was 
positioned in the right ventricle. Simultaneous measurement of the pressures in 
Figure 3. Eff ects of the extension patch.
Esophageal multiplane echocardiography after surgery. Panel A: Long-axis view of the LVOT at 130 degrees shows the “spinnaker sail” eff ect of 
the patch (between arrows), which moves the leafl et tissue away from the septum. Panel B: At 35 degrees, the patch is seen in cross-section. 
The patch causes a lateral displacement of the secondary chordae.
Ao = Ascending Aorta. LA = Left Atrium. LVOT = Left Ventricular Outfl ow Tract. 
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the LV (6F pigtail catheter) and in the ascending aorta (7F Judkins guiding catheter) 
allowed continuous monitoring of the LVOT gradient. Baseline hemodynamic data, 
including LVOT gradient at rest and at provocation using the Valsalva manoeuvre, 
were measured. After identifi cation of the septal branches of the LAD, a 1.5-2.5 x 10 
mm balloon was introduced over a 0.014-inch guide wire and positioned into the 
fi rst septal branch. If the position of the balloon was considered satisfactory, the 
guide wire was removed and the balloon infl ated. Subsequently, 1 ml of echocon-
trast agent (Levovist, Schering AG Berlin) was injected through the balloon catheter 
shaft. With echocardiography, the myocardial territory supplied by this septal branch 
was identifi ed and retrograde spill of contrast into the LAD or the right ventricle was 
excluded. If satisfying images were obtained, 1 to 5 ml of concentrated ethanol (at 
a rate of 0.5 ml / 30 seconds) was injected through the balloon catheter shaft under 
close electrocardiographic surveillance. After fi ve minutes, the balloon was defl ated 
and coronary angiography was repeated in order to confi rm the patency of the LAD 
and to confi rm discontinuation of the septal branch. If the LVOT gradient remained 
>30 mmHg, which was observed in seven patients, the result was regarded as sub-
optimal. Subsequently, the procedure was repeated in the same septal branch if the 
myocardial territory supplied by this branch was relatively large. Otherwise, other 
septal coronary vessels were judged on usefulness. After the procedure, the pace-
maker lead was left in situ for at least 48 hours and the patient was transferred to the 
clinical department for telemetric observation.
Follow-up
One-year follow-up data included mortality, NYHA class, medication and the earlier 
described echocardiographic variables (septal thickness, LVOT gradient, MR, SAM 
grade and left atrial and ventricular dimensions). The clinical status was assessed 
by one cardiologist (FJtC) and therefore not subject to interobserver variability. We 
performed a MEDLINE search (1995 towards the present) on studies in English lan-
guage. Using the search terms “hypertrophic cardiomyopathy” in combination with 
“septal ablation” or “myectomy”, we found 158 and 276 manuscripts, respectively. 
Based on the abstracts, we selected three articles that compared septal ablation 
versus septal myectomy.20-22
Statistical analysis
Continuous variables were presented as mean ± standard deviation values and were 
compared using Student’s unpaired t-test. Categorical variables were presented as 
counts and percentages and compared with the chi-square test, or when appropri-
ate, with Fisher’s exact test.
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RESULTS 
Baseline clinical characteristics
Baseline clinical characteristics of the patients treated by surgery or PTSMA only 
diff ered with respect to age (Table 1). PTSMA patients were older at time of inter-
vention (P<0.05).
Baseline echocardiographic measurements 
Mean septal thickness, LVOT gradient and mitral leafl et area in the surgical group 
matched that in the PTSMA group. Only, MR grade was higher in the surgical group. 
All patients demonstrated typical SAM of the AMVL.
Clinical outcome
Pre-interventional and post-interventional data at 1-year follow-up are presented 
in Table 1.
Outcome after surgery
There were no deaths associated with surgery. Three months after surgery, a patient 
was hospitalised with shortness of breath. Echocardiography demonstrated severe 
Table 1. Clinical and Echocardiographic Data at Baseline and at One-Year Follow-up
Pre-procedure One-year follow-up
Myectomy
(n = 29)
PTSMA
(n = 43)
Myectomy
(n = 29)
PTSMA
(n = 41)
Clinical data
 Mean age, years 44 ± 12* 52 ± 17
 NYHA class 2.8 ± 0.4 2.4 ± 0.5 1.3 ± 0.4†  1.5 ± 0.7†
 Number of drugs& 1.5 ± 0.7 1.5 ± 0.9 0.8 ± 0.9  0.9 ± 0.8
Echocardiographic data
 Septal thickness, mm 23 ± 4 21 ± 4 17 ± 2† 16 ± 4†
 LVOT gradient, mm Hg 100 ± 20 101 ± 34 17 ± 14†  23 ± 19†
 Mitral regurgitation grade 2.1 ± 1.1* 1.5 ± 0.8 0.6 ± 0.6†  0.8 ± 0.8†
 SAM grade 2.9 ± 0.3 2.8 ± 0.5 0.5 ± 0.7*,†  1.3 ± 0.9†
 Left atrium, mm 47 ± 9 47 ± 7 46 ± 11 45 ± 6
 LV-EDD, mm 43 ± 5 43 ± 6 44 ± 8 44 ± 8
 LV-ESD, mm 27 ± 5 25 ± 5 28 ± 7 30 ± 8†
 LV-EF, % 72 ± 6 71 ± 5 70 ± 8 69 ± 7
 MLA, cm2 16.7 ± 3.4 15.9 ± 2.7
N = Number of Patients. NYHA = New York Heart Association functional class. LVOT = Left Ventricular Outfl ow Tract. SAM = Systolic Anterior 
Motion. LV-EDD = Left Ventricular End-diastolic Diameter. LV-ESD = Left Ventricular End-systolic Diameter. LV-EF = Left Ventricular Ejection 
Fraction. MLA = Mitral valve Leafl et Area. * = P<0.05 versus PTSMA; † = P<0.05 versus baseline value; & = Beta-blocker and/or calcium 
antagonist. 
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MR at the site of the patch due to dehiscence. After surgical correction the patients 
clinical course was further uncomplicated. Mean NYHA class in the surgical group 
improved from 2.8 ± 0.4 to 1.3 ± 0.4 (P<0.05) at follow-up.
Outcome after PTSMA
Two patients died in the PTSMA group. One patient died during the procedure due 
to refractory ventricular fi brillation after induction of the infarction. The other pa-
tient died after the procedure due to cardiac tamponade caused by right ventricular 
perforation by a pacemaker lead. Since then, we changed the type of pacemaker 
lead to avoid this complications. Five other patients were successfully resuscitated 
for ventricular fi brillation within 24 hours after the intervention. One patient with 
late recurrence of ventricular fi brillation and another patient with late occurrence of 
non-sustained ventricular tachycardia were treated with an implantable cardioverter 
defi brillator. Four patients underwent permanent pacemaker implantation because 
of complete atrioventricular heart block after the procedure. In one patient a large 
anterior myocardial infarction (maximal creatine kinase 4,700 U/L) was induced due 
to spill of ethanol in the LAD. Four patients underwent repeat PTSMA after a mean 
follow-up period of 10 months for recurrence of complaints and signifi cant LVOT 
gradient. Mean NYHA class in PTSMA patients improved from 2.4 ± 0.5 to 1.5 ± 0.7 
(P<0.05) at follow-up.
Echocardiographic follow-up data
As seen in Table 1, decrease in septal thickness and LVOT gradient at 1-year follow-up 
were comparable in both groups. Mean residual MR after surgery did not diff er from 
that in the PTSMA group. However, post-surgical MR decreased at least two grades 
in 75% of surgical patients whereas this improvement was reached in only 10% of 
the PTSMA patients (P<0.0001). Mean SAM grade decreased signifi cantly more after 
surgery (P<0.001). In both groups, mean left ventricular end-diastolic dimensions 
did not change. Left ventricular end-systolic dimension remained unchanged after 
surgery whereas it signifi cantly increased after PTSMA (P<0.05). In both groups, left 
ventricular ejection fractions remained preserved at follow-up.
DISCUSSION
Both surgical septal myectomy and PTSMA were developed to reduce septal hyper-
trophy and to relieve LVOT gradient in patients with HOCM. Some of these patients 
also demonstrate structural anomalies of the mitral valve apparatus that are, how-
ever, not corrected with either intervention. This may predispose to residual SAM, 
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suboptimal alleviation of LVOT gradient and residual MR. Surgical implantation of a 
mitral valve prosthesis is not attractive due to the risks of thrombo-embolism and 
bleeding related to the need for anticoagulation therapy.23 One alternative that 
preserves native valve tissue is mitral valve plication.24 In our center, myectomy in 
combination with MLE is used in patients with an enlarged AMVL. Previously, we 
reported superior hemodynamic results as compared to myectomy alone16 and 
sustained hemodynamic improvement during long-term follow-up.7 In the present 
study, we compared this modifi ed surgical procedure with PTSMA in patients with 
an enlarged AMVL. We observed more peri-procedural complications and neces-
sity for re-interventions in PTSMA patients. Also, hemodynamic results (reduction in 
SAM and MR grade) were better in surgical patients.
Comparison of echocardiographic parameters after PTSMA and surgery in 
other studies
As summarized in Table 2, three earlier published studies compared the hemody-
namic eff ects and clinical outcome of PTSMA versus septal myectomy.20-22
LVOT gradient. Acute LVOT gradient reduction after PTSMA happens mainly due to 
a lesser peak acceleration rate of blood fl ow proximal to the obstruction.25 This may 
be caused by inhomogeneity in LV contraction due to ischemic septal dysfunction26 
and/or conduction abnormalities due to ischemia-induced bundle branch block.27 
Obviously, myectomy results in immediate septal thinning, LVOT widening and 
gradient reduction. In the long-term follow-up, maximal gradient reduction after 
PTSMA is achieved due to LVOT remodelling resulting in widening of the LVOT. That 
short-term LVOT gradient reduction may indeed be better with surgery was shown 
in the three-months follow-up study of Qin et al.21 Retrospective analysis of our data 
at three months also showed a signifi cant better reduction in LVOT gradient with 
myectomy (16 ± 11 mmHg vs. 27 ± 22 mmHg after PTSMA, P<0.05). At 1-year follow-
up, however, there were no signifi cant diff erences between surgery and PTSMA in 
our study and the studies by Nagueh et al.20 and Firoozi et al.22 Notably, all studies 
demonstrated a tendency toward a better reduction with surgery. At present, it is 
not known whether the timing of maximal LVOT reduction after an intervention is 
important in reducing morbidity and mortality. The small mean diff erences in al-
leviation of the LVOT gradient between surgery and PTSMA may be of importance 
because the severity of LVOT gradient is an independent risk factor for functional 
deterioration.28 After PTSMA, a residual LVOT gradient in the catheterization labora-
tory was an independent predictor of adverse outcome at later follow-up in a study 
by Chang et al.29 After myectomy, it was an independent predictor of mortality at 
prolonged follow-up in a study by Mohr et al.30
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SAM of the anterior mitral valve leafl et. In the study by Qin et al.21, MR as well as 
SAM of the AMVL reduced equally after surgery and PTSMA. Also in the study by 
Nagueh et al.20, who only reported on MR, an equal reduction was achieved with 
both treatment modalities. Interestingly, Qin et al.21 described two patients with an 
elongated AMVL who did not benefi t from PTSMA. In contrast to this observation, 
Flores-Ramirez et al.25 reported that PTSMA could indeed be eff ective in HOCM pa-
tients with redundant mitral leafl et valves. They stated that, after successful PTSMA, 
the streamlines of fl ow are straightened and ejection velocity proximal to the LVOT 
decreases. Consequently, the drag forces that pull the AMVL into the LVOT will di-
minish which results in decreased SAM. In the long-term, however, LVOT widening 
may be of more importance compared to changes in LV ejection dynamics. In the 
present study, we noticed a greater reduction in SAM after surgery as compared 
to PTSMA. This result favours the hypothesis that MLE has additional advantages 
over PTSMA for patients with an enlarged AMVL.7,16,31 These advantages include: (1) 
stiff ening of the central part of the buckling AMVL to prevent SAM by insertion of a 
Table 2. Comparison of Published Studies Comparing Surgical Myectomy with PTSMA
Author Intervention Nr. of 
patients
Follow-up NYHA class III/IV (%)
or mean class
LVOTG (mm Hg) MR mean grade, I/II
(%), mean volume (ml)
SAM grade
Pre Post Pre Post Pre Post Pre Post
Present study Myectomy 29 12 months 2.8 ± 0.4 1.3 ± 0.4† 100 ± 20 17 ± 14† 2.1 ± 1.1 0.6 ± 0.6† 2.9 ± 0.3 0.5 ± 0.7†,*
PTSMA 43 2.4 ± 0.5 1.5 ± 0.7† 101 ± 34 23 ± 19† 1.5 ± 0.8 0.8 ± 0.8† 2.8 ± 0.5 1.3 ± 0.9†
Nagueh 20 Myectomy 41 12 months 78% 2%† 78 ± 30 4 ± 7† 83% 51%† NA NA
PTSMA 41 90% 0%† 76 ± 23 8 ± 15† 88% 29%† NA NA
Qin 21 Myectomy 26 3 months 3.3 ± 0.5 1.5 ± 0.7† 62 ± 43 11 ± 6† 28 ± 12 8 ± 5† 1.1 ± 0.6 0.6 ± 0.5†
PTSMA 25 3.5 ± 0.5 1.9 ± 0.7† 64 ± 39 24 ± 19† 23 ± 12 9 ± 3† 1.4 ± 1.1 0.6 ± 0.8†
Firoozi 22 Myectomy 24 12 months 2.4 ± 0.6 1.5 ± 0.7† 83 ± 23 17 ± 12† NA NA NA NA
PTSMA 20 2.3 ± 0.5 1.7 ±0.8† 91 ± 18 21 ± 12† NA NA NA NA
Table 2. Comparison of Published Studies Comparing Surgical Myectomy with PTSMA, continued
Author Intervention IVS (mm) LV-EDD (mm) LV-ESD (mm) LA-EDD (mm)
Pre Post Pre Post Pre Post Pre Post
Present study Myectomy 23 ± 4 17 ± 2† 43 ± 5 44 ± 8 27 ± 5 28 ± 7 47 ± 9 46 ± 11
PTSMA 21 ± 4 16 ± 4† 43 ± 6 44 ± 8 25 ± 5 30 ± 8† 47 ± 7 45 ± 6
Nagueh 20 Myectomy 22 ± 7 13 ± 6† 42 ± 6 45 ± 5† 23 ± 5 28 ± 6† NA NA
PTSMA 23 ± 6 12 ± 3† 43 ± 5 47 ± 5† 21 ± 5 25 ± 4† NA NA
Qin 21 Myectomy 24 ± 6 17 ± 2† 44 ± 7 45 ± 6 NA NA 50 ± 7 47 ± 7
PTSMA 23 ± 4 19 ± 4† 40 ± 8 44 ± 8 NA NA 47 ± 8 46 ± 8
Firoozi 22 Myectomy 20 ± 6 17 ± 5† 40 ± 7 41 ± 6 20 ± 6 23 ± 7 48 ± 8 45 ± 8
PTSMA 20 ± 3 16 ± 3† 42 ± 4 44 ± 6 23 ± 5 26 ± 5† 47 ± 8 44 ± 9
NYHA = New York Heart Association functional class. LVOTG = LVOT Gradient. MR = Mitral Regurgitation grade. NA = Not Available. SAM = 
Systolic Anterior Motion. IVS = Interventricular Septal Thickness. LV-EDD = Left Ventricular End-Diastolic Dimension. LV-ESD = Left Ventricular 
End-Systolic Dimension. LA-EDD = Left Atrium End-Diastolic Dimension. * = P<0.05 versus PTSMA; † = P<0.05 versus baseline value.
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pericardial patch,14,32-34 (2) erection of the lax chordae attached to central portions 
of the AMVL through lateral shift caused by enlargement of the horizontal width of 
the anterior leafl et,31 (3) maintenance of valve tethering due to an enlarged leafl et 
area once the streamlines of fl ow are straightened after septal myectomy31 and (4) 
enhanced reduction in MR provided by greater leafl et area. The observation that the 
pre-interventional higher grade of MR in the surgical group was abolished to the 
same extent as after PTSMA, confi rms the observation that a larger leafl et contact 
area reduces MR for any given degree of SAM.17
Comparison of clinical parameters after PTSMA and surgery
Both our and prior studies reported no diff erence in mean post-interventional NYHA 
classifi cation between PTSMA and surgery.
Complications and re-interventions after PTSMA and surgery.
As summarized in Table 3, more complications were noticed after PTSMA. The need 
for permanent pacemaker implantation, as noticed in other studies occurred more 
often after PTSMA, despite careful contrast identifi cation of the target septal branch. 
This diff erence in incidence may be caused by induced transmural myocardial infarc-
tion as opposite to well-controlled, more precise myectomy. As seen in our study, 
PTSMA has also some relatively unique complications such as spill of ethanol into 
the LAD and ventricular fi brillation due to induced myocardial ischemia. Also more 
re-interventions were needed after PTSMA. In contrast to other studies,25 we could 
not fi nd a relation between re-interventions, the amount of ethanol used or peak 
creatine kinase values.
Table 3. Reported Complications after Myectomy or PTSMA.
Author Intervention Nr. of 
patients
Death Acute MI Ventricular 
fi brillation
Permanent 
pacing
Automatic 
ICD
Re-intervention
Present study Myectomy 29 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (3%)‡
PTSMA 43 2 (5%) 1 (2%) 6 (14%) 4 (9%) 2 (5%) 4 (9%)
Nagueh 20 Myectomy 41 0 (0%) 1 (2%) 4 (10%)
PTSMA 41 1 (2%) 9 (22%) 1 (2%)
Qin 21 Myectomy 26 0 (0%) 2 (8%) 0 (0%)
PTSMA 25 0 (0%) 6 (24%) 6 (24%)
Firoozi 22 Myectomy 24 1 (4%) 1 (4%)
PTSMA 20 1 (4%) 3 (15%)
MI = Myocardial Infarction. ICD = Internal Cardiac Defi brillator. ‡ = Re-intervention because of patch dehiscence.
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STUDY LIMITATIONS
This study was not a randomized trial but an analysis of two cohorts treated with 
a surgical and percutaneous therapy. The present results may not be generalized 
since all patients were selected by mitral leafl et area. Furthermore, the groups were 
dissimilar in respect of age and severity of MR. The choice of treatment, however, 
was not infl uenced by these parameters because after 1999 all patients were treated 
with PTSMA. It is unlikely that the advanced age in this group would have infl uenced 
the diff erences in hemodynamic outcome as compared to surgery. As described 
by Chang et al.29, age was not a predictor of outcome after PTSMA. It is not clear 
whether the lesser degree of MR in the PTSMA group infl uences the outcome in this 
study but in real clinical practice it seems likely that patients with more severe MR 
are referred to surgery.
IMPLICATIONS AND CONCLUSIONS
Both myectomy and PTSMA are eff ective therapies to diminish the LVOT gradient 
by reduction in septal thickness. After myectomy, maximal gradient reduction is 
achieved immediately. As mentioned above, the gradient reduction after PTSMA 
seems to follow a biphasic course and the maximal reduction is achieved somewhat 
later in time. In HOCM patients with an enlarged AMVL, myectomy in combination 
with MLE off ers the aforementioned additional eff ects to further reduce SAM. In the 
present study we found more peri-procedural complications and necessity for re-
interventions in PTSMA patients. Whether the immediate LVOT gradient reduction 
with the combined surgical approach will result in a better clinical outcome versus 
PTSMA during a longer follow-up period is unknown and merits further research.
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Hypertrophic cardiomyopathy (HCM) is an intriguing disease due to its heterogene-
ity in genetic, morphologic, and clinical spectrum. The insights in the prognosis and 
natural history of HCM have evolved tremendously over the past 40 years. The fi rst 
studies, which contained data derived from hospital-based populations, depicted 
a poor prognosis for HCM patients, in particular due to the high incidence of sud-
den cardiac death (SCD). More recent studies derived from community-based (or 
non-referral) centers suggest a more benign clinical course with an annual mortal-
ity of <1%. Another important fi nding is that most HCM patients remain a lifetime 
without symptoms. 
Approximately one-quarter of all HCM patients demonstrate a signifi cant (≥ 50 
mm Hg) left ventricular outfl ow tract (LVOT) obstruction. This type is referred to 
as hypertrophic obstructive cardiomyopathy (HOCM). The severity of the obstruc-
tion is usually related to the degree of complaints. In patients, who remain severely 
symptomatic despite optimal medical treatment, and in whom a signifi cant LVOT 
gradient can be demonstrated at echocardiography, either surgical septal myec-
tomy or percutaneous transluminal septal myocardial ablation (PTSMA) is indicated. 
At present, surgery is still regarded as gold standard.
The fi rst part of the current thesis provides an update on prognosis and natural 
history of HCM. The second part depicts the results of surgery and PTSMA. In this 
part, the two therapies are compared to provide better insight in their advantages 
and disadvantages.
CLINICAL INSIGHTS
The data concerning the natural history of HCM as described in this thesis were 
mainly derived from 225 consecutive patients, who were studied between 1970 and 
1999 at the HCM outpatient clinic of the Erasmus Medical Center Rotterdam. Follow-
up of this population revealed an annual cardiac mortality and an annual mortality 
due to SCD of 0.8% and 0.6%, respectively, which is in agreement with the fi ndings 
in other, community-based HCM populations. Another important fi nding was that 
LVOT obstruction was an independent predictor for clinical deterioration during 
follow-up for every increase of 10 mm Hg. Also, the presence of syncope was an in-
dependent predictor for SCD. Since SCD remains one of the most devastating com-
ponents of the natural history, it is important to estimate the risk for sudden death. 
Due to the relative low mortality rates in HCM populations, the identifi cation of risk 
markers for SCD, however, remains problematic. Besides, it would be most conve-
nient in daily practice to estimate the risk of SCD according to non-invasive markers, 
which are easy to obtain. Therefore, Elliott et al. (J Am Coll Cardiol 2000;36:2212-8) 
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analyzed six-year-SCD-free survival rates in a group of 368 HCM patients accord-
ing to fi ve predefi ned risk markers, including nonsustained ventricular tachycardia, 
syncope, blood pressure response during exercise, family history of sudden death 
and left ventricular wall thickness. The study demonstrated that the presence of 
two or more risk markers substantially increased the risk for SCD as compared to 
the presence of one or no risk marker. At multivariate analysis, increasing maximal 
left ventricular wall thickness and the presence of syncope in combination with a 
positive family history increased the risk for SCD.
INVASIVE TREATMENT
The therapeutic choice of a HCM patient depends mainly on the presence of symp-
toms, an outfl ow tract obstruction, and risk factors for SCD.
The majority of symptomatic HOCM patients are successfully treated with a beta-
blocker, a calcium antagonist or a combination of both medications.
In patients with (a) serious risk factor(s) for SCD or those with a previously aborted 
cardiac arrest, an automatic implantable cardioverter-defi brillator (ICD) has proven 
an eff ective treatment to prevent SCD. Implantation of an ICD for secondary preven-
tion (following cardiac arrest) or primary prevention (according to the risk factors) 
resulted annually in appropriate device intervention at 11% and 5%, respectively.
The standard therapy to treat HCM patients with persisting cardiac symptoms, de-
spite optimal medical treatment, and a dynamic outfl ow tract gradient ≥ 50 mm Hg 
is surgical septal myectomy. In the past 15 years, two alternatives to surgery have 
been proposed. First, chronic dual-chamber pacing was introduced as a relatively 
small intervention to reduce symptoms and LVOT obstruction. In randomized trials, 
however, clinical improvement could not be attributed to the presence or absence 
of cardiac pacing, suggesting a placebo eff ect. Since then, this therapy has been 
practically abandoned. Second, PTSMA has been introduced in 1995. The enthu-
siasm for this procedure can be perceived from the number of procedures so far 
performed, which outnumbers the number of surgical procedures performed over 
the past 40 years.
Both surgery and PTSMA are regarded as eff ective methods to improve hemo-
dynamic status and clinical condition in symptomatic HOCM patients. The results 
of the surgical and the PTSMA procedures, performed at the EMC Rotterdam have 
been compared. Two remarkable fi ndings, which are in agreement with the existing 
knowledge, were made. First, hemodynamic improvement was more marked after 
surgery. Second, PTSMA is burdened with more peri-procedural complications and 
necessity for re-interventions. At present, surgery will be advised for young, severe-
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ly symptomatic patients and for subjects with additional anatomic alterations of 
the mitral valve apparatus. A prospective, randomized trial would certainly put the 
choice for one of these therapies in better perspective. Such a trial, however, may be 
hampered due to the small number of patients necessitating invasive intervention. 
FUTURE PERSPECTIVES
HCM is a disease characterized by an autosomal-dominant inheritance, with incom-
plete penetrance. The prevalence of the disease in the general population is 0.2%. 
At present, more than 400 mutations have been identifi ed located in 11 disease-
causing genes. Ten of these genes encode for proteins of the cardiac sarcomere 
(Table 1).
It is intriguing to question oneself whether the growing genetic interest and 
experience in the fi eld of HCM is of clinical benefi t to the patient. Does a known 
genotype implicate the possibility to off er advanced clinical care to the patient? 
Does a specifi c genotype require a specifi c therapy and, more importantly, does it 
off er a clear insight in the risk for SCD? Does the current knowledge allows to draw 
conclusions concerning the genotype-phenotype correlations?
Genetic screening and an indisputable, DNA-based diagnosis of HCM would clearly 
off er advantages to specifi c family members of HCM patients. Certain members, in 
whom the diagnosis may not be established using conventional techniques, would 
be off ered clarity on the presence or absence of the disease instead of the insecurity 
that accompanies regular echocardiographic screening. The use of genetic screen-
ing, however, is limited due to the inability to locate the disease-causing mutation, 
which is the case in a substantial part of the HCM population. The limitations of 
Table 1. Eleven HCM-disease genes, 10 of them encoding cardiac sarcomeric proteins.
Gene Encoding protein Locus
MYH 7 β-Myosin Heavy Chain 14q12
MYBPC3 Myosin Binding Protein C 11p11.2
MYL 2 Regulatory Myosin Light Chain 12q23-q24.3
MYL 3 Essential Myosin Light Chain 3p21.3-p21.2
ACTC α Actin 15q11-q14
TPM1 α-Tropomyosin 15q22.1
TNNT2 Troponin T 1q32
TNNI3 Troponin I 19q13.4
TTN Titin 2q24.3
MYH6 α-Myosin Heavy Chain 14q12
PRKAG2 Protein Kinase A (γ-subunit) 7q36
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genetic screening and genotype-phenotype correlations as well as the diffi  culties 
to use genotyping as a tool in risk stratifi cation have been described in two stud-
ies, which were performed in centers from Europe (Richard et al., France) and the 
USA (Van Driest et al., Minnesota), respectively. In both centers, blood from many 
unrelated HCM patients was systematically screened for all protein encoding exons 
of the known HCM-causing genes. The goal was to estimate the frequency by which 
each of the disease genes are mutated and, furthermore, to propose a systematic 
strategy for genetic screening in clinical practice. Also, genotype-phenotype correla-
tions were analyzed for each disease-causing gene. The results of both studies were 
fairly comparative except for the number of patients with an identifi able mutation. 
In the French study, 63% of the patients could be genotyped compared to only 38% 
of the American population. As seen in Table 2, the majority of the disease-causing 
mutations were localized in two major genes; fi rst, the MYBPC3 gene in 26% and 
16% of the patients, respectively, and second, the MYH7 gene in 25% and 14% of 
the patients, respectively. Mutations of thin fi lament genes (i.e. the genes encod-
ing for the proteins Troponin T, Troponin I, α-Tropomyosin, and α Actin) accounted 
for only 8% and 4.6% respectively, which is less than previously assumed (~20%). 
Furthermore, the identifi ed genotypes were correlated to the (familiar) phenotypes. 
Correlations were performed for several disease genes:
MYBPC3:
Richard et al. found a benign or intermediate prognosis in 90% of the families carry-
ing a mutation in the MYBPC3 gene. In the study by Van Driest et al., families harbor-
ing a MYBPC3 gene mutation were not statistically diff erent from families with any 
Table 2. Relative frequency of genotypes as identifi ed in two large cohorts of unrelated HCM patients as well as in a Dutch population.
Richard et al.*
(n = 197)
Van Driest et al.†
(n = 389)
Rotterdam‡
(n = 228)
Genotype + 124 (63%) 147 (38%) 109 (47.8%)
 MYBPC3  52 (26%)  63 (16.2%)  86 (37.7%)
 MYH7  50 (25%)  54 (13.8%)  14 (6.1%)
 TNNT2   8 (4%)   6 (1.5%)   3 (1.3%)
 TNNI3   8 (4%)   4 (1.0%)   2 (0.9%)
 MYL2   5 (2.5%)   7 (1.8%)   3 (1.3%)
 TPM1   -   2 (0.5%)   -
 MYL3   1 (<0.5%)   -   -
 ACTC   -   1 (0.3%)   -
 >1 mutation   6 (3%)  10 (2.6%)   -
No mutation  73 (37%) 242 (62.1%) 119 (52.2%)
Genotype + = Number of patients with an identifi ed mutation. 
* = Richard et al. Circulation 2003. † = Van Driest et al. J Am Coll Cardiol 2004. ‡ = unpublished data.
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of the other mutations according to several parameters, including age at diagnosis, 
frequency of surgery or need for implantation of an ICD and the degree and distri-
bution of hypertrophy.
MYH7:
In the study by Richard et al., MYH7 gene mutations were most prevalent (45%) 
in families with a malignant prognosis (defi ned as ≥ 2 documented major cardiac 
events including sudden death, heart failure death, stroke death, heart transplanta-
tion, or resuscitated death related to HCM, each occurring before the age of 60 years). 
In the study by Van Driest et al., 15% of the HCM population harbored a MYH7 gene 
mutation. This group had a younger age at diagnosis, a higher frequency of family 
history in a fi rst-degree relative and demonstrated more hypertrophy as compared 
to the group without a MYH7 gene mutation.
TNNT2, TNNI3, TPM1, ACTC (thin fi lament genes):
In the study by Richard et al., families with a TNNT2 or TNNI3 mutation were equally 
associated with a benign or malignant prognosis. This gene, however, was mutated 
in only 16 out of 197 HCM patients. Comparatively, in only 18 out of the 389 patients 
in the study by Van Driest et al. the thin fi lament gene was mutated. This small group 
was statistically indiff erent from the remainder of the cohort according to the afore-
mentioned parameters. 
Exceptions:
Approximately 3% of the patients harbored more than one mutation, located in one 
or two diff erent genes. This genotype was clearly associated with a severe pheno-
type.
Patients, in whom no mutations could be identifi ed, were characterized by an 
older age at diagnosis and less ventricular myocardial hypertrophy. 
As a conclusion, disease-causing mutations, analyzed in a large population of unre-
lated HCM patients, are most frequently located in the MYBPC3 or the MYH7 gene. 
As seen in Table 2, these two genes are also most frequently mutated in the Dutch 
population, analyzed at the EMCR (unpublished data). Previous studies, based on 
screening of a small number of patients from relatively large families, reported a 
higher frequency of mutations in the TNNT2 gene. This HCM-gene is usually as-
sociated with a phenotype including mild or absent hypertrophy and a high risk 
of SCD. The diff erence with the French and the American study may be related to 
the method of recruitment. Patients in the studies by Richard and Van Driest were 
selected on the basis of proven left ventricular hypertrophy as demonstrated at 
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echocardiography. The authors suggest that systematic screening of HCM patients 
should start with the MYBPC3 and the MYH7 gene. Since it has been demonstrated 
that the presence of multiple mutations in one patient is strongly related to a ma-
lignant phenotype, screening should not be stopped after the identifi cation of a 
single mutation, especially in families with an adverse phenotype, but should be 
continued on the same gene and at least on the 2 major genes.
The huge variation in HCM genotype and phenotype make it practically very dif-
fi cult to propose a genotype-phenotype correlation that is useful to the medical 
specialist in daily practice. Also, the role of genetic and environmental modifi ers 
has not yet been elucidated. Currently, the practical role of genetics is limited to 
mutational analysis in patients with proven or suspected HCM. In case a mutation 
is identifi ed in a proband, screening may be off ered to his family members. This al-
lows an unequivocal diagnosis of HCM in suspected cases, bypassing regular clinical 
follow-up.
All data, acquired for clinical or research purposes, should concisely be gathered 
and combined to the familiar phenotypes in the benefi t of ongoing research. In 
future, this would allow us to use the genotype-phenotype correlation as a tool for 
risk stratifi cation for SCD or as indicator to choose a certain therapy. With the rapid 
progressions in molecular genetics, the next futuristic step might be the implemen-
tation of genetic engineering, in which the disease gene could be modulated in 
order to reduce or reverse the progression of left ventricular hypertrophy.
S
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Hypertrofi sche cardiomyopathie (HCM) is een intrigerend ziektebeeld met hetero-
geniteit in het genetisch, morfologisch en klinisch spectrum. In de afgelopen 40 
jaar, is het inzicht in de prognose en het natuurlijk beloop van de ziekte enorm 
toegenomen. De eerste observationele studies, welke waren gebaseerd op gege-
vens van naar tertiaire ziekenhuizen verwezen patiënten, suggereerden nog dat de 
ziekte een slechte prognose had en met name gekenmerkt zou worden door een 
hoge incidentie van plotse hartdood. De recente studies, waarvan de gegevens zijn 
gebaseerd op patiënten afkomstig uit niet-tertiaire centra, suggereren daarentegen 
dat het klinische beloop juist mild is. Deze studies berekenen de jaarlijkse cardiale 
mortaliteit op minder dan 1%. Een andere opmerkelijke bevinding is dat het meren-
deel van de HCM-patiënten bij leven helemaal geen klachten ervaart. 
Bij ongeveer een kwart van alle HCM-patiënten wordt met Doppler echocardiogra-
fi e een linker ventrikel (LV) uitstroombaan-obstructie van ≥ 50 mm Hg aangetoond. 
In dat geval spreekt men van hypertrofi sche obstructieve cardiomyopathie (HOCM). 
De hoogte van de gradiënt zou samen hangen met de ernst van de klachten. Indien 
een HOCM patiënt met maximale medicamenteuze therapie symptomatisch blijft 
en echocardiografi sch een uitstroombaan-obstructie van ≥ 50 mm Hg houdt, wordt 
of chirurgische septale myectomie of percutane transluminale septale myocard ab-
latie (PTSMA) voorgesteld. Van deze twee methoden, wordt chirurgie nog steeds als 
de gouden standaard gezien.
Dit proefschrift geeft in het eerste gedeelte de huidige inzichten in prognose en 
natuurlijk beloop van de ziekte weer. Daarnaast beschrijft het in het tweede gedeel-
te enerzijds de resultaten van de chirurgische ingreep en anderzijds van PTSMA. 
Ook wordt in dit gedeelte bekeken of de ene techniek is te prevaleren boven de 
andere door beide behandelingsmethoden met elkaar te vergelijken.
KLINISCHE INZICHTEN
De gegevens over het natuurlijk beloop van HCM, welke in het voorliggende proef-
schrift worden beschreven, zijn gebaseerd op een populatie van 225 opeenvolgen-
de HCM-patiënten, welke tussen 1970 and 1999 aan het Erasmus Medisch Centrum 
Rotterdam op een speciale HCM-polikliniek werden vervolgd. De jaarlijkse mortali-
teit in het vervolgonderzoek van deze groep ten gevolge van een plotse hartdood 
of een andere cardiale oorzaak werd berekend op respectievelijk 0.6% en 0.8%. Deze 
bevindingen zijn in overeenstemming met de resultaten van andere, niet-tertiaire 
centra. Een andere belangrijke observatie betrof de linker ventrikel uitstroombaan-
obstructie, welke een onafhankelijke voorspeller voor klinische verslechtering bleek 
te zijn. Tenslotte bleken patiënten die anamnestisch een collaps hadden ervaren, 
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een verhoogde kans te hebben op plotse hartdood. Aangezien deze plotse dood 
een van de meest tragische complicaties van de ziekte is, is inschatting van het ri-
sico op plots overlijden van groot belang. Door de relatief lage mortaliteitcijfers in 
HCM-populaties, blijft het echter gecompliceerd om meerdere risicofactoren voor 
het optreden van plotse cardiale dood te identifi ceren. Daarbij zou het in de dage-
lijkse praktijk eff ectief zijn om risicomarkers te gebruiken welke aan de hand van 
niet-invasieve methoden te bepalen zijn. Met dit doel voor ogen hebben Elliott et 
al. (J Am Coll Cardiol 2000;36:2212-8) een groep van 368 HCM-patiënten langere 
tijd vervolgd. De auteurs bestudeerden of de kans op plotse hartdood kon wor-
den ingeschat aan de hand van vijf, vooraf gedefi nieerde risicofactoren, te weten 
kamertachycardieën, collaps, inspanningsgerelateerde bloeddrukdaling, positieve 
familieanamnese (het voorkomen van plotse cardiale dood bij familieleden) en/of 
de ernst van LV hypertrofi e. De studie toonde aan dat de kans op vóórkomen van 
plotse hartdood bij patiënten met twee of meer risicofactoren duidelijk hoger was 
dan bij patiënten met 1 of nul risicofactoren. Met multivariate analyse kwamen de 
ernst van LV hypertrofi e en de combinatie van collaps en positieve familie anam-
nese als voorspellende risicofactoren voor het optreden van plotse hartdood naar 
voren.
INVASIEVE BEHANDELING
De therapie van keuze bij de behandeling van een HCM-patiënt wordt voornamelijk 
bepaald door het klachtenpatroon, de ernst van LV uitstroombaan-obstructie en de 
aanwezigheid van risicofactoren voor plotse hartdood. 
Symptomatische HOCM patiënten (oftewel degenen met klachten en een uit-
stroombaan-obstructie van ≥ 50 mm Hg) kunnen veelal succesvol worden behan-
deld met een bêta-blokkeerder, een calcium-antagonist of een combinatie van 
beide medicijnen.
Bij patiënten met (een) zwaarwegende risicofactor(en) voor plotse hartdood en bij 
degenen die succesvol werden gereanimeerd na een hartstilstand, is de implantatie 
van een automatische implanteerbare defi brillator (ICD) inmiddels een bewezen, 
eff ectieve behandeling gebleken ter preventie van plotse hartdood. Van de patiën-
ten die een ICD geïmplanteerd kregen als secundaire preventie maatregel (dwz. na 
een succesvolle reanimatie) of als primaire preventie maatregel (dwz. gebaseerd op 
risicofactoren), ontving respectievelijk 11% en 5% jaarlijks een terechte shock.
Bij patiënten met persisterende klachten onder optimale medicamenteuze thera-
pie met daarbij een LV uitstroombaan-obstructie van ≥ 50 mm Hg wordt gekozen 
voor een invasieve therapie, waarbij de huidige standaard chirurgische septale 
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myectomie is. In de afgelopen 15 jaar zijn er twee alternatieven voor chirurgie ont-
wikkeld. Het eerste alternatief was implantatie van een pacemaker. Deze relatief 
kleine ingreep zou de symptomen van de patiënt verminderen en de ernst van de 
LV uitstroombaan-obstructie reduceren. De klinische verbetering van de patiënten 
kon in gerandomiseerd onderzoek echter niet worden gerelateerd aan de werking 
van de pacemaker. Hieruit werd geconcludeerd dat het therapeutisch eff ect gro-
tendeels op een placebo-eff ect moest berusten en in de huidige praktijk wordt 
deze vorm van therapie dan ook nauwelijks meer toegepast. Het tweede alternatief, 
PTSMA, werd in 1995 geïntroduceerd. Het enthousiasme voor deze nieuwe techniek 
is af te lezen aan het aantal tot nu toe verrichte procedures. In de afgelopen 10 jaar 
zijn er namelijk meer PTSMA procedures uitgevoerd dan dat er septale myectomie-
procedures in de afgelopen 40 jaar zijn verricht.
Uit ons onderzoek blijkt dat de hemodynamische toestand en de klinische condi-
tie bij het merendeel van de patiënten zowel na chirurgie als PTSMA verbetert. De 
resultaten van de twee groepen patiënten die in het EMCR werden behandeld met 
behulp van chirurgie of PTSMA worden in dit proefschrift met elkaar vergeleken. 
In deze vergelijkende studie worden twee opvallende bevindingen gedaan welke 
in overeenstemming zijn met de bestaande literatuur. Ten eerste lijkt de verbete-
ring van de hemodynamiek na chirurgie meer uitgesproken. Ten tweede lijkt er 
een grotere kans te bestaan op proceduregerelateerde complicaties en noodzaak 
tot re-interventie na PTSMA. Hoewel er nog veel onduidelijkheden zijn, met name 
omtrent PTSMA, wordt geadviseerd om jonge, ernstig symptomatische patiënten 
te opereren evenals HOCM patiënten met anatomische afwijkingen van het mi-
tralisklepapparaat, een combinatie die bij dit ziektebeeld frequent wordt gezien. 
Een prospectief, gerandomiseerd onderzoek zou meer duidelijkheid kunnen geven 
welke van de twee behandelingen de voorkeur verdient. De opzet van een derge-
lijke studie wordt echter bemoeilijkt door het beperkte aantal patiënten dat jaarlijks 
voor behandeling in aanmerking komt. 
TOEKOMSTPERSPECTIEF
HCM wordt gekenmerkt door een autosomaal-dominant overervingspatroon met 
incomplete penetrantie. De prevalentie van de ziekte in de algemene populatie 
wordt geschat op 0.2%. Op dit moment zijn er meer dan 400 mutaties geïdenti-
fi ceerd welke zijn gelokaliseerd op één van de 11 bekende HCM-genen. Tien van 
deze genen coderen voor een op een sarcomeer (= segment van een fi bril van het 
hart) gelegen eiwit(zie Tabel 1).
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Een intrigerende vraag is of de groeiende kennis van, en de wetenschappelijke 
interesse voor dit vakgebied ook daadwerkelijk klinische voordelen biedt aan de 
HCM-patiënt. Kan men de patiënt bij wie het genotype is geïdentifi ceerd betere en 
meer geavanceerde zorg bieden? Dient de behandeling afgestemd te worden op 
het genotype en, nog belangrijker, geeft het genotype een duidelijker inzicht in de 
kans op plotse hartdood? Laat het huidige kennisniveau het toe een genotype aan 
een gedefi nieerd fenotype te koppelen? Deze vragen zullen binnen diverse centra 
verschillend beantwoord worden. Het is duidelijk dat genetische screening en de 
onomstotelijke, op DNA gebaseerde, diagnose van de ziekte HCM grote voordelen 
kan bieden aan bepaalde familieleden van de proband (= de persoon die het uit-
gangspunt vormt bij stamboomonderzoek). Deze bloedverwanten, bij wie de ziekte 
met behulp van de huidige diagnostische middelen niet kan worden aangetoond 
cq. uitgesloten, kunnen mogelijk zekerheid krijgen omtrent de diagnose met be-
hulp van DNA diagnostiek. Deze methode is echter niet altijd toepasbaar. In een 
aanzienlijk deel van de HCM-populatie kan namelijk geen mutatie worden geïden-
tifi ceerd. Er zijn studies van twee centra, één in Europa (Richard et al., Frankrijk) en 
één in de Verenigde Staten (Van Driest et al., Minnesota) waarin de beperkingen van 
genetisch screenen en van genotype-fenotype duidelijk worden geschetst. Zij be-
schrijven ook de onvolkomenheden in het gebruik van een genotype als risicofactor. 
In beide centra werd een grote groep, niet-familiair gerelateerde HCM-patiënten 
genetisch gescreend. In het bloed van de patiënten werden alle voor eiwitten code-
rende exons op de bekende, “HCM-veroorzakende”genen geanalyseerd. De opzet 
van de studies was om de bekende HCM-genen systematisch te screenen met als 
doel een goede strategie te bepalen voor het genotyperen van HCM-patiënten in 
de dagelijkse praktijk. Daarnaast werd getracht een verband te leggen tussen geno-
type en fenotype. De resultaten van beide studies stemden redelijk overeen. Er was 
Tabel 1. Overzicht van 11 HCM-genen, waarvan 10 coderen voor een sarcomeereiwit.
Gen Coderend eiwit Locus
MYH 7 β-Myosin Heavy Chain 14q12
MYBPC3 Myosin Binding Protein C 11p11.2
MYL 2 Regulatory Myosin Light Chain 12q23-q24.3
MYL 3 Essential Myosin Light Chain 3p21.3-p21.2
ACTC α-Actin 15q11-q14
TPM1 α-Tropomyosin 15q22.1
TNNT2 Troponin T 1q32
TNNI3 Troponin I 19q13.4
TTN Titin 2q24.3
MYH6 α-Myosin Heavy Chain 14q12
PRKAG2 Protein Kinase A (γ-subunit) 7q36
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alleen een groot verschil in het aantal patiënten bij wie een mutatie kon worden 
geïdentifi ceerd, namelijk in 63% van de Franse en slechts 38% van de Amerikaanse 
patiënten. 
Het merendeel van de geïdentifi ceerde mutaties werd gelokaliseerd op twee 
HCM-genen (Tabel 2), te weten het MYBPC3 gen (26% en 16% van de patiënten, 
respectievelijk) en het MYH7 gen (25% en 14% van de patiënten, respectievelijk). 
Het dunne fi lament gen (= het gen dat codeert voor het sarcomeereiwit Troponine 
T, Troponine I, α-Tropomyosine, of α Actine) was slechts bij respectievelijk 8% en 
4.6% van de patiënten gemuteerd hetgeen beduidend minder is dan de beschreven 
~20% uit eerdere studies. In de twee studies werd ook het geïdentifi ceerde geno-
type gecorreleerd met het bijbehorende (familiare) fenotypen. De volgende relaties 
werden gevonden:
MYBPC3 gen:
In de studie van Richard et al. bleek 90% van de families met een mutatie op het 
MYBPC3 gen een benigne of intermediaire prognose te vertonen. In de studie van 
Van Driest et al., bleken families met een mutatie op dit gen niet te onderscheiden 
van families met een mutatie op een ander HCM-gen zover het betreft de leeftijd 
waarop de diagnose werd gesteld, de noodzaak tot chirurgie of implantatie van een 
ICD of de ernst cq. verdeling van de hypertrofi e.
MYH7 gen
In de studie van Richard et al. bleken MYH7 genmutaties aanwezig te zijn in 45% 
van de families met een slechte prognose (gedefi nieerd als ≥ 2 gedocumenteerde 
Tabel 2. Verdeling van mutatiefrequentie van de 11 bekende HCM-genen in twee populaties met niet familiair-gerelateerde HCM-patiënten.
Richard et al.*
(n = 197)
Van Driest et al.†
(n = 389)
Rotterdam‡
(n = 228)
Genotype + 124 (63%) 147 (38%) 109 (47.8%)
 MYBPC3  52 (26%)  63 (16.2%)  86 (37.7%)
 MYH7  50 (25%)  54 (13.8%)  14 (6.1%)
 TNNT2   8 (4%)   6 (1.5%)   3 (1.3%)
 TNNI3   8 (4%)   4 (1.0%)   2 (0.9%)
 MYL2   5 (2.5%)   7 (1.8%)   3 (1.3%)
 TPM1   -   2 (0.5%)
 MYL3   1 (<0.5%)   -
 ACTC   -   1 (0.3%)
 >1 mutatie   6 (3%)  10 (2.6%)
Geen mutatie  73 (37%) 242 (62.1%) 119 (52.2%)
Genotype + = Aantal patiënten met een geïdentifi ceerde mutatie. 
* = Richard et al. Circulation 2003. † = Van Driest et al. J Am Coll Cardiol 2004. ‡ = niet gepubliceerde data.
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belangrijke cardiale events, te weten plotse hartdood, dood door hartfalen of CVA 
of harttransplantatie optredend beneden de leeftijd van 60 jaar). Bij Van Driest et 
al. werd een MYH7 genmutatie bij 15% van de 389 patiënten geïdentifi ceerd. Deze 
patiënten waren gemiddeld jonger op het moment van diagnose, vertoonden 
echocardiografi sch meer hypertrofi e en vermeldden frequenter een positieve fa-
milieanamnese bij een eerstegraads verwant in vergelijking met patiënten zonder 
MYH7 genmutatie.
TNNT2, TNNI3, TPM1, ACTC (dunne fi lament genen):
In de studie van Richard et al., bleek de verdeling tussen een slechte en een goede 
prognose bij families met een TNNT2 of TNNI3 genmutatie gelijk te zijn. Dit gen 
toonde echter bij slechts 16 van de 197 HCM-patiënten een mutatie. Ook in de stu-
die van Van Driest et al. werd bij slechts 18 van de 389 patiënten een mutatie op een 
dun fi lament gen gevonden. Er waren geen statische verschillen tussen deze groep 
en de rest van het cohort met betrekking tot de eerder genoemde parameters.
Uitzonderingssituaties:
In ~3% van de populatie werden meerdere mutaties per patiënt geïdentifi ceerd. De 
mutaties konden gelokaliseerd zijn op hetzelfde of op twee verschillende genen. 
In zowel de Franse als de Amerikaanse studie bleek een dergelijk genotype dui-
delijk geassocieerd te zijn met een maligne (= ongunstig) fenotype. Patiënten bij 
wie geen mutatie kon worden geïdentifi ceerd, werden gemiddeld pas op oudere 
leeftijd gediagnostiseerd en vertoonden echocardiografi sch minder hypertrofi e.
Concluderend lijken de HCM-veroorzakende mutaties het meest frequent gelegen 
te zijn op het MYBPC3 en het MYH7 gen indien men grote populaties met niet fami-
liair-gerelateerde HCM-patiënten zou screenen. In tabel 2 is af te lezen dat mutaties 
ook in de Rotterdamse situatie het meest frequent op deze twee genen werden 
aangetroff en (niet gepubliceerde data). In eerdere studies, waarin meerdere perso-
nen binnen enkele grote HCM-families werden gescreend, lag de mutatiefrequentie 
in het TNNT2 gen juist hoog. Een mutatie op dit gen wordt geassocieerd met een 
fenotype waarbij weinig tot geen hypertrofi e kan worden aangetoond en een sterk 
verhoogd risico op plotse hartdood. Een verklaring voor dit verschil met de Franse 
en Amerikaanse studie kan worden gevonden in de wijze van rekrutering. De pa-
tiënten in de studie van Richard en Van Driest werden namelijk alleen geïncludeerd 
indien de diagnose HCM, gebaseerd op echocardiografi sch aantoonbare hypertro-
fi e van de LV, zeker was.
De suggestie van beide studies is om bij een systematische screening in de prak-
tijk te beginnen met het MYBPC3 en het MYH7 gen. Aangezien de aanwezigheid 
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van multipele mutaties in één patiënt echter duidelijk is gerelateerd met een ma-
ligne fenotype, dient screening niet te worden gestopt na de identifi catie van een 
mutatie maar, met name in families met een slechte prognose, voortgezet op de 
rest van het gen en tenminste op de twee belangrijkste genen.
Door de enorme variatie in genotype en fenotype, is het in de praktijk erg moeilijk 
om de koppeling tussen deze twee, de zgn. genotype-fenotype correlatie, goed te 
defi niëren. Ook is het nog onduidelijk of verschillen in omgevingsfactoren (“en-
vironmental modifi ers”) invloed kunnen hebben op een fenotype. Wat betreft de 
praktische toepasbaarheid, beperkt de rol van genetische screening zich voorals-
nog tot de identifi catie van genmutaties bij patiënten met een bewezen HCM of 
bij hen die van de ziekte verdacht worden. Indien een genmutatie bij een proband 
wordt geïdentifi ceerd bestaat de mogelijk om ook de familieleden screening aan te 
bieden. Hiermee kan hen zekerheid worden geboden omtrent de aanwezigheid van 
een HCM-gen en een langdurige, poliklinische follow-up worden bespaard.
Alle genetische gegevens, verkregen uit klinisch of wetenschappelijk oogpunt, 
dienen nu, meer dan ooit, nauwkeurig te worden gedocumenteerd en gecorreleerd 
met het familiaire fenotype. Alleen op deze manier kan de genotype-fenotype cor-
relatie in de toekomst gebruikt gaan worden als risicomarker voor bijvoorbeeld 
plotse hartdood of als houvast bij de keuze voor een bepaalde therapie. Een toe-
komstvisie met genetische manipulatie, waarbij het HCM-gen gemodifi ceerd wordt 
en de ontwikkeling van hypertrofi e kan worden beperkt of voorkomen, lijkt gezien 
de huidige snelle ontwikkelingen in de moleculaire genetica niet ondenkbaar.
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Aan het einde van een proefschrift komt het moeilijkste gedeelte. Op een beperkte 
hoeveelheid papier een poging wagen alle mensen te bedanken die de 10 jaar wer-
ken en promoveren in het Erasmus Medisch Centrum (toen nog “Dijkzigt”) mogelijk 
hebben gemaakt. De kans dat iemand niet wordt vernoemd is aanwezig maar in dat 
geval is de dank voor de prettige samenwerking niet minder.
Allereerst gaat mijn dank uit naar Dr. F.J. ten Cate. Beste Folkert, vanaf mijn sol-
licitatie gesprek in 1995 tot aan het afronden van mijn specialisatie en promotie, 
ben jij betrokken geweest bij mijn klinische en wetenschappelijke vorming. Jouw 
brede kennis van de hypertrofi sche cardiomyopathie en de durf om aan nieuwe 
therapieën te beginnen voordat anderen dat deden hebben geleid tot de kern van 
dit boekje. De vele klinische uren werk waar een groot deel van dit boekje op geba-
seerd is, liggen in jouw handen.
Mijn dank gaat uit naar mijn promotor, Prof. Dr. M.L. Simoons. Beste Maarten, het 
tot stand komen van dit proefschrift is een voorbeeld van jouw idee dat niets onmo-
gelijk is. Het verlengen van mijn “AGNIO”-arbeidscontracten en de aanmoedigingen 
om het schrijven vol te houden hebben allemaal bijgedragen aan het volbrengen 
van dit proefschrift.
De overige leden van de promotiecommissie, Prof. Dr. Cees Visser, Prof. Dr. Ben 
Oostra, Prof. Dr. Wim van der Giessen en Prof. Dr. Nico de Jong wil ik bedanken voor 
hun bereidwilligheid dit proefschrift te beoordelen. I would like to thank Prof. Elliott, 
who is such an experienced and honoured person in the fi eld of hypertrophic cardio-
myopathy, for his interest in the present thesis and his presence at the defence.
Mijn dank aan Dr. M.J. Koffl  ard. Beste Marcel, met name in de eerste jaren heb je 
mij geholpen met de wetenschappelijke bezigheden zoals data verzamelen, analy-
seren en het schrijven van artikelen. Daarnaast heb ik van jou geleerd dat promotie 
onderzoek meerdere kanten heeft en dat communicatie voor een goede samen-
werking belangrijk is. Dat samenwerking tot mooie resultaten kan leiden blijkt wel 
uit het “review” verhaal dat met trots voorin het boekje prijkt.
Mijn paranimfen, Marco en Ruud, wil ik danken voor de steun bij de voorbereiding 
van deze dag. Marco, nadat we elkaar een tijdje uit het oog hebben verloren, zijn 
we elkaar weer tegen gekomen “in het circuit” waarbij uiteraard de verhalen over de 
goede tijden met jouw en Alex naar boven kwamen. Dat jij vandaag als paranimf 
wilt optreden, verheugt me. Ook in de nabije toekomst hoop ik contact te houden, 
hoewel dit gezien de afstand meer telefonisch zal zijn. Op naar het volgende (jouw) 
boekje. Ruud, ik ben trots dat jij mij vandaag als paranimf wil bijstaan. Het is zeker 
niet de eerste keer dat je me helpt. Als middelbare scholier, als student, als co-as-
sistent en als arts stond ik meerdere malen bij je op de stoep, met of zonder mijn 
“bontjas”. Belangrijkste boodschap voor vandaag, als je aanwijzingen en tips aan mij 
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doorspeelt, doe dit dan niet al te cryptisch. Ik los dat soort puzzels namelijk niet zo 
snel op als jij dat doet.
Mijn co-auteurs wil ik danken voor de hulp bij het tot stand komen van de ver-
schillende publicaties. 
Dr. M.L. Geleijnse. Beste Marcel, we begonnen als collega’s “arts-assistent” in Dijk-
zigt waar ik je als eerste leerde kenner als de bezitter van een waanzinige cabrio. 
Daarna zorgde jij voor een vrolijke noot in een voor mij moeilijk jaar. Jouw aanbod 
om mee te helpen met het “chirurgie versus percutaan” verhaal was een essentieel 
begin om het laatste voorbereidingsjaar van dit boekje in te luidden. Daarnaast is 
“het laten beleggen en eten van een goed stokbroodje” een belangrijk leermoment 
geweest om te beseff en dat er meer is dan alleen wetenschap.
Mijn dank aan Dr. van Herwerden. Beste Lex, jij hebt letterlijk het werk achter de 
schermen verricht waaraan een zeer belangrijk deel van dit boekje is ontleend. Ik 
heb altijd met veel bewondering jouw unieke chirurgische technieken om de HOCM 
patiënten te behandelen, bestudeerd en bekeken. De manier waarop jij je vak uit-
oefent verdient respect.
Prof. Dr. P. Serruys. Beste Patrick, de gedrevenheid om nieuwe technieken te ont-
dekken en te introduceren binnen het Thoraxcentrum, heeft het mogelijk gemaakt 
dat Folkert samen met jouw afdeling de PTSMA behandeling in Rotterdam heeft 
geïntroduceerd en verder ontwikkeld. Jouw commentaar op het “myectomie versus 
PTSMA” verhaal (“… deserves Circulation.”) hangt nog steeds ingelijst aan de muur. 
Daarnaast zal ik de prachtige “Acunav”-beelden niet vergeten.
Beste Willem van Dockum en Jurriën ten Berg, de samenwerking met jullie kwam 
in het latere (PTSMA) gedeelte van het boekje tot stand. Hoewel we samenwerking 
al heel lang in gedachten hadden (Nice, 1999, uit mijn hoofd) ben ik blij dat de 
HCM-patiënten en de behandelmethoden nu wel konden worden samengevoegd. 
Hoewel wetenschap altijd gecombineerd moest worden met een drukke baan, 
hebben we een aantal mooie manuscripten geschreven die ongetwijfeld tot mooie 
publicaties zullen leiden. 
Beste Wim Vletter, jouw aandeel is van onmisbare waarde geweest. De schitte-
rende echobeelden hebben de uren analyseren een stuk vergemakkelijkt.
Mijn dank gaat uit naar de vele collega’s in het Erasmus MC waarmee ik in de 
afgelopen jaren erg prettig heb samengewerkt. Mijn dank aan jullie voor de support 
om het schrijven naast de klinische rondes vol te houden. De gezellige “klets”-mo-
menten met de andere assistenten in “onze” kamer hebben hier zeker aan bijgedra-
gen. Daarnaast verpleging op afdeling en IC, Corry en de “poli”-dames (ook echo 
en ritmeanalyse zal ik niet vergeten), Angela Peterse voor de gezellige en serieuze 
gesprekken, Ron van Domburg voor de “statistische begeleiding” en promotietips, 
Yvonne Hoedemaekers voor de genetische adviezen, Adrie, Rob en Mark van de 
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computergroep voor de eerste hulp bij soft- en/of hardware problemen, Miranda 
en Willeke voor de hulp bij de afronding van het boekje, Rene Frowijn, Jan Tuin, 
Jurgen Ligthart en Frits Wilbrink voor de hulp bij de creatie van de mooie foto’s; 
dank jullie hartelijk.
Ik wil ook mijn voormalige collega’s uit het Ikazia danken voor die onvergetelijke 
twee jaar. Wil, ik heb bewondering voor jouw eindeloze geduld om te luisteren en 
uiteraard voor de buff erfunctie tussen “ons” en de “bazen”. Dr. Rob Ouwendijk, be-
dankt voor het geduld mij te blijven accepteren tijdens de vele assistentenvergade-
ringen. De bijzondere telefonische onderwijssessies met Dr. Rini Baggen (telefoon 
in de koffi  ehouder!) zal ik ook niet snel vergeten. Adrienne, Martijn, Ben, Liesbeth, 
Maaike, Ram en Marcel; met z’n allen kom je de tijd door, met of zonder examens. 
Zonder elkaar had ik het nog zo net niet geweten.
Dank aan mijn collega’s in Zevenaar voor het geduld om te wachten op mijn 
komst aangezien ik eerst het boekje naar de drukker moest brengen en op zoek 
moest gaan naar een ander huis. Op naar een goede en gezellige samenwerking.
Als laatste komen de voor mij belangrijkste personen die eigenlijk als eerste ge-
noemd moeten worden, familie en vrienden.
Lieve Marianne en Ab. Jullie hebben dit voor mij mogelijk gemaakt. Zonder jullie 
steun, hulp en liefde was al dit moois nooit van de grond gekomen. Pap, telkens 
zorgde jij er voor dat alles weer voor elkaar kwam. Waar ik ook heen moest voor 
school, waar ik ook ging wonen. De eindeloze ritten door de polder en over de Ve-
luwe, “eff e” 300 km op een dag, ik mis het best. Mam, jouw constante hulp bij het 
overhoren van mijn huiswerk, het oplossen van mijn problemen, jouw duwtjes in de 
rug als ik ze nodig had; ze zullen altijd in mijn geheugen gegrift staan. Hoewel jij er 
op deze dag niet bij zult zijn, kijk je met me mee, zoals we hebben afgesproken. Pap 
en Henny, jullie wens ik alle goeds toe in de toekomst.
Toos en Karel, jullie hebben een belangrijke bijdrage geleverd aan mijn gelukkige 
jeugd. Toos, met dit boekje in de hand hebben we een moment om net weer wat 
sterker aan elkaar te denken dan dat we gewoonlijk al doen. Karel heeft ook zo zijn 
eigen plek om rustig mee te genieten. Ik hoor hem zeggen; “Wat een uitzicht, joh”. 
Mijn schoonmoeder ben ik door de loop van de jaren altijd dankbaar geweest. 
Was het niet dankzij de gastvrijheid gedurende meerdere weken dat ik mijn prope-
deuse jaar alsnog ben doorgekomen; alles tegen de vergoeding van een stuk echte 
“Staphorster” kaas. De vele uren die we bij jou hebben doorgebracht “op de Stille” 
zijn er bij elkaar waarschijnlijk meer dan op de Meppelweg. 
Carla en Gerard, wat heerlijk dat ondanks de drukte van alle zaken jullie er altijd 
zijn als het nodig is. Nu kunnen jullie even gezellig op de koffi  e komen op weg naar 
Frankfurt.
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Ruud en Marion, bij jullie begon de studie. Dit was volgens mij ook de eerste keer 
dat ik, uitgebreid de krant lezend, eerder wakker was dan Marion. Juist ja, ik had 
mijn bed nog niet gezien die nacht. Ik hoop dat we in Zevenaar net zo’n mooi huis 
gaan treff en als dat van jullie.
Greet en Dick, jullie zijn in de afgelopen paar jaar wel een heel bijzondere rol in 
ons leven gaan spelen. Wie had dat verwacht op het moment dat we hier gingen 
wonen. De laatste tijd hebben we veel gezelligheid met elkaar en de kinderen ge-
had. In het begin echter zou ons gezin wel eens gestrand kunnen zijn als we al jullie 
hulp niet hadden gehad. Hulp op lastige momenten, gezellig aanschuiven als onze 
magen knorden, een gezellig dagje Brabant; het heeft ons er doorheen gesleept. 
Het was altijd belangeloos en gemeend.
Joost, Jeroen en Seraphim. We zijn alle vier op weg om de toekomst meer vastig-
heid te geven. Geen rommelige studentenkamer meer maar gewoon een huis, kids 
en een auto (of twee) voor de deur. Het feit dat we na regelmatige radiostiltes weer 
gewoon doorkletsen bij een onverwacht telefoontje zegt denkt ik genoeg over 
onze vriendschap. Daar komt geen boekje tussen.
Joke en Cor, jullie zijn ook een belangrijk deel van ons leven gaan uitmaken. Het 
plezier dat Laurens en Casper bij hun oppasmoeder hebben is groot. Het plezier dat 
dat ons geeft is niet te beschrijven. Ik zal ze voor ik naar bed ga na de nachtdienst 
echter geen gedag meer komen zeggen. 
Lieve Natasja, daar staan we dan. Bijna 17 jaar later, allebei de opleiding afgerond, 
promotie bijna achter de rug. We zullen zien wat de toekomst gaat brengen voor 
ons.
Laurens en Casper, Casper en Laurens. Drie jaar. Een bijzondere tweeling. Jullie 
zijn het mooiste geschenk in mijn leven, voor altijd.
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